Study of cell surface phenotypes by high performance liquid chromatography by Wu, Zhiwei




Thesis presented for the degree of Doctor of Philosophy of the University of 
Edinburgh in the Faculty of Science
1990
ABSTRACT
Size-exclusion high performance liquid chromatography was developed to study 
surface membrane proteins of malignant lymphocytes. The membrane proteins were 
separated in accordance to their molecular sizes or complexed sizes and displayed, in 
conjunction with SDS-PAGE, as two-dimensional matrices on which the location of 
proteins is determined by both retardation in the HPLC column and the mobility on 
the SDS-PAGE gels. Any association or induced-interaction between proteins are 
reflected by predictable changes of the retention times, thus by the location on the 
two-dimensional matrix.
Individual membrane proteins in the mixture were identified or separated by the 
changes of their retardation in the column when mAb-Ag complexes formed by 
applying specific monoclonal antibodies to the extracts of vectorially labelled cells. A 
number of surface markers have been identified and several new components are 
characterized. This study has demonstrated that (1) SE-HPLC is a potent method for 
analysis of complicated mixtures, particularly when a complete separation is not 
necessary (2) the technique has advantages for the study of non-covalent interactions 
between proteins, particularly valuable for antibodies of low affinity (3) the method 
is powerful for compositional study and initiative investigation of the complexity of 
mixtures.
By using this technique in conjunction with SDS-PAGE, B-CLLs were found to 
have heterogeneous surface phenotypic presentations with respect to both quantity 
and quality. The HPLC-SDS PAGE study revealed that the expression levels of 
individual surface components in B-CLL patients were at a correlated fashion and, 
across the patient panel, present a continuous spectrum of such relationships, 
confirmed the earlier reports of immunological studies by Maddy et.al. that individual 
B-CLL patients can be ranked in a sequence according to their expression level of 
CD45 isoforms and that this sequential variation of CD45 is in correlation with levels 
of slg and CD21. In addition, this study discovered a group of uncharacterized 
proteins, band 4.1 ( 160KD ), band 4.3 ( 135KD ) and band 2 ( 300KD ) which are 
also correlated with CD45RA, CD21 and slg. A comprehensive reportiore of B-CLL 
phenotypes has been established with respect to the membrane protein expression.
• •ii
Cell activation study was conducted to investigate the relationship between surface 
glycoproteins and cell differentiation. TPA-induced B-CLL cells were shifting their 
phenotypes from the 230KD-( of CD45 )dominated form ( 1A type ) to 200KD- and 
ISOKD-dominated form ( IB type ), with correlated reduction of CD21, band 4.1, 4.3 
and band 7.1 and induction of band 2, further substantiated the conclusions drawn 
from the in vitro unactivated B-CLLs, PLL and T-CLL. Parallel study was also 
carried out in normal tonsilar B, B+T cells. Fluorescent activated cell sorter ( FACS 
IV ) was employed as a complementary means in this study. The study confirmed the 
previous observation and defined three new surface components closely associated 
with cell differentiation and strongly supports the idea that heterogeneity of 
phenotypes reflects the in vivo differences of cell maturity, and proposes that these 
new components are associated with certain stages of malignant cell maturation. The 
significance of such profiles and their relationships were discussed with respect to the 
cell differentiation, the relationship to PLL, HCL and normal B lymphocyte.
As preliminary studies, non-ionic detergent Triton X-100 was examined for 
solubilization of cell membrane proteins. Antibody-induced capping of B-CLL 
lymphocytes was also conducted to investigate the interactions and relationships of 
surface proteins and cytoskeleton, preliminary results were presented and discussed.
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CHAPTER 1 INTRODUCTION 
1. Structure and Constituents of Plasma Membranes
Eukaryotic cells are organised with sophisticated membrane systems. The plasma 
membrane envelops the cell and separates it from its surroundings. The internal 
membrane systems divide the cellular organelles into different functional 
compartments with distinct biochemical enviroments. The biochemical importance of 
the membrane was gradually realized in the 1940's and 50's when biochemical 
studies revealed that some enzymatic reaction systems in mitochondria and 
chloroplasts could proceed only if the organells or membraneous envelops of the 
organelle membrane are maintained intact. In some cases, disruption of the 
membrane integrity could completely abolish the enzymatic properties.
Two major classes of molecules consisting of membranes are lipids and proteins. 
The proportion of lipids and proteins in eukaryotic membranes ( Singer and 
Nicolson, 1972 ) varies among different species and different organelles. 
Carbohydrates are also found in great abundance in eukaryotic plasma membranes, 
linked to membrane proteins and lipids where they face the exterior of the cell.
The contemporary model for membrane structure, the Fluid Mosaic Model, was 
proposed by Singer and Nicolson in 1972 ( Singer and Nicolson, 1972 ). The model 
emerged from several earlier proposals including those of E. Overton at the turn of 
the century, of Danielli and Davson (1935) and J.D. Robertson (1959). The Singer- 
Nicolson model proposes that the biological membrane is constructed of two layers 
of phospholipid molecules ( bilayer ) which are oriented with their polar ends facing 
outwards to aqueous surroundings while the non-polar hydrocarbon tails pointing to 
the interior of the bilayer, interacting with each other by hydrophobic forces which 
stabilize the phospholipids matrix. The fluid mosaic model suggests that the 
membrane lipids are in a mobile, fluid state and free to diffuse laterally and that 
proteins are suspended individually or in aggregates in globular units either 
penetrating the bilayer ( integral proteins ) or attached to the surface of the lipids ( 
peripheral proteins ). Recent studies show that lipids in the immediate vincinity to 
the proteins are immobilized to certain extent and 'trapped1 in a fixed shell
surrounding the membrane proteins, imposing restrictions on the lipid fluidity. 
Integral proteins comprise about 70-80% of the total membrane proteins.
The carbohydrate groups attached to membrane proteins and lipids form two 
groups of complexed molecules, glycoproteins and glycolipids, respectively. The 
carbohydrate residues of glycoproteins and glycolipids are found to be almost 
exclusively on the outer surface of the plasma membrane. According to the Singer- 
Nicolson model, interactions between the carbohydrate groups can form a network 
that anchors the membrane proteins and restricts their movement. The glycoproteins 
are demonstrated to play an important role in the function of receptor and immune 
recognition.
In the cytoplasmic side of cells, there is a group of protein polymers comprising 
distinct arrays of complexes, the cytoskeleton. Microfilaments, microtubules and 
intermediate filaments are among the major elements of this complicated network. 
The first indication that cytoskeleton may be associated with some membrane 
proteins came from observations on the capping phenomenon in lymphocytes ( 
Tilney and Detmers, 1975 ). In the plasma membrane of a cell capable of cap 
formation, actin is found to be directly associated with the cap structure. Nicolson 
and Painter (1973) showed that the spectrin molecule may be directly connected to 
the bases of the red blood cell glycoproteins on the cytoplasmic face of the plasma 
membrane.
2. Haematopoiesls. Neoplasia and Surface Markers of B Lymphocytes
2.1. Haematopoiesis
Lymphocytes develop from pluripotent haemopoietic stem cells, which give rise to 
all of the blood cells, including erythrocytes ( red cells ), leucocytes ( white cells ) 
and platelets. The leucocytes are engaged in cell recognition and immune response to 
provide defensive functions. On the basis of morphology and function, the 
leucocytes can be divided into four subgroups: granulocytes, monocytes, T and B 
lymphocytes. The first two provide non-specific defence while the T and B 
lymphocytes are involved in cell recognition and specific immunity.
In mammals, the haematopoietic stem cells are primarily detected in the 
embryonic yolk sac before being located in the liver ( in foetuses ) and bone 
marrow ( in adults ) which are refered to as primary lymphoid tissues. Although 
most of the lymphocytes will not survive after they develop in a primary lymphoid 
organs, some of their progeny migrate from these haematopoietic tissues to, or via 
thymus ( T cell ), secondary lymphoid organs mainly the lymph nodes, spleen and 
gut-associated lymphod tissues where the cells proliferate and differentiate into 
lymphocytes and from where the lymphocytes travel via blood stream to the 
peripherallymphoid organs where T and B lymphocytes are specified and react with 
foreign antigens.
Lymphocytes of B lineage are believed to be committed to the production and 
processing of immunoglobulin molecules. Under normal circumstances, the B cells 
are maintained to a steady number of cells with a high daily turnover rate ( 10** in 
the mouse ( Ling, 1983 )). The B lymphocytes, according to the expression of their 
surface phenotypic markers, can be subdivided into many different subsets, 
representing different stages of maturity/differentiation or functional capacity in 
the immunity. This study concerns two major surface proteins which are widely 
regarded to be associated with such staging immunoglobulins and CD45 antigens. 
Immunoglobulins, which distinguish B lymphocytes from T lymphocytes, are 
demonstrated to be closely associated with certain functional stages of B cell 
development. CD45 ( used to be called as the Leukocyte-common Antigen, L-CA ) 
is another major cell surface molecule of all lymphoid and myeloid cells ( Scheid 
and Triglia, 1979; Sarmiento et.al., 1980 ). The antigen comprises a family of 
glycoproteins with broad heterogeneity in apparent molecular weight dependent 
upon cell types ( Omary, et.al., 1980; Woollett, et.al., 1985 ). Combining with other 
surface markers ( or the clusters of differentiation, CD ), it becomes possible to 
elaborate the diversity of B lymphocytes and their development.
2.2. Neoplasia
Almost all human cancers are derived from a single cell, i.e. monoclonal origin as 
suggested by the expression of a single Ig light chain ( Aisenberg and Block, 1976 ) 
and unique Ig-idiotype specificities ( Hamblin et.al., 1980 ). It is conceivable that 
they are, at least initially, relatively homogeneous in cell type characteristics which
are determined by the cell lineage and developmental states of the involved cells. 
However, distinct phenotypic features are often observed in malignant cells as the 
cells transformed from individual precursor cells may continue some limited 
differentiation. Malignancies in haematopoietic system share these features and have 
a broad range of potential 'target' cells as the system contains several diverse cell 
types.
Neoplasias of the haematopoietic system are believed to be a result of defective 
differentiation as well as an uncontrolled proliferation ( Caligaris-Cappio et.al., 
1984; Anderson et.al., 1984; Dighiero and Binet, 1987 ) when homeostatic control is 
disrupted by a malignant transformation. The outcome of such a disruption is the 
imbalanced accumulation of malignant cells of clonal origin and these cells are 
unable to differentiate past a certain stage of maturity, referred to as 'maturation 
arrest'.
Chronic lymphocytic leukaemia ( CLL ) was first described by Turk (1903). The 
CLL lymphocytes are characterized by their morphological features as small, resting 
cells together with surface phenotypic features defined by monoclonal antibody, 
lectins and erythrocyte resetting techniques. These characterizations also give rise to 
the classification of other leukaemias, namely, 'prolymphocytic leukaemia' ( PLL ), 
'hairy cell leukaemia' ( HCL ) and some types of lymphomas. The differences of 
these leukaemias will be described later.
The mechanisms of the malignancy are still obscure and often contradictory 
evidence is presented. Generally, however, it is believed that maturation arrest and 
uncontrolled proliferation are responsible for the neoplasia, either independently or 
together. It suggests that the leukaemia has a counterpart in the normal lymphocytes, 
i.e. arising from a normal population of haematopoietic cells, whose development is 
deterred by some external factors, such as the presence or absence of certain growth 
factors which impair the normal haematopoiesis, or internal factors such as genetic 
defects. Evidence is accumulating in supporting the 'normal counterpart' theory. 
CDS cluster ( Tl, Leul, T101 ) is a pan-T monoclonal antibody and is consistently 
found in most B-CLL cells ( Boumsell et.al., 1978; Wang et.al., 1980 ), therefore, 
confirmed the presence of dual B- and T-cell marker in CLL with heterologous 
anti-T sera. A small subpopulation, corresponding to about 2-5% of B cells in
lymph nodes, was found CD5 positive, together with characteristics of low slg and 
formation of rosettes with mouse erythrocytes ( Bofill et.al., 1985; Antin et.al., 1986 
), corresponding to the features of B-CLLs. Therefore, it was suggested that this 
subpopulation was the normal counterpart of the B-CLL lymphocyte. Brooks et.al. 
(1981) described a monoclonal antibody, FMC7, and showed that most of the B- 
CLL cells were negative whereas most B prolymphocytic leukaemic cell and hairy 
cell leukaemic cells, which are largely CDS", were positive. This finding leads to a 
hypothesis that the FMC7+ subpopulation could be the normal counterpart of both 
prolymphocytic and hairy cell leukaemias. However, the surface phenotype of the 
leukaemic cell is not necessarily matched to that of the target cell because the 
transformed individual precursor cells may still undergo some differentiation, 
developing distinct phenotypic features, i.e. there may be a partial maturational 
arrest. The phenotype of leukaemic cells reflects the lineage relationships of the 
target cell together with the developmental level at which the dominant subclone has 
been detained after its limited further development.
However, sometimes more is implied than just a block to normal differentiation 
or normal sequential gene expression. In both animals and man, there are two 
outstanding features in cancer cells that oncofoetal or foetal phase specific genes are 
expressed ( Alexander, 1972; Sheridan et.al., 1976 ) with the presence of many other 
parameters of cell structure and function, which is considered as a consequence of 
'gene derepression' ( Odell, 1977 ). As a result, the dominant subclones in the 
malignant cells may lack the sequential expression of membrane properties which 
would normally be anticipated in an activated proliferating progenitor cell with 
progressive maturation or, in the main, the neoplastic cells may present surface 
phenotypes with some distinct features associated with defective maturation or 
genetic bases.
The aim of this study is to exploit such distinct membrane properties by 
analysing the cell surface polypeptides and phenotypic heterogeneity, as a whole, of 
leukaemic lymphocytes. The correlations between some membrane proteins and 
possible implication of such correlations have been examined and discussed. By 
discovering the progressive expression of these surface receptors, it is attempted to 
understand certain relationships with respect to differentiation or maturation of the 
cells.
Biochemical methodology has been employed as a major approach to the project, 
in conjunction with immunological techniques, particularly the fluorescence 
activated cell sorter ( FACS ). Size exclusion high performance liquid 
chromatography ( HPLC ) has been developed to fulfill the project. Monoclonal 
antibody was used, in combination with HPLC, to identify specific surface receptors 
and to examine their interactions with other membrane components as well as 
possible cytoplasmic components.
2.3. Surface Markers of B Lymphocyte 
2.3.1. Immunoglobulins
Immunoglobulin molecules consist of two identical heavy chains ( H ) and two 
identical light chains ( L ). In higher vertebrates, there are five classes of H chains- 
a, 8, e,Vand /n, comprising five different classes of antibodies, IgA, IgD, IgE, IgG and 
IgM, respectively. There are two types of light chains, K. and .A . Combinations of 
different heavy and light chains not only generate five classes of antibodies but also a 
number of subclasses of IgG and IgA immunoglobulins.
Both heavy and light chains contain two segments of distinct compositions, a 
variable region at their amino-terminal ends and a constant region at the carboxyl- 
terminal ends. It is the variable regions of H and L chains that act as the antigen- 
binding site. The variability of the amino-acid sequence of the variable regions gives 
rise to the diversity of the antibody. These features have been demonstrated to have 
important genetic implications.
The study on genomic DNA shows that a single C gene segment encodes the constant 
( C ) region of an Ig chain but each heavy chain V region is coded for by three gene 
segments, V, J and D while light chain V region by V and J. The random combination 
of these variable region genes makes a substantial contribution to the antibody 
diversity.
The choice of the particular gene segments that encode the class of heavy chain 
produced is a commitment of the B cell differentiation, function and the order of the 
CH genes in the germ line. During B cell development or antigen challenge, there is a 
switch in the constant region of the genes from making one class of antibody to 
another. Synthesis of Ig u heavy chains is first detected in large, cycling cells known as 
'pre-B' cells. These proliferating cells lack Ig light chain and the synthesised u heavy 
chains remain in the cytoplasm. As the cells divide into small, non-proliferating or 
'resting' pre-B cells, the gene rearrangement of the Ig light chain loci initiates synthesis 
of complete IgM molecules, giving rise to small 'immature' or 'primary' B cells featured 
a low level surface IgM expression. These 'immature' B cells, then, depart from the
primary lymphoid organs-the bone marrow and circulate to the primary follicles of the 
peripheral or secondary lymphoid organs during which the heavy chain switching 
occures and results in the transcription and translation of other heavy chain isotypes. 
It has been found that, at this stage, the majority of the circulating B cells possess both 
surface IgM and IgD although surface IgG and IgA might be expressed along with 
slgM ( Abney et.al., 1978 ). These cells, capable of producing surface immunoglobulin, 
are regarded as 'mature' or 'immunocompetent' cells but remain in a resting and 
quiescent state undergoing constant re-circulation between the secondary lymphoid 
tissues unless these circulating cells are challenged by antigens.
Once the resting B cells are stimulated with antigen, they are triggered to undergo 
the antigen-dependent development and differentiate to either antibody-secreting 
plasma cells ( terminally differentiated B cells ) or to small 'memory' cells. During the 
B cell differentiation, surface Ig expression is changed to the production of secretory 
immunoglobulin and continuously switching of Ig isotype is simultaneous with the 
process, which is associated with the maturation of immunocompetent B cells 
expressing slgM and slgD via an immunoblast stage to plasma cells secreting low 
affinity IgM with the loss of slgD.
Neoplasia is generally monoclonal origin, i.e. developed from a single cell at any one 
of the preceding stages of differentiation of cells of the series. The typical slg profile 
found in CLL is s!gM+ s!gD+, with occasional other isotypes. The expression of slgG 
together with slgM and/or slgD was observed but its incidence and significance are 
controversial ( Stevenson, et.al., 1981; Kumararatne and Ling, 1983 ). The expression 
of slg on CLL cells is markedly reduced ( Digliero, G., 1980 ). CLL cells are found to 
contain some amounts of cytoplasmic Ig ( Han et.al., 1982 ). The cytoplasmic Ig may be 
IgM or IgM + IgD and may be associated with a more heterogeneous slg phenotype ( 
Han et.al., 1982 ). Interestingly, CLL lymphocytes which express slg weakly usually 
secrete free light chain either exclusively or in great excess over Ig in culture ( 
Hannam-Harris et.al., 1982 ). However, there are no conclusive associations between Ig 
phenotypes and particular lymphomas although excess free light chain secretion of CLL 
may indicate immaturity but the indication is not compelling because the phenomenon 
could be resulted from a sluggish response of H-chain synthesis in neoplastic state.
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2.3.2. CD45 Antigen
CD45 antigen is a group of high molecular weight glycoproteins, exclusively 
confined to cells of haematopoietic origin ( Scheid and Triglia, 1979 ). Various names 
are applied to this family, including B-200, T-200, Leukocyte Common Antigen and 
the mouse allotypic marker Ly-5. Recently, the antigen has been assigned with the 
cluster of differentiation number CD45 in the Third International Leucocyte Typing 
Conference ( McMichael et.al., 1987 ).
CD45 is one of the most abundant cell surface proteins in lymphocytes, comprising 
approximately 10% ( Williams and Barclay, 1985 ) of total cellular proteins. Several 
members of this family have been described and there are at least four forms detected 
by SDS-PAGE with apparent molecular weight ranging from 170KD to 240KD. The 
selective expression of individual members of the antigen is controlled in a cell-type- 
specific fashion that is conserved throughout the mammalian evolution ( Trowbridge, 
I.S., 1978; Newman et.al., 1984; Woollett et.al., 1985; Maddox et.al., 1985 ). B 
lymphocytes only express the highest molecular weight form of the antigen while 
thymocytes express the lowest ( see references above ). T lymphocytes exhibit a more 
complicated pattern of expression and, usually, a combination of several members of 
the family with the predominance of lower molecular weight forms depending upon 
cell subset ( Lefrancois and Bevan, 1984; Woollett et.al., 1985; Lefrancois and 
Goodman, 1987 ). Moreover, there are evidence showing that the different patterns of 
the CD45 expression can change upon cell activation. Recently, the gradual 
understanding of the molecular basis of the CD45 family has greatly facilitated the 
elucidation of the molecular diversity of the antigen and its heterogeneous expression.
Based on the nucleotide sequences of cDNA clones, the primary structures of rat and 
mouse CD45 molecules have been predicted. It has been found, by Northern blot 
analysis and SI mapping assay, that there are three different size classes of mouse 
CD45 mRNAs although the precise molecular basis for the heterogeneity of the CD45 
family is not yet fully understood. A complete amino acid sequence of a member of 
the human CD45 antigen deduced from cDNA sequences has recently been established 
( Streuli et.al., 1987 ).
Streuli et.al. (1987) deduced the complete amino acid sequence of a member of the 
human CD45 antigen from cDNA sequences and have shown that there are at least five 
different forms of CD45 mRNAs generated by a single human CD45 gene. Three 
cDNA clones, LCA.260, LCA.l and LCA.6/2, are isolated from human tonsil and SB 
cell line cDNA library and the LCA.260 and LCA.l sequences have extensive deletions 
relative to the LCA.6 sequence. Another human LCA cDNA clone, LCA.l 11, is the 
same as LCA.260 except for a few differences ascribable to polymorphism. The three 
distinct structures defined by the clones LCA.6, LCA.260/LCA.111, and LCA.l suggest 
that there are at least three different classes of human CD45 mRNAs.
By analysing a genomic DNA clone isolated from a human placental DNA library ( 
Lawn et.al., 1978 ), seven exons, tentatively called exons A, B, C, D, E, F and G, were 
located in this cloned genomic DNA. The comparison of the CD45 cDNAs and gene 
sequences has proven that the variable CD45 mRNA structures are generated by 
differential splicing of three exons, A, B and C. Therefore, a single human CD45 gene 
is responsible for multiple forms of mRNAs that encode proteins of different 
structures. These different mRNAs are generated by differential usage of three exons 
by alternative splicing. Each exon can be either included in or excluded from a CD45 
mRNA independently of the other two exons. In principle, the number of different 
forms of the CD45 mRNA and proteins can be up to eight. So far, there is no any 
convincing evidence suggesting differential usage of any other exons. Although the 
estimated number of the CD45 mRNA is eight, some of the different forms should 
have similar molecular weights because of the similar sizes of the three variable exons, 
together with the enormous sizes of the CD45 mRNAs and proteins. SDS-PAGE might 
not be able to distinguish some mRNAs and their products, which may account for the 
fact that only four different forms are seen by SDS-PAGE.
Intriguingly, exons A, B and C are expressed in a cell-type-specific fashion, B 
lymphocyte uses all three variable exons and expresses a member of CD45 antigen with 
the largest molecular weight; thymocyte splices between exons D and the exon for the 
leader sequence, deleting exons A, B and C and expresses the lowest molecular weight 
form of the CD45 while T lymphocyte appears to adopt a number of combinations and 
expresses several chains of CD45 with various molecular weights.
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The structure of the CD45 glycoproteins has been infered from the study of cDNA 
clones for human, mice and rats. All three species possess very similar structures. The 
mature protein is 1118-1304 amino acids long depending upon species and individual 
chains of CD45, the human CD45 is a protein of 1304 amino acids. The whole 
molecule is oriented in the membrane bilayer with the amino terminus pointing outside 
of the cell. Based on hydrophobicity analysis, the potential transmembrane region of 
the molecule is 22 amino acids long, located in amino acid positions 553-574 from the 
amino terminus. The extracellular domain has 552 residues and the large cytoplasmic 
domain has 707 residues. The extracellular domain possesses a signal sequence of 23 
hydrophobic amino acids at the beginning of the protein sequence, which is very likely 
the signal peptide for the transfer of the protein across the cellular membrane. 
Comparison between human, mice and rats CD45 sequences shows that the cytoplasmic 
domains are highly conserved with approximately 85% homology but the extracellular 
portion is less conserved with only about 33% homology except the signal peptide 
which is very well conserved ( about 90% homology ), as is the membrane-spanning 
peptide. In human, the extracellular domain of CD45 has an insertion of 161 amino 
acids near the NH2-terminus. The cysteine-rich sequences in the extracellular domain 
are highly conserved, which may suggest that higher-order structure, rather than the 
primary structure, is important for functions of the extracellular portion of the CD45 
molecules.
Both potential N- and O-linking sites are notably abundant in CD45 peptides, most 
of which are segregated within the extracellular domain. The O-linked glycosylation 
sites are probably encoded within the exon for the leader sequence and exons A-E 
found at the amino-terminal end of the molecule. In human CD45, the potential N- 
linked glycosylation sites on the extracellular domain are variable ( Streuli et.al., 1987 
), which is consistent with the observed molecular weight range of the antigen. It 
appears that most of the O-linked carbohydrates is located at the end of the amino 
terminus ( Barclay et.al., 1987 ) while the N-linked is distributed along the whole 
extracellular domain. The extensive glycosylation could play significant roles in the 
function of the antigen as the extracellular segment of the molecule lacks sequence 
conservation.
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There are two types of antibodies to CD45 antigen with respect to their specificities: 
antibodies that are reactive with common epitopes for all members of the CD45 family 
for a given species, and antibodies that recognize restricted epitopes which are 
designated as CD45R ( Cobbold et.al., 1987 ). In the light of the genetic basis of the 
CD45 family, the specificity diversity is likely to be generated through variable exon 
splicing. It is most likely that the common epitopes are coded for by exons common to 
all members while the restricted epitopes can be generated either by sequences encoded 
by the variable exons or by cell-type-specific modification, such as glycosylation, of 
the regions encoded by either variable or common exons.
The cell-type-specific expression of CD45 members suggests that the use of the 
variable exons must change in a programmed way during cell differentiation. In murine 
haematopoietic cell developmemt, CD45 ( Ly-5 ) is detected on the first recognizable 
committed B-cell precursor by monoclonal antibodies 14.8 ( Kincade et.al., 1981 ), 
RA3-6B2 ( Coffman, 1982 ) and 100C5 ( Dumont et.al., 1983 ). 14.8 recognizes 
restricted CD45 determinants, precipitating the higher molecular weight forms of the 
antigen. RA3-6B2 is one of the few anti-Ly-5 ( CD45 ) antibodies that identify only 
the B-cell-restricted determinants. However, events before the acquisition of Ly-5 ( 
CD45 ) are less certain. In B lineage lymphocytes, cells preceding the large pre-B cells 
are found to exhibit a phenotype of Lyb2+ and CD32+ but CD45" ( Holmes et.al., 1986
Interestingly, the expression of the CD45 family members appeares to change upon 
cell activation. In T cell, changes of CD45 expression have been demonstrated when 
cells are stimulated with either concanavalin A ( Con A ) or in a mixed lymphocyte 
reaction ( Lefrancois and Bevan, 1984 ). Evidence also shows that CD45 carbohydrate 
structures differ amongst leukocyte populations and both T and B cell CD45 
carbohydrate structures change upon activation ( Brown and Williams, 1982; Childs 
et.al., 1983; De Petris and Takacs, 1983; Lefrancois and Bevan, 1984; Lefrancois et.al., 
1985 ). T-cell clones have been found usage of variable exons dissimilar to those by 
peripheral T cells ( Lefrancois and Bevan, 1984; Lefrancois et.al., 1986; Lefrancois and 
Goodman, 1987 ).
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The tumour cells differ from normal B-cells in frequently expressing the T-cell 
forms of CD45 molecules, i.e. the lower chains of the antigen. It has been shown that 
chronic lymphocytic leukaemia ( CLL ) exhibits a broad spectrum of the expression 
combinations of CD45 members, ranging from CD45RA-predominant to CD45RO- 
predominant--typical of T-cell features ( Smith et.al., 1985; Roxburgh and Cooper, 
1987 ). Changes of CD45 expression in neoplastic cells ( Maddy et.al., 1989 ) have been 
documented when TPA is used to activate the cells. TPA is found capable of 
converging the CD45 expresson of B-CLL cells towards a CD45RO-predominant ( 
180KD ) state, i.e. acquisition of CD45 features similar to T lymphocytes.
2.3.3. Other Surface Markers
(1) CD5
Only a minor population of adult B cells express CDS antigen and this 67KD 
molecule was originally regarded as T cell marker ( OKT1, Leul ). However, most of 
the B-lineage CLL lymphocytes are CDS positive ( Royston et.al., 1980 ). CD5+ B-cells 
were first detected in the lymph nodes around the seventeenth week of gestation ( 
Bofill et.al., 1985 ) and then become evident in the primary follicles of the spleen, but 
are only occasionally observed in BM ( Bofill et.al., 1985; Caligaris-Cappio and 
Janossy, 1985 ). CD5 + B-cells are largely confined to peripheral lymphoid organs. The 
murine equivalent of this antigen is Ly-1 which has been established as a marker 
defining a distinct B cell lineage ( Hayakawa et.al., 1983). The fact that normal human 
B cells express mouse erythrocyte receptors ( MRBC, see below ) together with CDS 
suggests that they are probably identical populations or at least overlapping in the 
expression of two markers. Both MRBC+/CD5+ B cells and their murine counterparts 
share the features of slgM and slgD positive and of either or light chain. It has 
been proposed that MRBC+/CD5+ B cell population may represent a separate lineage 
observed at different stages of differentiation and may be the normal counterpart of 
B-CLL ( Dighiero and Binet, 1987 ). CDS-positive B cells appear to be associated with 
autoimmune disease ( Plater-Zyberk et.al., 1985 ).
(2) Common Acute Lymphoblast Leukaemia Antigen ( CALLA ) ( CD10 )
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This antigen was first defined by the monoclonal antibody J5 ( Ritz et.al., 1980 ) 
and is detected on 70% cells of acute lymphocytic leukaemia and on normal bone 
marrow cells which express Tdt and HLA-DR. The antigen is not present on normal 
peripheral blood lymphocytes and is considered as a marker of the B-committed 
progenitor and pre-B stages of development. The molecular weight of this antigen is 
98KD.
(3) CD19
The cluster of CD19 antibody contains B4, HD37, 4G7 and SJ25-C1, all of which 
recognize a B-lineage-restricted protein of apparent molecular weight of 95KD. The 
antigen appears at about the same time of immunoglobulin gene rearrangement or 
earlier and is expressed by majority of blood B cells, B cells within germinal centres. 
The antigen is retained throughout differentiation in the primary tissue until the 
plasma cell stage. CD19 is the only specific antigen which is expressed on B- 
progenitors and present until the terminal plasma cell stage.
Most B-cell malignancies are CD 19 positive, including B-cell precursor, CLL and 
most lymphomas. Evidence from phenotypes of cells of acute lymphoblastic leukaemias 
of non-T type suggests its expression proceeds cALL antigen ( CD10 ).
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(4) CD20
The antigen defined by the CD20 cluster of antibodies is a phosphorylated protein of 
35KD. The prototype antibody in this cluster is Bl ( Stashenko et.al., 1980 ). The 
antigen is demonstrated to be essentially restricted to the B-lineage cells, although there 
is disagreement about whether it is found on dendritic cells. CD20 antigen is strongly 
expressed in B cells as detected by immunoflurescent assays and its expression may 
quantitatively vary with cell maturation ( Gordon et.al., 1984 ) and tends to be lost 
upon cell activation.
(5) CD21
CD21 is a single chain protein of apparent molecular weight 140KD when reduced ( 
Lida et.al., 1983 ) and 120KD when not reduced. The prototype antibody is B2 ( 
Nadler et.al., 1981 ). The antibodies of this cluster ( B2, BL-13 and HB5 ) stain some 
T-ALL cells and follicular dendritic cells strongly, but are otherwise considered as 
restricted to B cells. B cells in the mantle zone stain strongly and B cells in lymphoid 
tissue are found to express significantly higher CD21 than B cells in blood. CLL B cells 
are positive although never strong with respect to immunoflurescence. The expression 
of CD21 appears to be later in B cell differentiation than that of CD20 antigen and is 
present throughout the B lineage from the pre-B stage. The antigen disappears when B 
cells are activated ( Boyd et.al., 1985 ).
CD21 has been found to serve as receptors both for Epstein-Barr virus and for the 
complement component C3d ( Lida et.al., 1983; Shaw et.al., 1986 ). Some anti-CD21 
antibodies are capable of inducing a strong proliferative response in the presence of T 
cells ( Nemerow et.al., 1985 ).
(6) CD22
This antigen is defined by antibodies HD6, HD39, 29.110 and SHCL-1 etc. ( Nadler, 
L.M., 1986 ). The immunoprecipitation shows two diffuse bands of apparent molecular 
weights of 130KD and 140KD, both highly glycosylated. The molecular weights of 
both bands on SDS-PAGE are dependent on reduction and non-reduction of the
15
samples. Majority of blood B cells ( 75% ) bear the antigen but tissue B cells and 
malignant cells show complicated patterns. Some pre-B lines are positive as are a 
proportion of ALL cells and the antigen is present in the cytoplasm in some ALLs and 
early B-cell precursors ( Dorken et.al., 1987 ) although the later are at a more advanced 
differentiational level. CD22 is expressed in about 25% CLL lymphocytes while most 
lymphomas and hairy cell leukaemias react with anti-CD22 antibody. The same as 
CD21, this antigen is lost when cells are activated. The expression and distribution of 
this antigen present a complicated pattern, therefore, a direct correlation between its 
expression and cell differentiation is less compelling.
(7) MHC Antigens
MHC antigens are expressed on the cells of all higher vertebrates. The two principal 
classes of the MHC antigens are Class I and Class II, comprising a set of cell-surface 
glycoproteins. MHC Class I consists of a 45KD glycoprotein transversing the plasma 
membrane. The antigen is ubiquitously expressed on the surface of almost all nucleated 
somatic cells and of highly polymorphic characteristics. A small protein of 11.5K.D, 
132-microglobulin, is noncovalently associated with the extracellular domain of the 
MHC Class I molecule. MHC Class II antigen is another highly polymorphic cell- 
surface glycoproteins but has a much narrower tissue distribution, being expressed by 
most B cells, some T cells, some macrophages and macrophagelike cells. The MHC 
Class II glycoproteins are composed of two non-covalently bonded polypeptides  
an a chain of 35KD and a 13 chain of 28KD. Both chains are oriented transmembrane 
bilayer.
(8) Mouse Erythrocyte Receptors
Receptors for mouse red cells ( MRBC ) are detected on small proportion of B cells 
in the bone marrow, blood and peripheral lymphoid organs ( Stathopoulos and Elliott, 
1974; Gupta et.al., 1976 ) but not on monocytes, granulocytes or T cells. In the blood 
and tonsils, MRBC+ cells usually also express both slgM and slgD, but in bone marrow 
and foetal liver, cells which are MRBC positive do not exhibit any surface Ig ( Kagan 
et.al., 1979 ). The MRBC receptor, therefore, is regarded as a marker of an early stage 
of B cell development, expressing with or before the appearence of cytoplasmic u chain
16
and conserving up to the immuno-competent stage. Most B-CLL is MRBC positive but 
PLL and HCL are found unreactive with MRBC.
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3. Size Exclusion High Performance Liquid Chromatography
3.1. Principle
Size exclusion liquid chromatography ( SEC ) ( Porath and Flodin, 1959 ) is also 
often referred to as gel chromatography, gel filtration and gel permeation 
chromatography. The technique, described in detail by Yau et.al. (1979), is a potent 
method for the separation and characterisation of proteins, enzymers and other 
macromolecular substances. Recently, as the improvement of packings and the packing 
techniques, the size exclusion LC has been widely applied to a broad variety of sample 
types for different separation problems.
Size exclusion chromatography ( SEC ) separates molecules according to their 
effective size in solution. Solute size in SEC is determined by molecular hydrodynamic 
radius which is the radius of gyration of the solute in the mobile phase. Sample 
molecules of differnt hydrodynamic radii are retarded by a porous packing particle to 
different extents. A mixture of sample molecules passes through the packing particles; 
if some of the molecules are too big to enter the pores, they are totally excluded from 
the porous passages and eluted directly through the column along with the mobile 
phase, appearing first in the chromatogram. Those small molecules which are able to 
permeate almost the entire particle and likely to go through the whole porous channel 
will be retained the most and eluted most slowly. Solutes of intermediate sizes are less 
able to access to the walls of the pores because of steric hindrance and retained less by 
the pores. The extent they are retarded by the packing is dependent on their relative 
sizes. As a result, in SEC separation big molecules have shorter retention and come out 
earlier than small ones. Conceivably, most of the sampling molecules will be eluted 
before solvent molecules which are usually very small and entirely permeate the pores. 
Therefore, the retention of solvent molecules on the column, tO, is the time for mobile 
phase molecules to move from one end of the column to the other.
Theoretically, separation in SEC is strictly based on the molecular size. Effects from 
other mechanisms, such as adsorption, are usually undesirable and minimum and can be 



















Fig 1. Hypothetical calibration plot of a size exclusion column to 
show the fractionation characteristics. Molecules bigger than 
10^ or smaller than 10 will be eluted as single peaks C or 
F, respectively. Only molecules of proper sizes ( within the 
range of selective permeation ) are fractionated and 
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Fig 2
_2. Selection of the proper size exclusion packing for the optimum separation of two 
adjacent bands. T0 is the total exclusion time and Tt is the total permeation. Columns A, 
B and C have different characteristics of selective permeations. The retention distances 
( AT ) of two molecules, 10 and 10 , respectively, by three columns are 
ATg > ATA > AT£. See the text for details. The figure is adopted from Snyder and 
Kirkland (1979) with modifications abcde
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3.2. General Consideration of the Separation 
3.2.1. Calibration Plots
A calibration plot is a graph of sample molecular size versus relative retention for a 
particular packing, which reflects the ability of the packing or the column to separate 
different molecules on the basis of their molecular weights. Fig 1 shows a hypothetical 
plot of sample molecular weight versus retention time Tr. Point A is a total exclusion 
point where molecules too large to enter the pores of the packings are entirely 
excluded, eluted as a single band at the front of the chromatogram with a retention 
time of TQ. Molecules with smaller molecular weight than B, the point for total 
permeation, would permeate the packing particles totally and will be retained for a 
time corresponding to retention time Tt. Molecules with molecular weight between A 
and B will gradually spend longer time in the column as their size decreasing and the 
retention time ( volume ) points construct a plot, the calibration plot. The molecular 
weight range between the total exclusion and the total permeation is called the 
fractionation range of a column where a column performs best.
It is conceivable that in a certain molecular weight range, a wider fractionation 
range would yield better separation. Although there are several theoretical parameters 
for the efficency of separation, the measuring of band center spacing is probably the 
most straightforward; the further apart the two bands, the better their separation is. 
Compounds are separated best when their molecular weights are within the column 
fractionation range. Fig 2 shows calibration plots of three columns with different 
packings, compounds a and b, with molecular weights of 10^ and 10^, respectively, are 
separated on these three columns, A, B and C. For packings A and C, both compounds 
are near either exclusion limits or permeation limits of both columns, respectively, so 
that the spacing between the bands is small, i.e. the differences of the retention times, 
TA and TB, are small and the separation is poor. With column B, the size of the 
interested compounds falls within the fractionation range and the resultant band center 
spacing, TC, is large. Therefore, the separation is improved.
Choice of an appropriate column, or pore size, is the key issue when embarking an 
analysis of proteins. Once the optimum pore size is determined, satisfactory
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resolutioncan be achieved by combining two or more columns with the same pore size. 
Although an appropriate calibration plot for a given packing is usually provided by the 
manufacturer with the column, it is desirable for the individual columns to be tested 
and calibrated under experimental conditions.
3.2.2. Mobile Phases
The major consideration of the mobile phase choice is its ability to dissolve the 
sample molecules and low viscosity at the operation temperature. In SEC, the resolution 
is usually not affected by the mobile phase.
Compatibility with the column packing is another consideration for the mobile 
phase. With the silica-based packings, a wide selection of solvents can be used but pH 
must be maintained within the range of 2-8.5 for aqueous solvents because dissolution 
of siliceous particles will occure beyond this pH range.
Sometimes, interactions ( i.e. adsorption ) between the sample molecules and the 
packing surface can be a problem and it is the case particularly with silica-based 
packings where retention of solute molecules, in addition to the desired size exclusion, 
is often observed. Elimination of such unwanted retention can be achieved by using a 
mobile phase that is much more strongly competitive for the active sites of adsorption 
than the solutes. Adsorption can be judged by the elution of sample molecules after the 
total permeation volume ( Vo ). Band tailing may sometimes be an indication but is not 
reliable. Appropriate ionic strength is effective in eliminating adsorption on silica 
substrates in aqueous medium and normally 0.1-0.5 M is recommended. However, 
caution must be excercised in selecting the mobile phase ionic strength as the effect on 
retention is complicated and often short of prediction. Careful examination is needed 
for individual systems and samples.
In the aqueous mobile phase, the type of anion used has a significant influence on 
undesired adsorption of solute molecules to siliceous surface during chromatography, 
by probably the effect of counter-ions. Phosphate and sulfate seem to be more 
effective than monovalent anions, such as chloride. With an unmodified silica packing, 
a weakly acidic ion exchange phenomenon may occure at pH > 4-5 because the acidic
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SiOH residues of the silica can interact with charged groups of the solutes. Therefore, a 
surface-modified silica packing is much preferred and, even so, the mobile phase 
should still be adjusted to obtain the optimum separation.
3.2.3. Temperature
For most of the biological analysis of SEC, column operation at ambient temperature 
should be satifactory. However, for samples of low solubility or mobile phase with high 
viscosity, temperature may need to be increased. Generally speaking, column efficiency 
and resolution can be improved at above-ambient temperature by the lowering of the 
viscosity of the aqueous mobile phase, but the sample molecules must be sufficiently 
stable under such a temperature.
With most of low-concentration detergent extracts of membrane proteins, HPLC 
fractionation under room temperature is able to generate satisfactory resoluiton with 
convenience.
3.2.4. Sample Size
Both the sample volume loaded onto a column and the sample weight in the volume 
can affect the final resolution which can be theoretically predicted. Too big a volume 
of sample results in band broadening, while overloaded sample weight causes 
deteriorating of column efficiency, resulting in asymetrical bands. Typically, sample 
volume in the 25-250 ul range is recommended for high efficiency columns. As a 
general rule, larger volumes of more dilute sample solution rather than smaller volumes 
of more concentrated samples are preferred for chromatographic analysis.
In the separation of membrane protein preparations, sample size should be well 
controlled to avoid poor resolution and low efficiency, because of the use of detergent 
and of macromolecules involved, which may present higher viscosity. A special caution 
must be taken that viscosity decreases sharply upon drop of temperature. Empirically, 
the sample solution charged should not have a viscosity greater than twice that of the 
mobile phase.
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Size exclusion chromatography is capable of delivering powerful initial separation 
and an overall picture of sample composition when a proper combination of the 
operation parameters is achieved. Among many advantages, those distinct ones are 
listed below:
(1). SEC is one of the gentlest method in protein separation, without involvement of 
any high-energy forces or chemical interactions during the process. This is essential 
particularly when higher structures of proteins are of importance, such as in the 
separation of membrane surface receptors. This is also true when non-covalent 
interactions of proteins are concerned. As SEC is a gentle process, samples do not 
suffer from loss or reaction, therefore, recovery is usually high.
(2). With the help of calibration plots, molecular weights of unknown components can 
be easily worked out. Therefore, SEC is particularly useful for unknown samples that a 
single run is normally able to provide sufficient information on the molecular weight 
distribution and the composition. This technique is potent for an exploitory 
investigation.
(3). As the separation usually falls within the fractionation range, the retention of any 
known molecules is predictable, which is characteristic of SEC, and saves time when 
collection of only interested fractions is sufficient. And also, it is possible that a series 
of injections of different samples can be carried out with a proper time interval 
whereas without risking to overlap one chromatogram with another. Under the same 
principle, repeated loading of the same sample at predetermined times can make 
collection of big amount of a particular fraction possible.
(4). The study of protein interactions can be facilitated by the SEC, especially the in 
vitro induction of such complexes by using specific agents, i.e. antibody. Because of its 
gentle nature of the technique, such complexes should stay complexed during 
separation and their retentions are predictable under the basis of calibration plots.
(5). With the modern HPLC, the column packing does not tend to accumulate strongly 
retained compounds and the columns usually do not degrade and they perform 
reproducibly over a long period.
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CHAPTER 2. GENERAL ASPECTS OF METHODS AND MATERIALS
All chemicals and reagents used in this study were obtained from Sigma, BDH, 
Pharmacia and Fisons unless otherwise stated. 'Analar' grade was selected for most 
of the purpose. % composition refers to volume/volume.
1. Preparation of the Cells
1.1. Leukaemic Lymphocytes
Freshly collected blood from leukaemic patients was loaded on pre-warmed ( 20° 
C ) Ficoll-Hypaque ( Pharmacia ) and centrifuged at 800 g for 20 min. The 
lymphocytes were partitioned and harvested from the interface with a thin pipette. 
The cells, then, were washed free of plasma and platelets in an isotonic HEPES 
buffer consisting of 133 mM NaCl, 1.3 mM KC1 buffered to pH 7.4 with 10 mM 
HEPES ( RBC ) and the cells were transfered to the similar buffer but with 5 mM 
MgCl2 and 2 mM CaCl2 ( WBC ) pH 7.4, prior to lactoperoxidase-catalysed surface 
protein iodination. For the antibody treatment of intact cells or capping assay, the 
cells were washed with RPMI1640 medium supplemented with 2% Foetal calf serum 
( FCS ). The viability was routinely > 95% by acridine orange/ethidium bromide 
staining ( Parks et.al., 1979 )
1.2. Normal Lymphocytes
Normal lymphocytes were prepared from tonsils freshly obtained after 
tonsilectomy:
A. The tonsil lymphatic tissue was scraped out with a scalpal blade and suspended in 
RBC pH 7.4 buffer containing 50 U/ml pencillin and 50 ug/ml streptomycin ( Flow 
Lab. ). Cell clumps were dispersed by repeated passage through a syringe without a 
needle and the suspension left in room temperature for 20 min to allow the 
settlement of large particles. This procedure can be repeated until a clump-free 
supernatant was produced. The cells were washed three times in the same buffer 
until the supernatant became clear.
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B. Dead cells were removed on prewarmed Ficoll-Hypaque ( 20° C ) for 20 min at 
800 g ( Davidson and Parish, 1975 ). Viable mononuclear cells were collected from 
the interface and given two washes at 20° C to get rid of residual Ficoll 
contamination.
C. Monocytes were depleted by incubating the cells on glass Petri dishes at 37° C 
for 1 hour in RPMI1640 supplemented with 10% human serum, 50 U/ml penicillin 
and 50 ug/ml streptomycin at the concentration of IxlO7 cells/ml. Non-adherent 
cells were collected , washed with WBC buffer pH 7.4 and resuspended in 
RPMI1640-10% PCS medium containing 0.1% NaN3 and 50 U/ml penicillin + 50 
ug/ml streptomycin at approximately 2xl07/ml.
D. T lymphocytes were removed by resetting with neuraminidase-treated sheep 
erythrocytes ( SRBC ). A 10% haematocrit of SRBC ( about 3xl09/ml ) was washed 
twice with the RBC pH 7.4 buffer and pelleted by centrifugation at 1000 g and 
resuspended in 3 ml WBC buffer pH 7.4. 100 ul neuraminidase ( Vibrio Comma, 
Behringwerke AG, Marburg, liu/ml ) was added, and the suspension incubated at 
37° C for 20 min. After being washed twice in WBC buffer pH 7.4, the cells were 
resuspended in 15 ml RPMI1640 containing 10% PCS, 0.1% NaN3 and 50 U/ml 
pennicillin and 50 ug/ml streptomycin at about IxlO^/ml. 5 ml lymphocyte 
suspension ( 2xl07 ) was mixed with 5 ml SRBC suspension ( 1x10^ ), gassed with 
10% CO2 -in-air and centrifuged at 400 g for 5 min to allow the cells to settle down. 
The mixture was left on ice overnight. The pellet was then gently dispersed and 
resuspended and loaded over Ficoll-Hypaque, centrifuged at 400 g for 30 min to 
remove the rosetted T cells.
E. The cells in the interface were collected and washed in the WBC buffer pH 7.4 
twice. The purified B lymphocytes were checked for T cell contamination and 
viability by using monoclonal antibody to T-cell markers and acridine 
orange/ethidiium bromide staining, respectively. The T cell contamination was 
routinely less than 5%. The viability was > 95%.
2. Surface Labelling of Lymphocytes
31
2.1. lodination by Lactooeroxidase Catalysis
Cells were suspended in 0.9 ml ice-cold WBC buffer pH 7.4 with cell numbers up 
to 1.5xl08 . 20 ul 0.5 M glucose, 5 ul 0.1 mM K 127 I and 0.06 unit glucose oxidase ( 
Aspergillus niger  Sigma ) were added into the cell suspension at 4° C. 1.5 units 
lactoperoxidase ( Bovine w7&--Sigma ) was added followed immediately by the 
addition of 100 uC7 Na^5j ( Amersham ). The cell suspension was immediately 
incubated in 37° C water bath for 20 min. The cells were then washed twice with 
ice-cold WBC buffer pH 7.4 containing 5 mM K^l, to remove unbound iodine, 
once with RBC buffer pH 7.4 and then resuspended in 200 ul RBC buffer pH 7.4.
2.2. Tritiation of Surface Glvcoproteins
The tritiation method employed in this study was of the neuraminidase/galactose 
oxidase treatment based on Gahmberg and Hakomori ( 1973 ). To 5-8x10? cells in 1 
ml WBC buffer pH 7.4 were added 25 ul neuraminidase and 50 ul galactose oxidase 
and the cell suspension was incubated at 37° C for 20 min. The cells were pelleted 
and washed twice in WBC buffer pH 7.4, once in WBC buffer pH 8.0 and 
resuspended in 1 ml WBC buffer pH 8.0. The cells were then incubated at 20° C for 
10 min with 2 mCf tritiated sodium borohydride. Unbound tritium was washed away 
with WBC buffer pH 7.4, then RBC buffer pH 7.4. The tritiated cells were 
suspended in 200 ul RBC buffer pH 7.4.
3. Triton X-100 Extraction of Cells
200 ul cell suspension was added with an equal volume of Triton X-100 
extraction solution consisting of 1% Triton X-100 ( Sigma ), 1 mM PMSF, 0.5 TIU 
aprotinine, 1 mM EDTA and 5 mM iodocetomide in RBC buffer pH 7.4. 
lodocetamide was present in the Triton X-100 extraction medium to prevent 
formation of artifactual disulfide bonds. After being on ice for 10 min, insoluble 
material was spun off at 2000 rpm ( 900 g ) for 10 min.
4. Size Exclusion Chromatography
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The description of the SE-HPLC technique will be detailed in Chapter 4. 
5. Gel Electrophoresis and Protein Staining 
5.1. SDS-PAGE
The HPLC fractions were prepared for SDS-PAGE by adding an equal volume of 
SDS sampling buffer and dithiothrietol ( DTT ) to 100-175 ul fraction at a final 
concentration of 50 mM and the mixture was heated to boiling for 4 min.
One dimensional SDS-PAGE in the discontinuous buffer system of Laemmli 
(1970) was used for the separation of the proteins. The slab gel apparatus was 
constructed as described by Studier (1973). The polyacrylamide gels ( 150 mm X 140 
mm ) were cast between two glass plates ( 180 mm X 180 mm ), separated by 1.5 
mm thick perspex spacers. The plates and spacers were clamped together by metal 
spring clips and sealed on three sides with 1% agrose. A perspex sample comb was 
used to produce 16 sample wells, each 6 mm wide, 15 mm deep and 3 mm apart in 
a 10 mm length stacking gel.
5.1.1. The Fomular of the SDS-PAGE solutions 
Acrylamide Stock Solution ( 23% )
30 g Acrylamide ( BDH )
0.8 g N,N'-Methylene Bisacrylamide ( BDH )
Add 100 ml H2O
If the solution is MADE UP to 100 ml, according to the following recipe, the 
concentration of the gradient running gel will be 8-15%.
Running Gel Buffer
19.2 g Trizma Crystals, pH 8.7 ( Sigma )   1.5 M Tris
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0.4 g SDS ( BDH )— — - — ------ —— —-- 0.8% (W/V)
Adjust pH to 8.8 with HCI , make up to 100 ml
Stacking Gel Buffer Stock Solution
6.06 g Tris
0.4 g SDS
Adjust pH to 6.8 with HCI, make up to 100 ml




Make up to 1000 ml
10% Ammonium Persulphate ( APS ) 
SDS Sampling Buffer
0.125 M Tris-HCL ( pH 6.8 )
20% ( W/V ) SDS
30% Glycerol
0.002% ( W/V ) Bromophenol Blue
ImM EDTA
6-11.5% Gradient Running Gel Solution
6% (ml) 11.5%
Acrylamide Stock Sol. 4.0 7.5




TEMED 5 ul 5 ul 
Stacking Gel Solution
Acrylamide stock solution 3.3 ml





Running Gel Buffer 2 ml 
H2O 6 ml
5.1.2. The polvacrvlamide gel solution and the buffer are described as follows:
Three different concentrations of the running gels were used in this study 
depending on requirements. Running gels of 15% and 8-15% or 6-11.5% linear 
gradients of acrylamide were polymerized by the addition of ammonium persulfate 
and N,N,N',N'-tetramethylethylene diamine ( TEMED ). The running gel solutions 
with each concentration were prepared separately and placed in gradient-forming 
chambers. Using a peristatic pumping system, the gradient gel solutions were mixed 
and directed between the glass plates. The gel top should be adjusted to horizontal, 
and a layer of 10 X diluted running gel buffer was layered carefully on the gel 
surface and, usually, the polymerized gels were stored away in a cold room 
overnight for a complete polymerization.
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Before use, the overlaying solution was removed with a syringe and the gel 
surface was washed once with stacking gel solution lacking TEMED. The stacking 
gel ( 4% acrylamide ) was poured onto the running gel and the comb inserted. 
Within about 20 min, the stacking gel polymerized and the comb and the lower 
spacer were removed. The gels then were affixed to a standard electrophoresis tank 
filled with electrode buffers. Samples were loaded on with a 100 ul Hamilton 
syringe. For big samples, they could be introduced in two loadings. The first loading 
was usually 110 ul and was electrophoresed for a while at a high current of 60 mA 
to allow the sample to go into the stacking gel and then the rest of the sample was 
introduced. It is preferable to run the samples at a high current in the stacking gel 
to avoid diffusing until the bromophenol blue dye front reached the running gel 
when the current was lowered down to 45 mA. Running time was approximately 4 
hours.
5.2. Fixation and Staining of Proteins
After electrophoresis, proteins were visualised either by Coomassie Blue or Silver 
staining.
A. Coomassie Blue Staining: proteins on the gels were fixed and stained with 0.025% 
( W/V ) Coomassie Brilliant Blue R250 ( Sigma ) in acetic acid : methanol : water ( 
10:45:45 ) solution overnight at room temperature and destained with acetic acid : 
methanol : water ( 10:20:70 ) for approximately four hours at 50° C.
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B. Silver Staining: gels were fixed for 8 hours in acetic acid: methanol: water ( 2:5:13 
) solution and rinsed in distilled water for 1 hour with at least one change of water. 
The gels were then soaked in 7 ug/ml dithiothreitol ( DTT ) solution in water for 2 
hours with continuous agitation, transferred into 0.15% silver nitrate without rinse, 
incubated for two hours. After being rinsed rapidly twice with water, the silver 
stained gels were developed with 100 ul of 40% formaldehyde in 200 ml of 3% 
potassium carbonate under continuous agitation. As the image was appearing and at 
an appropriate stage of the development, half of the developing solution was poured 
off and 10 ml of 2.3 M citric acid put in to stop the reaction. The stopping 
procedure should be carried on for at least 30 min. The gels could be either stored 
in distilled water for a short period or vacuum-dried between two sheets of 
cellophane ( Bio-Rad Ltd ). The dried gels were presented as a transparent matrix.
6. Fluorography
Radioactive-labelled molecules on the gels were detected by autoradiography or 
fluorography. Gels of iodinated proteins were exposed to pre-flashed X-ray film ( 
Kodak X-Omat H Film ) or higher sensitivity Hyper film-MP ( Amersham ), both 
backed with an intensifying screen ( Ilford Fast Tungstate ) in a metal cassette at - 
70° C for periods of up to five weeks. Gels containing tritiated materials, after 
being fixed and stained , were rinsed for 15 min in distilled water and incubated in 
Autofluor ( National Diagnostics, US ) for 1 hour. Gels were vacuum-dried onto 
Whatman No. 17 filter paper at 60° C. Autofluor-processed gels can not be dried on 
cellophane sheets. Dry gels were exposed to pre-flashed X-ray films backed with an 
intensifying screen, at -70° C.
Exposed films were developed in Kodak LX 24 developer at 5.6 X dilution for 4 
min at room temperature.
7. Antibody-Induced Capping of CLL Cells
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The lateral movements of cell surface antigens of B-CLL were investigated. 
IxlO8 cells suspended in 1 ml 10% FCS-RPMI1640 medium containing 50 U/ml 
penicillin and 50 ug/ml streptomycin ( Flow Lab ) were reacted with monoclonal 
antibody, incubated on ice for 50 min or at room temperature for 15 min. The cells 
were washed twice with ice-cold phosphate buffer saline ( PBS ) pH 7.4 and were 
further incubated with goat anti-mouse Ig-FITC ( F(ab>2 fragments ) in 37° C for 
various periods of up to 24 hours with continuous rotation. Cells without treatment 
of the first antibody were cultured with goat anti-mouse Ig F(ab>2-FITC as a 
control. Cells were washed and resuspended in WBC buffer pH 7.4.
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CHAPTER 3. STUDY OF TRITON X-100 EXTRACTION 
1. Introduction
Before embarking upon a solubilization procedure, two questions must be considered: 
the first is how effective is the solubilization and the second is how the activity and 
function of the solubilized proteins are affected by the detergent employed during the 
procedure. The criterion of solubility is, by its nature, operational and really depends 
upon the requirement of the subsequent analysis. The most commonly quoted criterion is 
the retention of a protein or activity of a protein in the supernatant after sedimentation 
at 1.05x10 g for 1 hour with reference to the density of the medium. In this study, the 
solubility of proteins and protein complexes is defined at the operational way of 
performing the HPLC size exclusion column, i.e. supernatant of centrifugation under 
minimum gravity which sediments materials unapplicable to a HPLC column.
The choice of an appropriate detergent is probably the most complex issue as no 
single detergent has ever emerged to be ideal for all purposes. Triton has been found to 
solubilize many ligand-binding proteins with the retention of functions ( Strauss et.al., 
1979 ). Triton X-100 usually does not appear to induce conformational changes in 
proteins leading to loss of their biological properties( Dorken and Koehler, 1961; 
Burkhard and Stolzenberg, 1972; Cuatrecasas, P., 1972; Meunier et.al., 1972; Umbreit 
and Strominger, 1973; Simons et.al., 1973; Rubin and Tzagoloff, 1973 ). As Triton X-100 
appears to be very inefficient in breaking protein-protein interactions, most proteins 
preserve their quaternary structures in the presence of high concentrations of Triton X- 
100 ( Helenius and Simons, 1972; Snary et.al., 1974; Crumpton and Hayman, 1974 ). 
From these points, Triton X-100 is suitable for this study.
This chapter explores the characteristics of Triton X-100 solubilization of lymphocyte 
membrane proteins. The effectiveness of the detergent and its concentration are carefully 
examined. In comparison, some other non-ionic detergents, including Brij96 and Brij99, 
are also under investigation.
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^-Materials and Methods
Cell surface proteins were either radioiodinated or tritiated as stated in Chapter 2. 
Contaminating erythrocytes were removed as follows: cells were pelleted in WBC buffer 
pH 7.4, 1 ml lOx diluted WBC buffer pH 7.4 was added to the pellet and the cells were 
immediately dispersed and left on ice for 20 seconds. The cell suspension was quickly 
transferred to 10 ml normal concentration WBC pH 7.4 buffer. The cells were then 
pelleted and resuspended in the same buffer. This procedure can be repeated as 
necessary. Normally 80-90% of the white cells were viable by acridine orange/ethidium 
bromide staining after this treatment.
The effectiveness of Triton X-100 extraction was investigated as illustrated in Table
o1. The lodmated cells were resuspended in RBC buffer pH 7.4 at 2x10 per ml. A 
volume of the suspension was mixed with an equal volume of Triton X-100 detergent 
solution with a concentration of twice the final one, and incubated on ice for 10 min. 
The cells were then centrifuged at 1000 g for 10 min. The supernatants were applied for 
analysis on 15% polyacrylamide SDS gels after reduced with 50 mM DTT.
The Triton X-100 insoluble pellets were subjected to further extractions. They were 
dispersed and washed twice in Triton X-100 extraction medium of the appropriate 
concentration to minimize protein contamination from the supernatants. The pellets were 
then suspended in 100 ul SDS extraction medium with an addition of 10 ul DNAase I to 
digest the DNA released from the nuclei. The mixture was incubated at room 
temperature for 60 min. EDTA, PMSF and iodocetamide were present to prohibit 
proteolysis. The insoluble matter was spun out and the supernatant was subjected to 
SDS-PAGE analysis on 15% polyacrylamide gels.
Here the presence of DNAase I also serves to destabilize F-actin filaments, thereby 
loosening the actin filaments, and to release any trapped materials ( Hitchlock et.al., 
1976; Blikstad et.al., 1978 ).
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XabjeJL The solubilisation of membrane proteins by 0.025% Triton X-100









1 vol 1 vol
1 vol
1 vol
1 vol 1vol 1 vol
Ivol
1 vol 2 vol Ivol
(1) Incubation time: 10 min
(2) TX-IOO(V) / cell(V) = 2 / I, 10 min incubation
(3) Incubation time: 30 min
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3. Results
0.01% Triton X-100 extracted virtually nothing as shown by the autoradiograph ( Fig 
1 ) and the Coomassie Blue stained gel ( Fig 5 ). The cells after the extraction were still 
intact as seen by optical microscopy although more fragile when washed. A further 
solubilization of the cell pellet with 0.5% Triton X-100 resulted in the identical bands as 
those cells extracted directly by 0.5% Triton X-100.
0.05% was a turning point for the solubilization ( Fig 1 and Fig 5 ). It was able to 
solubilize all of the components which 0.5% does ( Fig 1 ). But the extraction was 
incomplete and the re-extraction of the pellets yielded more of the same components. 
Above 0.1% Triton X-100, no significant increase of the solubilization was observed. A 
43KD iodinated component, which was one of the predominant bands in the extract, was 
effectively extracted by 0.5% Triton X-100 but a significant amount was still left in the 
insoluble fractions ( Fig 2 ).
As 0.05% was found to be the turning point, 0.025% Triton was tested under different 
conditions as illustrated in Table I to examine the solubilization in detail. Fig 3 shows 
that 0.025% Triton X-100 failed to release the membrane proteins as nearly few proteins 
were detected by the Coomassie Blue staining and the autoradiographs. The gels only 
revealed a minor amount of surface membrane proteins in the supernatant, implying that 
the cell membrane was not broken up by the Triton which was confirmed by 
microscopic examination. It was conceivable that the inability of 0.025% Triton X-100 to 
break down the membrane bilayer may be due to insufficient free Triton X-100 
molecules to disrupt membrane lipids. Therefore, an experiment was conducted to 
examine the effect of the ratio of Triton to cell numbers at 0.025% concentration. 
Radiolabelled-cell suspension, split into two equal parts, was treated with Triton X-100 
at a final concentration of 0.025% but one part was at cell suspension : Triton=l:l ( v/v ) 
while another one at cell suspension : Triton=l:2 ( v/v ) ( Table 1 ). The mixtures were 
incubated on ice for 10 min under identical conditions. The autoradiographs showed no 
significant differences between the two treatments. However, if the 0.025% Triton X- 
100 cell suspension ( cell suspension : TX-100=1:1 ) was incubated for a period of 30 
min, three times of the normal incubation, it was found that protein solubilization was 
markedly increased and higher molecular weight components were released as shown by 
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Fig 1. Solubilization of I radiolabelled B-CLL cell membrane proteins by a series of
Triton X-100 concentrations. The extracts were analysed by SDS-PAGE on a 
\5% polyacrylamide gel. The fluorography was recorded on Kodak X-ray films. 
Human erythrocyte membrane proteins were used as molecular weight markers.
Fig 2. I radiolabelled materials of Triton X-100 insoluble pellets. Insoluble pellets 
after solubilization with different Triton X-100 concentrations ( the bottom 









Fig 3. Solubilization of I radiolabelled membrane proteins by 0.025% Triton X-100 
under various conditions. (I) 10 min incubation (2) 0.025% TX-100, 10 min re- 
extraction of (1) (3) TX-IOO(V) : cell(V) = 2 : 1, 10 min incubation (4) 30 min 
incubation (5) 0.05% TX-100 (6) 0.05% TX-100 re-extraction of (5). The 
samples were reduced and separated by SDS-PAGE on a 15% polyacrylamide fix 
gel.
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The analysis of the insoluble materials demonstrated that two radioactive surface 
components were tightly associated with the pellet cytoskeletal mesh at a significant 
quantity ( Fig 2 ). One has an apparent molecular weight of 43KD and another of about 
28KD. Components of similar molecular masses have also been found in the 
supernatants, but whether they are identical to those of the pellets are still an open 
question. The 43KD component co-migrated with the red cell actin. Two weaker 
radioactive components were also detected in the pellet, their molecular weights were 
68KD and 56KD, respectively. On the Coomassie Blue stained gels, more bands were 
detected ( Fig 4 ), including a 70KD, a 45KD, a 33KD, a 28KD and a 17KD, 
respectively. By overlaying the autoradiographs with the related Coomassie Blue-stained 
gels, it was found that the 43KD radiolabelled band and the 45KD Coomassie Blue- 
stained band were distinct molecules. The radioactive band co-migrated with the red cell 
actin on SDS-PAGE but not the Coomassie Blue stained one. The 43KD iodinated 
component was one of the major bands in both Coomassie Blue stained ( Fig 5 ) and 
autoradiographs while the 45KD band was, if any, weakly iodinated and its total 
quantity is at a much lower level than 43KD. The 43KD could be G-actin. The 28KD 
band was the only band overlaid with each other on autoradiographs and Coomassie 
Blue-stained gels. 17KD and 70KD components were not surface-iodinated ( Fig 2 ).
It was of interest that several radioactively labelled components tended to be easily 
released by low concentrations of Triton X-100. These components consisted of a 68KD, 
a 55KD, a 43KD and a 28KD ( Fig 3 ). Radiolabelled cell pellets, which had been 
extracted with 0.025% Triton X-100, were subjected to a second extraction with the 
same Triton X-100 medium, or solubilized by 0.5% Triton X-100. The SDS-PAGE 
analysis found that both 68KD and 55KD bands were absent from both the second 
0.025% Triton X-100 and the 0.5% Triton X-100 extractions ( Fig 3 ). The bands were 
entirely released by the first 0.025% Triton X-100 treatment. In a separate study, it was 
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Fig 4. Coomassie Blue stained Triton X-100 insoluble proteins extracted by SDS, 
corresponding to Fig 2, note the difference of the radiolabelled 43KD band and 
the Coomassie Blue stained band.
Fig 5. Coomassie Blue stained Triton X-100 soluble proteins extracted by different TX- 
100 concentrations. Its corresponding fluorograph is Fig 1. It is noted that 0.01% 
failed to solubilize any proteins.
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4. Discussion
The cytoplasmic face of plasma membranes is believed to be the meeting place for the 
transmembrane proteins and the cytoplasmic structures. The interaction between these 
two cellular structures plays an important role in conducting signal transduction and cell 
responses to its surroundings. Extensive studies have been conducted on the structures 
and constituents of the cytoskeleton in the red blood cell which serves as an excellent 
model for such purposes ( Branton et.al., 1981 ). Whether the knowledge of the red 
blood cell cytoskeleton can be extended to nucleated cells has remained a question. 
However, numerous studies have demonstrated that these cells possess abundance of 
filamentous cytoskeletal networks within the cytoplasm and these networks are associated 
with the transmembrane surface proteins at the inner face of the bilayer ( Bourguignon 
and Singer, 1977; Hirokawa and Tilney, 1982 ). The understanding of solubilization 
characteristics of membrane proteins might be capable of depicting such relationships 
and interactions. This study has examined the concentration effect and perturbation of 
non-ionic detergent on the lymphocytic plasma membrane and the cytoskeleton- 
associated fraction.
Once a detergent has been selected, an empirical rather than a logical process ( 
Racker, E., 1983 ), two groups of factors need to be elaborated to ensure the 
reproducibility and the consistency of the solubilization. One is the ionic strength and 
the pH of the medium employed in the experiment. Precipitates could occure when 
anionic detergents are used at an acidic pH, which, though, is not common for non-ionic 
detergents, like Triton X-100, unless buffers with a very high ionic strength are present.
o
The second factor is the detergent-protein ratio. We found that up to 1.5X10 cells can 
be efficiently solubilized by 200 ul 0.5% Triton X-100 and further increase of either 
detergent concentration or the detergent-protein ratio does not result in any increased 
extraction. It should be born in mind that if the concentration of proteins to be 
solubilized is close to that of the detergent, the free detergent concentration after 
solubilization is highly dependent on the initial detergent-protein ratio.
In exercise of solubilization, caution must be taken as contaminants can be found in 
non-ionic detergents such as Triton X-100 and Brij35 ( Ashani and Catravas, 1980; 
Chang and Bock, 1980 ), and they vary between different batches of the detergents and 
after storage in aqueous solution. One of the most significant contamination for this 
study is the oxidising compounds which react with sulphydryl groups of proteins and
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also with carbonyl compounds. Inclusion of iodocetamide in the extraction medium can 
partly prevent the formation of such artefactual disulfide bonds.
The Coomassie Blue stained proteins on SDS-PAGE demonstrates that the 
concentrations of Triton X-100 below 0.05% are unable to break the membrane bilayer 
and release proteins from the cells except a few surface proteins solubilized at a very 
small quantity, which will be discussed below. The gels exhibited few surface and 
cytoplasmic components in the Triton extracts of below 0.05%. At 0.05%, the membrane 
bilayer is apparently broken down, abruptly releasing of cytoplasmic proteins and 
membrane surface proteins. In our system, 0.05% is found to be the minimum 
concentration capable of effectively dislodging the membrane proteins from the lipid 
matrix.
Although 0.025% failed to disrupt the membrane bilayer it perturbates and destabilizes 
the lipid bilayer and dissociates some external membrane proteins. The solubilization of 
68KD and 55KD components indicates such an effect and, hence, shows that both 
molecules are originated from the external peripheral face of the membrane. It is 
rational that the membrane lipid bilayer gradually sequesters the detergent molecules and 
the monomeric form of the detergent binds to hydrophobic segments of the membrane 
proteins, which probably accounts for the fact that some detergent can cause the 
expansion of membrane area ( Seeman, P., 1966; Kwant and Van Steveninck, 1968 ).
The 43KD band is associated with the cytoskeletal matrix although it can be extracted 
into the supernatant at a significant quantity. Both the soluble and insoluble 43KD 
components comigrating with the erythrocyte actin on SDS-PAGE but they showed 
slightly differing patterns on gel. With regard of its apparent molecular weight, the 
band, or part of the band, could be G-actin. The two 43KD components from soluble 
and insoluble fractions might be two different forms of actin. However, this 43KD 
component is heavily iodinated and comprises one of the major bands in the lymphocytic 
membrane. Actin has been found to express on the surface of B-CLL lymphocyte ( 
Bachvaroff et.al., 1980 ). It is not yet known whether this band is entirely attributed to 
actin or some other bands as well. In a membrane preparation study with mild non-ionic 
detergent Tween-40 in this investigation, a 43KD component was observed as a 
predominant component associated with Triton X-100 insoluble material from the 
prepared membrane. This band also is surface-iodinated and a 34KD and a 28KD 
radioactive bands were found to co-pellet with it as well.
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Moore and Dedman (1982) identified a number of polypeptides in extracts of various 
tissues. These polypeptides had molecular weights of 67KD, 34KD, 30KD and 11KD on 
SDS-PAGE. Recently a group of polypeptides with similar molecular weights have been 
identified in Ca+-chelator extracts of lymphocytic plasma membrane and intestinal 
epithelial brush border membranes ( Owens and Crumpton, 1984; Gerke and Weber, 
1984 ). One common feature of these polypeptides is that they are all preferentially 
associated with the non-ionic detergent insoluble complex of the membrane ( Mescher 
et.al., 1981; Davies et.al., 1984 ). The complex comprised predominantly actin and 
proteins of 120KD, 68KD ( termed p68 ), 33KD and 28KD. The 68KD component 
identified in this study suggests its exterior origin or even transmembrane because of its 
association with the insoluble fraction and capable of being iodinated. In term of the 
molecular mass, this component is identical with p68 described by Owens and Crumpton 
(1984) but is contrast to their observation that p68 is allocated in the cytoplasmic side of 
the plasma membrane.
Knowledge of the plasma membrane protein-cytoskeleton matrix function is very 
limited. Structurally, the matrix may serve to stabilize the membrane bilayer and by such 
stabilization to maintain high surface tension. The matrix may also, functionally, mediate 
the interactions between membrane proteins and cytoplasmic organelles by providing 
anchorage points for transmembrane proteins and cytoskeletal filaments. Abnormalities 
discovered in neoplastic cells may support such assumptions and suggest possible 
correlations between structural defects of the cytoskeleton and functional anomalies of 
the membrane receptors.
In conclusion, Triton X-100 concentrations not below 0.1% are able to efficiently 
solubilize most of the membrane proteins of lymphocytes. Further increase of TX-100 
concentration above 0.1% does not significantly increase extraction. 0.5% is chosen as the 
routine concentration as (1) it is the mostly quoted concentration (2) it has wide 
tolerance to variation of cell number.
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CHAPTER 4. SELECTION AND CALIBRATION OF COLUMNS 
1. Introduction
The central element of the size exclusion ( SE ) chromatography is the column as the 
separation is largely controlled by the packing materials used. Traditionally, SE- 
chromatographic analysis of synthetic organic polymers has been made with cross-linked, 
semirigid polystyrene gel packings. The disadvantage of these semirigid polystyrene 
particles is that column input pressure must be limited to a relatively low level which 
restricts their application in modern SE-HPLC. Recently, small, rigid inorganic silica- 
based packings have been of increasing interest and utility. Better performance has been 
possible after chemical bonding organo-silanes to derivatize the silica surface is used ( 
Phannkoch et.al., 1980; Schmit et.al., 1980; Roumeliotis and Unger, 1981 ). This 
modification deactivates the silica surface and provides the chemical inertness for 
protein separation. In order to overcome dissolution problems which reduce the useful 
operating lifetime of the column and generate voids in the packed bed, Stout and 
DeStefano (1985) found that porous silica microspheres treated with zirconium salt and 
then a hydrophilic organo-silane can sustain wider pH range and give longer lifetime of 
column performance.
With certain types of samples, different packing materials of similar pore size could 
generate different separation while for a particular column, different combinations of 
analytical paremeters will result in different resolutions. Of the most important 
paremeters, the ionic strength of mobile phase and flow rate are usually examined and 
adjusted before embarking on a routine investigation and will have distinctive effects on 
the behaviour of the column.
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2. Materials and Methods
Following columns from different manufacturers were tested during the course of the 
initial work:
(1) Du Pont Zorbax bioseries GF-250 and GF-450. Both columns are surface-stabilized, 
hydrophilic gel filtration columns. The columns are expected to produce optimum results 
when typical aqueous buffer solution under pH range of 3.0-8.5 is employed as a mobile 
phase. The column characteristics are:
GF-250: Particle size: nominal 4-5 um 
Pore size: 150 A
Optimum MW: 10-250KD ( for spherical molecules ) 
Column configuration: 250 mm x 9.4 mm ID
GF-450: Particle size: nominal 6.0 um 
Pore size: 300 A
Optimum MW: 25-900KD ( for spherical molecules ) 
Column configuration: 250 mm x 9.4 mm ID
(2) E. Merck's ( F.R.Germany ) Lichrospher 100 Diol and 500 Diol columns. These two 
columns are surface modified amorphous silica which is a reaction product of silica with 
( 3-( 2,3-epoxypropoxy ) propyl ) trimethoxysilane. The column characteristics are as 
follow:
100 Diol: Particle size: 5 um
Column configuration: 250 mm x 4.0 mm ID
500 Diol: Particle size: 10 um
Column configuration: 250 mm x 4.0 mm ID
The columns were carefully connected, using the shortest tubing to optimize the 
performance as discussed in Chapter 1. At least 200 ml mobile phase was run through 
the column whenever a new buffer was employed.
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Gilson model 302-303 piston pumps, fitted with a 10SC pump head, were used for 
this study. Recommended flow rates for GF-250 and GF-450 columns are from 0.5 to 
2.0 ml/min. Although resolution is flow rate dependent ( Yau et.al., 1979 ) a typical 
flow rate of 1 ml/min was chosen for the daily chromatography although other settings 
were examined. ARheodyne Model 7125 syringe loading sample injector, fitted with a 
100 ul sample loop, was used for loading samples.
The refill speed is a parameter which determines the time required for the piston 
return stroke. The refill speed is normally set at its highest value which on Gilson model 
302-303 is 9. However, the mobile phase must be carefully degassed when a high refill 
speed is applied.
Precompression setting is essential to minimize pumping pulsations. The duration 
required for the precompression is a function of (a) the operating pressure (b) the 
compressibility of the mobile phase (c) the pump head model and (d) the flow rate as 
well. The setting ( 0-9 ) is in linear relation to the working pressure for Model 10SC 
pumping head if the delivered liquid fixed. The setting effect is evaluated on the 
detector baseline. For the subsequent work, setting 5 is found adequate for most of the 
situations.
0.2 M phosphate buffer saline ( pH 7.4 ) containing 0.5% Triton X-100 ( or other 
non-ionic detergent relavant to the detergent in the cell extraction medium ) was used as 
the mobile phase ( eluent ). The buffer was freshly made, warmed up to about 60° C 
with Triton X-100 added dropwise. The buffer was then cooled down to 20° C. 0.005% 
sodium azide was used as an anti-microbial agent. The buffer was filtered through 
Nylon 66 membrane filters with a 0.045 urn pore size ( Anachem, UK ) and then 
degassed in an ultrasonic bath for 20 min. The column was equilibrated with the newly 
prepared buffer.
Table 1 and 2 in the Appendix III list the standard proteins used for the calibration 
and their retention times in the abovementioned buffer with or without detergents. All 
proteins were dissolved in the phosphate buffer saline pH 7.4. The protein concentration 
was monitored by spectrometery and adjusted to similar levels for easy comparison of 
the out-put signals. In order to avoid column blockage all samples were subjected to 
centrifugation at 1000 g for 4 min.
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100 ul sample was loaded to the column. The elution of the proteins were monitored 
by a Gilson HM holochrome UV/VIS detector at 243 nm which was found to be a 
window for the protein detection with the presence of Triton X-100 and the eluting 
profiles and the retention times were recorded.
Various working conditions and columns were tested as described in the result. The 
operating temperature of the columns was ambient, usually between 20-25° C.
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3. Results
100 Diol and 500 Diol columns were examined under the recommended conditions 
using 0.05 M phosphate buffer pH 7.4 running at the flow rate of 0.2 ml/min and 0.5 
ml/min, respectively. 100 ul standard protein sample, dissolved in the same medium as 
the mobile phase, was injected and the eluted proteins were detected by the UV monitor 
at 243 nm. The elution profiles were recorded for calculating the retention times which 
were measured as the distance between a peak and the injection of a sample. Table 1 
shows the retention times of the standard proteins. Log of molecular weight was plotted 
against the retention time in minute as in Fig Ic ( 100 Diol not shown ) with respect to 
the use of ' Time ' fractionation mode. The data presented here were the means of three 
independent runs, the maximum deviation of the retention time did not exceed 0.1 min. 
For different runs in the same batch, the operation pressure varied within 1 bar.
Two Zorbax columns were tested under the recommended conditions by using the 
same standard proteins as for the Diol columns. The resultant calibration plots of GF- 
250 and GF-450 are shown in Fig 1 ( a and b ). Comparing the Log MWs versus 
retention time ( min ) plots of two sets of columns, two Du Pont columns apparently 
give better separation and slightly improved linearity ( Fig Id ). Between GF-250 and 
GF-450, the latter one has better performance at fractionating high molecular weight 
components as shown by Fig Id. Fig 2 shows the resolution of the standard protein 
mixture by a GF-450 column eluted with 0.2 M phosphate buffer pH 7.4 under the flow 
rate of 1 ml/min. Therefore, the GF-450 was shosen for further examination under 
different flow rates and ionic strengths. Fig If shows the effects of the mobile phase 
ionic strength on the protein retardation on the column. The changes of protein 
retardation demonstrated the marked differences of separation when buffers with 
different ionic strengths were used. In 0.1 M phosphate buffer pH 7.4, proteins were 
eluted in about 6 min and proteins were greatly compressed within 4 min, resulting in 
poor resolution, particularly for big molecules.
The retention of proteins was also affected by the flow rates used. It was found that 
the efficacy of separation was in the order of 0.5 ml/min, 1 ml/min and 1.5 ml/min, but 
dropped down at 2 ml/min as judged by the plot slop. For further analysis, mixtures of 
standard proteins were applied to the column under different conditions as examined 
above, the UV absorbance profiles suggested that 0.2 M phosphate buffer of pH 7.4 with
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1 ml/min flow rate is an appropriatecombination. Fractionation of actual cell membrane 
extracts confirmed this setting.
The presence of non-ionic detergents yielded no significant effect on the retention of 
the standard proteins tested. Fig le shows that the retention times of proteins with or 
without 0.5% TX-100 were almost identical. Similar foundings were also true for other 
columns and other detergents, such as Brij 99.
Urease behaved abnormally on all the columns tested. It was greatly retarded, showing 
much longer retention time.
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Calibration curves of HPLC size exclusion columns to show the resolution 
differences and the effect of Triton X-IOO and ionic strength, (a) GF-250 (b) 
GF-450 (c) Diol-500 (d) the comparison of three columns by overlaying (a), (b) 
and (c) (e) the effect of TX-IOO on the retention of proteins (f) the effect of 
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Fi£_2. The graphic profile of HPLC-SE separation monitored by an UV detector, 
showing the resolution of a mixture of seven standard proteins by a GF-450. (1) 
IgM (2) thyoglobulin (3) spectrin (mono) (4) B-lactoglobulin (5) carbonic 
anhydrase (6) a-lactalbumin (7) cytochrome C.
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4. Discussion
The analysis of the plots of Log MWs versus retention times and the overall assessment 
favour the GF-450 for this study. Although GF-250 achieved similar separation at the 
molecular weight range of less than 150KD, bigger molecules, such as IgM and 
thyroglobulin are totally excluded. GF-450 column has shown sharp responses and high 
reproducibility within the molecular weight range of 20KD to 900KD. Several proteins 
showed anomalous retention on the column with respect to the linearity of the plots. 
Cytochrome C was abnormally retarded on both GF-250 and GF-450. This might be 
attributed to its basic and highly negative-charged nature. Ferritin was also, for some 
reason, retarded abnormally by GF-250 column. Bearing in mind that gel 
chromatography does not separate molecules strictly by their molecular weights but 
rather by an entropy-driven process, resulting from the differences in the hydrodynamic 
volume occupied by the substances, as determined by their radii of gyration ( Yau et.al., 
1979 ). Geometrical shapes of proteins and other factors such as ion-exchange and 
hydrophobic interactions ( Regneier and Noel, 1976; Phannkock et.al., 1980; Schmit 
et.al., 1980; Roumeliotis and Unger, 1981 ) also affect the behaviour of the proteins in 
the column. Thus the relationship between Log MW and retention time is in fact only 
quasi-linear. These anomalous phenomena, therefore, are not totally unexpected.
Examination of the chromatographic behaviour of proteins as a function of ionic 
strength indicates that the elution of proteins is influenced to a different extent. IgM 
and Thyroglobulin were retarded while spectrin was excluded. The results presented here 
are concordant with the previous investigation ( Stout and DeStefano, 1985 ) although 
the operating conditions are different. It is known that retention of proteins is affected 
by the ionic strength in a random fashion, without any correlation between the retention 
volume ( or time ) and physical properties of proteins as found by Engelhardt and 
Mathes ( Engelhardt and Mathes, 1981 ), Roumeliotis and Unger's ( Roumeliotis and 
Unger, 1979, 1981 ).
The operational paremeters established in this study render GF-450 column the best 
separation of the proteins across a wide range of molecular weights which should cover 
the membrane protein investigation. Triton X-100, within the examined concentration 
range up to 1%, has no measurable effect on the retention of the standard proteins.
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CHAPTER 5. HPLC ANALYSIS OF CELL EXTRACTS 
1. Introduction
The investigation of membrane proteins undertakes two different steps in 
methodology: the isolation and purification of the interested proteins from an usually 
complicated mixture and characterization of these separated components.
Conventional techniques for analysis of complicated protein mixtures present two 
major disavantages: (1) interactions except by covalent forces between polypeptides 
are prone to be disrupted (2) the separation usually involves a multi-step process 
which hinders high reproducibility and comparative study of samples. Another 
limitation of the conventional methods is that they are unable to construct an overall 
image of membrane protein composition although IEF-SDS PAGE does but 
glycoproteins are frequently poorly focused, giving rise to poorly defined dots which 
limits the resolution of the method.
Size exclusion chromatography, on the other hand, though having relatively lower 
resolution, is capable of retaining weak interactions while separating proteins 
according to their molecular sizes. The fractionation of the separated proteins should 
be able to reflect the nature state of the protein complexing and interactions, as well 
as the constituents. When individual fractions are analysed on SDS-PAGE to develop 
a second dimension, the elucidation of disulfide bondings of proteins can be achieved 
by selecting the electrophoretical conditions, either with reduced or non-reduced 
samples. The two-dimensional matrix of HPLC-SDS PAGE gives a comprehensive 
profile of the membrane protein composition ( Wu and Maddy, 1989 ). The profiles 
are highly reproducible and comparable between different samples. As size exclusion 
packings do not bind sample molecules and all molecules are eluted before the total 
permeation, therefore, quantitative analysis becomes feasible. The potential and more 
advantages of this technique are gradually realized when its application is extended.
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2.__Ma(erials and Methods
Cells were surface-iodinated by lactoperoxidase catalysis or tritiated as described in 
Chapter 2. Proteins were extracted into 0.5% Triton X-100 medium containing 2 mM 
EDTA, 1 mM PMSF and 0.5 TlU/ml aprotinin. Antibody treatment of either 
detergent extracts or intact cells was as described in Chapter 2. The Triton X-100 
extracts were spun at 1000 rpm for 4 min prior to chromatography to pellet any 
possible precipitates. Routinely, 100 ul extract was applied to the column, which was 
equivalent to about 2.5x107 cells.
A precolumn ( length: 20 mm ) packed with Diol 150 ( Lichosphere, DuPont ) was 
placed between the pumping system and the main column to trap impurities or 
particulates in the aqueous mobile phase and samples. Proteins were monitored at 243 
um. All the control samples were fractionated and collected by a programmed time 
mode as follow:
Wait: 7.0 min 
Time: 0.2 min 
Collect: 24 fractions
With these parameters, the largest molecules normally appeared in about fraction No. 
5 or 6 and the very front fractions reserve the flexibility of collecting molecular 
complexes for most occasions. However, in some cases a shorter waiting time was 
adopted as described in the text. 0.2 min collecting time yielded approximately 200 ul 
fraction at the flow rate of 1 ml/min. An equal volume of SDS sampling buffer was 
added to each fraction and the mixture was incubated in 50° C water bath for 15 
min. Such fractions could be left in 4° C cold room for several weeks without 
noticeable proteolysis but were normally analysed within 48 hours.
Usually, 175 ul of each fraction was subjected to SDS-PAGE analysis on a 6-11.5% 
polyacrylamide gradient gel under reduction or non-reduction conditions--with or 
without 50 mM dithiothreitol ( DTT ) ( Chapter 2 ). Proteins were stained by silver 
as outlined in Chapter 2 and the gels were vacuum-dried between two sheets of
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cellophane and exposed on Kodak X-ray films for various periods of 4-20 days. For 
tritiated samples, a tungsten intensifying screen was used.
Cell extracts of three different concentrations of Triton X-100, from 0.1% and 
0.5% up to 1%, were examined to elucidate the effects of the Triton X-100 
concentration on the protein retention times. The detergent content in the phosphate 
mobile phase was equal to that in the sample. The other conditions were the same as 
the standard conditions.
The working temperature of the HPLC system was ambient, normally within 20- 
25° C. For the same batches of samples, running pressures should remain stable. 
Elevated pressure usually indicates a blockage of the guard column and requires 
replacement.
Two-column combination was performed occasionally to improve resolution. Two 
combinations were tested: a GF-250 connected to a GF-450 or 2 GF-450s connected 
in tandem. All the working parameters were set the same as those for one column but 
with doubled waiting time, ie. 14 min.
In order to investigate the intermolecular disulfide bondings of the membrane 
proteins. HPLC of Triton X-100 extracts reduced before chromatography was 
performed with a mobile phase either with or without 50 mM DTT. After the 
fractionation, the samples, either with or without further DTT reduction for both 
cases, were run on SDS gels.
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3. Results
3.1. Typical Patterns of CLL Lymphocytes and Designation of the Components
The two dimensional autoradiographic profiles of the lymphocytes present complex 
but well resolved patterns, particularly at the higher molecular weight range at which 
most of the proteins were clearly defined by their distinct HPLC fractionation and 
SDS-PAGE locations, although some may overlap with each other their peak 
distributions usually effectively indicate the differences of their identities ( Wu and 
Maddy, 1989 ). As the proteins of 50-300KD were the focus of our present research 
interests, therefore, usually the first 15 fractions were analysed while the later 
fractions were also investigated whenever necessary.
A typical HPLC-SDS PAGE pattern of CLL lymphocyte Triton X-100 extracts is 
shown in Fig 1. Fig 1 demonstrates the efficacy of the size exclusion process in 
separating protein mixtures. The overall distribution of the radio-labelled membrane 
proteins on the SDS-PAGE indicated that the fractionation was based on the apparent 
physical sizes of molecules or complexes. One of the earliest proteins eluted was a 
group of proteins with apparent molecular weights of 180-230 KD, which were later 
identified as CD45 antigen ( old name the leucocyte common antigen, LCA ). The 
230KD band with a retention time of about 8.0 min and the 200KD band of 8.4 min, 
were progressively resolved and fractionated into different fractions according to 
their molecular masses. Frequently, a radioactive band of 100KD was also detected in 
fraction 4-5, suggesting a possible complex form of the band, which was 
demonstrated by non-reduced samples on SDS gels to have been derived from a larger 
complex ( see below ).
As the matrix of a whole cell extract is usually complicated, a matched diagram 
can help to elucidate the complexity ( see following chapters, and Wu and Maddy, 
1988 and 1989 ). A binomial labeling system was introduced to name the HPLC-SDS 
PAGE two-dimensional matrix of the autoradiography as shown by the schematic 
presentation of the fluorography. The first arabic figure stands for the sequential 
position of a protein from high molecular weight down to low molecular weight on 
SDS-PAGEs while the second indicates the HPLC fraction mumber. In order to avoid
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confusion caused by naming some minor bands, which were gradually identified as 
the analysis extended, under the same system ( see below ), the fraction number is 
put into a bracket. Thus CD45 can be designated as band 1, the 230KD band of the 
antigen in fraction No. 5 can be labeled band 1(5) and the 200KD component band 
1(7). The second arabic figure does not precisely define the exact fraction of a band 
because the majority of the bands occupy more than one fraction. Nine major bands 
have been defined in this way but minor bands will be quoted by using a dot 
following the first figure according to their relative positions, such as band 7.1 while 
band 7.1(15) indicates band 7.1 in fraction 15. This system will be quoted in the 
following chapters although standard nomenclatures will be used for proteins of 
known identities.
In fraction 9-12, a strongly iodinated band of 220KD was observed in all CLL 
lymphocytes, normal tonsilar B cells and PLL. This band is named band 3. Below 
band 3 are a pair of bands which were found in certain patients with variable levels 
of expression which will be discussed in Chapter 7. The lower band has been 
identified to be CD21 by a monoclonal antibody specifically against CD21 cluster ( 
see Chapter 6 ). The higher band of the pair, having a molecular weight of 150KD, 
is designated as band 4.1 while CD21 is, alternatively, called band 4.2. It was found 
and confirmed, by non-reduced samples on SDS gels, that there is a sharp fine band, 
though having longer retardation on column, comigrating with CD21 on SDS PAGE. 
This band is numbered 4.3.
The area around 100KD is complex and similar in most of the cells examined. A 
strong diffuse band was present in all CLLs, PLL and normal tonsilar B cells. This 
band is named band 6.1. Other experiments showed that this band contains at least 
two polypeptides, one of them is gpL115 ( CD43 ) ( Remold-O'Donnell et.al., 1984 ), 
named here as band 6.2. Just below band 6.2 there is one, or maybe more than one, 
band(s) which has been demonstrated to be the surface Ig ( IgD or IgM or both ) 
heavy chain. Sometimes it becomes apparent that the upper band of the pair consists 
two bands with distinct retardations on the column. The band with slightly shorter 
HPLC retention was found to have different features from the H chain of the slg and 
is assigned band 7.2 while slg as band 7.3.
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FigJ.. (a) A typical IIPLC-SDS PAGE two-dimensional matrix ( the first 15 fractions of
I ?5 the cllcction ) of I radiolabcllcd B-CLL membrane proteins, (b) the schematic
presentation of the fluorograph. In some patients, there is a high molecular 
weight component of 300KD above band 1, as shown in Chapter 6. The details 
















































































































































































Fig 3. Demonstration of the covalent association between band 9 and an unnumbered 
component of 200KD. The 200KD component is not 125I radiolabelled but 
stained by silver while band 9 iodinated but not silver-stained, (a) with reduction 
(b) without reduction. The upper panel is the fluorography and the lower panel is 
the silver-stained patterns. The figure shows that, without reduction, band 9 
complexes with the silver-stained 200KD band, having a complexed MW of 
220KD which can be revealed by both silver staining and fluorography.
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In fraction 13-15, most of the bands were in the molecular weight range of 80- 
20KD. A strongly iodinated band was found in fraction 14-16 with an apparent 
molecular mass of 78KD which is designated as band 7.1. The next band of 45KD is 
the a chain of the Class I MHC antigen ( see Chapter 6 ) numbered band 8.1 while 
the B2~ m'crogl°bulin can be recovered in the later fractions with longer retention. 
Two 38KD bands were also found in the fraction 14-16, designated band 8.3. A pair 
of bands ( band 8.4 ) have been identified as the a and 13 chains of the Class II MHC 
antigen with apparent molecular weights of 35 and 28KD, respectively.
Fig Ib shows the whole designation of the iodinated surface polypeptide bands on 
the HPLC-SDS PAGE two-dimensional matrix. However, caution must be taken as 
the actual pattern can be more complicated and delicate, thus gives an oversimplified 
picture of the complexity of the surface membrane protein composition. Many other 
minor components can be detected but difficult to define and name.
3.2. Reduction, Non-reduction of the HPLC Fractions and Pre-reduction of Sample 
Extracts
SDS gel electrophoresis of the HPLC fractions without reduction yielded markedly 
different patterns. Fig 2 shows the comparison of the same fractions either reduced 
with 50 mM DTT or not reduced prior to the SDS-PAGE electrophoresis. The 
polypeptides affected by SDS-PAGE without the reduction of samples were:
(1). band 4.2, which has been identified to be CD21 by monoclonal antibody, 
reduced its molecular weight from 140KD to 120KD under non-reduction treatment 
of the fractions before SDS-PAGE.
(2). There are at least three bands in the band 7.2, 7.3 group, they have very similar 
retentions on the column and very close mobilities on SDS-PAGE gels. The upper 
band of 78KD and the lower band of 75KD, band 7.3(9-11), could both be recovered 
at 340KD and 320KD, respectively, without reduction before electrophoresis. With 
both the 78KD and 75KD components retarded to the top of the gel, a 22KD 
component disappeared simultaneously from the same fractions. The molecular masses 
of these bands and their behaviour upon reduction suggest that they are membrane
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immunoglobulins, the higher molecular weight bands were the heavy chains of either 
slgD ( 75KD ) or slgM ( 78KD ) or both while the 22KD component was the light 
chain. In the meantime, Band 7.2 were demonstrated to be distinct components 
consisting of two bands of 75KD and 77KD, respectively, which were not affected by 
reduction before SDS-PAGE.
(3). In the same fractions of that of slg ( fraction 9-11 ), a new component was 
revealed in the position where the slgD or slgM heavy chains shifted up when the 
fractions not reduced. This diffuse band has an apparent molecular weight of 70- 
76KD on 6-11.5% SDS-PAGE ( Fig 4 ).
(4). Running samples without reduction could reduce the molecular weight of the 
Class I MHC a chain by about 4KD. But no visible change was found on the B chain.
(5). Class II MHC B chain was greatly affected by non-reduction which brought its 
molecular weight down to about 25KD.
(6). Under the non-reduced conditions, band 9 of 100KD was retarded to the 
position of the second band of the CD45 antigen, having a molecular weight of 
220KD, which suggests that other component(s) must be associated with the band via 
disulfide bonds. This point was proven by silver stained gels ( Fig 3 ). The gel shows 
that the band 9 was not stained by silver while a 200KD component in the same 
fractions, not iodinatable, could be silver-stained. When non-reduced samples were 
analysed by SDS-PAGE, band 9, together with the 200KD component, was shifted 
up to 220KD which was detectable by both the silver-staining and the 
autoradiographs. In those patients who do not possess band 9, no such changes have 
been observed.
3.3 Two-column Combination
As expected, combining two columns should improve separation of the polypeptide 
mixture and help to understand the interactions between proteins. Two GF-450 
columns resulted in higher resolution than GF450-GF250, particularly for the 
components of high molecular mass ( Fig 5 ). The autoradiography of the 2 x GF-450
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separation of the Triton X-100 extracts is shown in Fig 5. It is seen that the 
polypeptides of the CD45 family have been clearly separated from other components. 
Band 9, for some reasons, co-migrates with the earliest fractions of the CD45 
polypeptides, ie. 230KD band, in a similar fashion as in one column chromatography. 
Thus, the separation of the band 9 from the CD45, proportionally, was much less 
than other polypeptides.
A sharp, fine band ( band 4.3 ) co-migrating with CD21 ( band 4.2 ) but separated 
from other components on SDS-PAGE became apparent under the two-column 
combination, demonstrating its distinct location with an apparent molecular weight of 
135KD.
Band 7.2(8-9) ( in one column system ) was revealed in fracton 17-19 when the 
heavy chains of slg were retarded and fractionated into fraction 20-24. This band was 
shown not to be affected by non-reduction on SDS-PAGE.
No separation was observed for the group of proteins of band 7.1, 7.4, Class I and 
Class II MHC. The relative retention times of this group of polypeptides were not 
affected except band 8.3(13-14) which was separated from the group.
It has been noticed that the retention times of the eluted polypeptides in two- 
column combination were less than doubled retention times of a single column.
3.4. Effect of Triton X-100 on Retention Time
Although the presence of Triton X-100 of up to 1% has no effect on the 
retardation of the standard proteins, different detergent concentrations resulted in 
different retention patterns of cell extracts. Fig 6 demonstrates the influence of three 
Triton X-100 concentrations from 0.1, 0.5 to 1%. There was not much change in 
those early fractions ( big molecules ) whilest the retardation of the small molecules 
was shortened by higher detergent. From the figure it is apparent that the Triton 
concentration had a bigger effect on the smaller molecules. During the process of 
chromatography under different detergent concentrations, no significant change of the 







Fi&_4. Demonstration of a 78KD and a 75KD components by SDS-PAGE analysis of 
non-reduced samples on a 6-11.5% polyacrylamide gradient gel. (a) reduced ( 





Fig 5. A HPLC-SDS PAGE profile of B-CLL extract fractionated by a two-column ( 2 
x GF-450 ) combination, showing the complete separation of the CD45 antigen 
from other surface proteins and revealing the overlapping of some bands on an 
one-column system.
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The effects of Triton X-IOO concentration on the retention of membrane proteins. 
Proteins extracted with three different TX-100 concentrations were eluted with 
0.2 M phosphate buffer pi I 7.4, containing corresponding TX-100 
conccMiiations (a) 0.1% (b) 0.5% (c) 1.0%. There is a general tendency for the 












4.1. Reduction and Non-reduction
The results presented above suggest that few CLL lymphocytic membrane 
polypeptides interact with each other via disulfide bondings. On the HPLC-SDS 
PAGE matrix, only two membrane proteins have been detected to associate in this 
way. Band 9 increased its apparent molecular weight from 100KD when reduced to 
220KD when not reduced, indicating that the 220KD form is a disulfide-bound 
complex. Further experiment revealed that the 100KD iodinated polypeptide was 
actually associated with a 200KD component which is not surface iodinated but 
distinctively stained by silver ( Fig 3 ). The fact indicates that (1) this 200KD 
component is probably located at the cytoplasm and (2) that the 100KD polypeptide 
may contain high intramolecular disulfide bonds because of its much greater change 
of the mobility on SDS-PAGE with or without reduction. Band 9 is consistently 
observed in certain patients, which helps to rule out the artifact possibility. Another 
surface molecule which has been proven, by reduction and non-reduction, to be 
intermolecularly bonded is slg. Their apparent molecular weight without reduction 
appears to be that of a dimer. However, other researchers ( Vitetta et.al., 1971 ) have 
identified only monomeric membrane-bound IgM or IgD. Their abnormal mobility on 
SDS-PAGE could be attributed to irrational behaviour of proteins on non-reduced 
SDS gels ( Segrest and Jackson, 1972; Dunn and Maddy, 1976 ). But this point still 
reserves further investigation.
The failure of labeling of the Ig light chains of some patients by iodine although 
both silver stained patterns and FACS indicated the presence of the light chains is not 
understood. It could be that the light chain is shaded by steric effect and prevented 
from access of molecules like catalyst lactoperoxidase.
The HPLC patterns of Class I and Class II MHC under reduction and non- 
reduction are in agreement with the structural information on the Class I in mouse ( 
Coligan et.al., 1981 ) and man ( Orr et al, 1979 ) and on the Class II ( HLA-DR ) B 
chain ( Kratzin et. al., 1981; Kaufman & Strominger, 1982 ) and a chain ( Kaufman 
& Strominger, 1982 ), respectively.
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Analysis of HPLC fractions with reduction or non-reduction before SDS-PAGE is 
certainly a very simple but effective technique for understanding the membrane 
protein interactions, particularly those via disulfide bondings. It is also useful for the 
identification of some polypeptide bands overlapping with each other on SDS gel 
when fractions were reduced as exemplified by band 7.2. Moreover the difference of 
a band's mobility under reduced and non-reduced conditions could be taken as a 
rough indication of the extent of intrachain disulfide bonding of a polypeptide 
although caution must be taken as the numbers of amino acids between two cysteins 
can greatly affect the mobility.
Great dilution of DTT in protein extraction medium can result in reforming of 
disulfide bonds and impurities in the detergent could also be responsible for this 
phenomenon. Therefore, pre-reduced sample subjected to chromatography should be 
eluted in a medium containing equivalent amount of DTT.
4.2. Effect of Non-ionic Detergent on Retention
The effect of non-ionic detergent Triton X-100 on the membrane protein 
retardation during chromatography is different from the standard proteins described 
in Chapter 4. Generally speaking, all detergent-bound membrane proteins were eluted 
earlier with respect to the calibration curve constructed from the standard proteins. 
That membrane proteins possess certain portion of non-polar segments which could 
bind Triton X-100 may account for the phenomenon. The observation that small 
molecules were more affected by the presence of the detergent is well in line with 
this assumption. Another feature which is likely to contribute to the shorter 
retardation of the membrane proteins is their heavy glycosylation. The enormous 
protruding of sugar residues could greatly enlarge gyration radii of a protein, hence 
exaggerating the actual molecular size. A simple experiment can be designed to test 
this hypothesis by cleavage of the sugar structures.




Theoretical plates are proportional to the effective length of a column ( Yau et.al., 
1979 ). Elongation by combining columns is an efficacious and economic way of 
achieving higher resolution as shown by two tandemly connected GF-450s. It is 
helpful for the separation of complex mixtures and the understanding of membrane 
protein interactions which are hard to achieve on one-column system. Because 
molecular interactions are usually not disrupted by the process of chromatography, 
unproportional retardation of the components by column combination may indicate 
such interactions.
In conclusion, one GF-450 column is able to separate membrane proteins 
effectively, the method is particularly useful for investigations which do not require 
total separation of individual proteins. The two-dimensional profiles provide a 
comprehensive view of the membrane protein constituents and their relationships as 
well as the relative levels of their expressions. The combination of HPLC and SDS 
gels exploits a new approach in protein separation and characterization.
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CHAPTER 6. IDENTIFICATION OF LYMPHOCYTIC SURFACE ANTIGENS BY
HPLC-SDS PAGE
1. Introduction
HPLC size exclusion chromatography, which separates the membrane components 
according to their molecular sizes, constructs the first dimension of the matrix, by the 
size distribution of the membrane proteins as either simple or complexed forms. The 
subsequent SDS-PAGE analysis forms the second dimension, showing the individual 
polypeptides of the disintegrated proteins and complexes, again in order of their sizes 
( Wu and Maddy, 1988 ).
Several proteins have been identified, either by their molecular weights on the 
matrix or by other characteristics revealed by certain analytical conditions as 
discussed in Chapter 5. However, a more definitive understanding of the patterns is 
possible by the use of appropriate antibodies. In principle, when an antigen is 
complexed with its antibody it should be eluted earlier than it is in its free state 
because of the enlarged molecular weight of the complex. A monoclonal antibody 
should only form a simple 1:1 binary complex with its antigen, therefore, the 
retention of the complex should be predictable. If a second antibody, either against 
the first antibody or different epitopes of the antigen, is used, an even larger 
complex will be formed and a shorter retention be expected ( Wu and Maddy, 1989 ). 
In this study, the combined molecular weight of the complex ( antigen-1st antibody- 
2nd antibody ) would be no more than 600KD even for the largest antigen ( see 
discussion below ), well within the total exclusion limit of GF-450. Using the 
method, the identities of several components of the matrix have been elucidated and 
confirmed.
The protocol introduced here provides not only a method of antigen identification 
but also an approach for separating antigens.
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2. Materials and Methods
CLL B lymphocytes were prepared as described in Chapter 2. The B cell viability 
and T cell contamination were monitored as in Chapter 2.
2.1. Antibody Treatment of Cell Extract
Monoclonal antibodies were added to 0.5% Triton X-100 extracts of surface- 
iodinated B-CLL cells. The quantity of the antibody was added to the saturation 
concentration based on the flow cytometric titration. Routinely 150 ul extract, derived 
from 2-3x10^ cells, was adequate for each treatment. The mixture was incubated on 
ice for 45 min before HPLC. A cell extract treated under parallel conditions without 
the addition of antibody was used as a control. For most of the antigen-antibody 
complexes, the standard HPLC operating conditions and collecting mode were found 
to be adequate.
2.2. Antibody Treatment of Intact Cells
Cells were processed and ^5j labelled as stated ( Chapter 2 ). About 10** surface- 
radiolabelled cells were washed once with FACS medium ( RPMI1640 containing 2% 
FCS and 0.1% NaN3 ) and suspended in this medium at 4-5xlO^/ml cells. Monoclonal 
antibodies were added to the suspension to the saturation concentration determined by 
flow cytometry. The suspension was then incubated on ice for 45 min with two 
inversions. Then the cells were pelleted, washed twice with RBC buffer pH 7.4 to 
remove unbound antibodies and extracted into 0.5% Triton X-100 medium.
2.3. Addition of a Second Step Antibody
10 ul rabbit anti-mouse Ig ( 3.7 ug ) ( Dakopatts, lot 056 ) was added to 100 ul 
Triton X-100 extract. The mixture was mixed gently and incubated on ice for 45 
min. Direct Triton X-100 extract of cells treated with only the second antibody was 
employed as a control. In the HPLC investigation of the samples, the collecting 
parameters were as follow:
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Delay: 4.0 min 
Fraction Time: 0.2 min 
Collect: 36 fractions
















































Twelve monoclonal antibodies have been tested in a panel of patients with B-CLL. 
Some antibodies were tested several times in the same or different individuals. The 
positive observations were usually further confirmed by at least one more test in 
different individuals. Eight out of twelve formed complexes identified by the HPLC. 
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Fig 1. Demonstration of the CD45RB determinant shifted on HPLC by mAb PD7/26 
binding, (a) control (b) the TX-100 extract treated with the mAb. Three 
components from the band 1 group were clearly moved forward for at least 









Fig 2. Demonstration of a 180KD band present in tonsilar T lymphocytes rather than B 
lymphocytes, (a) pure tonsilar B cells, showing a single predominant 230KD 
chain of CD45 antigen (b) tonsilar B+T mixture, showing the presence of a 
180KD component ( marked ). The proteins were analysed by SDS-PAGE on a 
6-11.5% polyacrylamide gradient gel. The fluorograph also shows the 
enhancement of band 4.1 intensity in B+T mixture.
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Fig 3. Identification of CD43 ( gpL115 ), CD21, MHC Class II and EZB54 antigens on 
HPLC-SDS PAGE matrix of B-CLL cells, (a) CD43 ( gpL115 ), note that two 
components were shifted together by the antibody (b) CD21 (c) MHC Class 
II (d) EZB54, 125KD, the antigen can be found in fraction 17-18 when no 
antibody is added (e) the 3H-labelled CD43 shifted by a monoclonal antibody 
specifically against CD43. The antigen is marked by an arrow. Note that only one 
component was shifted in contrast to the iodinated samples where two 
components were moved. The upper panel fluorographs are the controls. All tests 
were performed in TX-100 extracts and the samples reduced and separated on 6- 



















PD7/26 reacted with three components of the CD45 family rather than four ( 
Okamura et.al. 1982 ). Using PD7/26, three bands of the CD45 family could be 
moved forward 3 fractions and clearly separated from other surface proteins ( Wu and 
Maddy, 1989 ). The apparent molecular weights of the three reactive bands were 
230, 215 and 200KD in our 6-11.5% gel system ( Wu and Maddy, 1989 ), 
respectively. The affinity seemed to be very similar for all three bands with respect 
to the intensity of the shifted bands ( Fig Ib ), which were proportional to their 
original intensity. The light chain of the antibody, which can be silver stained, was 
found in the same fractions of the shifted components on the SDS-PAGE gels of the 
reduced samples although CD45 antigen itself is poorly stained by silver. Carefully 
checking of the silver stained gels and the autoradiographs showed that no other 
bands moved concomittantly with the shifted CD45 antigen.
Monoclonal antibody F8-11-13 has been described in detail ( Dalchau and Fabre, 
1981 ), and reacts preferentially with a determinant on 2 higher forms of CD45 
antigen encoded for by exon A. By using mAb F8-11-13, a single band at 230 KD 
was clearly shifted for two fractions, no other bands have been observed in the same 
fractions. However, prolonged exposure revealed a component of about 215KD with a 
small amount of radioactivity.
There was a diffuse band at 180KD , gradually eluted after the 200KD component 
of the CD45 family. This band could be UCHL1 with respect to its molecular weight 
although one test with UCHL1 antibody failed to confirm this. In order to elucidate 
whether this 180KD component is expressed by normal T cells, pure tonsilar B cells, 
B and T cell mixture were analysed on HPLC and it was found that normal B 
lymphocytes ( E-rosetting negative ) did not possess this 180KD component while the 
mixture of B and T cells showed a band of 180KD in addition to a 230KD and a 
200KD bands ( Fig 2 ). This 180KD component can be clearly revealed by 
neuraminidase-treated tritiated B-CLL samples on the HPLC.
F10-44-2 reacts with a component of 80KD ( Dalchau et.al., 1980 ), now defined 
as CDw44 cluster which was co-eluted with and resolved by SDS-PAGE ( gradient 6- 
11.5% ). with slightly higher MW than the heavy chain of IgM. The antigen was
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moved forward by the antibody about 2 fractions on HPLC. It was shown that a 
80KD band of the same fractions could be affected by non-reduction prior to 
electrophoresis ( see Chapter 5 ), reducing its molecular weight to about 70KD but 
previous report showed that the mobility of CDw44 antigen on SDS-PAGE was 
variable upon reduction and non-reduction ( Stoll et.al., 1989 ). It is not certain 
whether this band and the F10-44-2 antigen are identical molecules. The HPLC-SDS 
PAGE profiles of the F10-44-2-treated samples demonstrated that (1) the band 7.1 
was not CDw44 because it does not react with F10-44-2 (2) band 7.3 consists, at 
least, two polypeptides, one is the heavy chain of slg and another CDw44 which 
overlaps with slg.
Remold-O'Donnell et al. ( 1984 ) reported a monoclonal antibody gpL115, now 
assigned as CD43, to identify the Leucocyte Sialoglycoprotein ( LSG ). The antibody 
precipitated a glycoprotein with an apparent molecular weight of 115KD without 
neuraminidase treatment and 150KD with neuraminidase treatment. Our test with 
gpL115 antibody on the surface-iodinated cell extracts resulted in a two-fraction shift 
of a 115KD and a 100KD polypeptides which correspond to band 6.1 and 6.2, 
respectively, on HPLC-SDS PAGE matrix ( Fig 3a ). The 115KD component is likely 
to be the CD43 antigen as normal tonsilar B cells and PLL do not possess this band. 
The discret distribution of band 6.1 following gpL115 mAb binding suggests that 
band 6.1 may consist of more than one component. This component has been found 
present in the majority of the patients. CD43 antigen was also investigated on 
tritiated samples by HPLC-SDS PAGE and again shown to bind a molecule of 150KD 
following neuraminidase treatment ( Fig3e).
The antibodies defining the CD21 cluster precipitate a protein of 140KD. The 
molecule is a single chain and reduces its apparent molecular weight under non- 
reduction on SDS-PAGE ( Lida et.al., 1983 ). Band 4.2 has similar properties and its 
identity was confirmed by applying the mAb RFB6 ( SAPU, code 054-201 ) in the 
HPLC chromatography. The antibody was able to move nearly all of the band 4.2 
away from the fractions where the antigen eluted when no antibody was applied ( Fig 
3b ). Band 4.3 was not affected by the antibody at all. Thus band 4.2 consists solely 
of CD21 and band 4.3 is not part of CD21 as was also concluded from the reduced- 
and non-reduced samples by SDS-PAGE analysis ( Chapter 5 ).
88
I JR 4. Separation of Ml 1C Class I molecules by applying a second antibody to the 
mAb-Ag complex, (a) control, the MHC Class I antigen is fractionated in the 
later fractions not included here (b) W6/32 to intact cells (c) mouse anti-rabbit 




















_5. Detailed examination of the fractions containing the W6/32 mAb-Ag complexes. 
Two components were moved forward by adding the antibody, (a) W6/32 treated 
(b) control. The fractions were reduced prior to the SDS electrophoresis.
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The Class I MHC antigen was detected by a monoclonal antibody W6/32 in both 
intact cells and Triton X-100 extract of the cells. W6/32 is an anti-Class I MHC 
monoclonal antibody ( Parham et.al., 1979 ). One crucial difference of the shifted 
antigen was found between the treatment of intact cells and the Triton extract of the 
cells. With the intact cells, W6/32 binding resulted in reduced retention times of both 
a chain and B2" micr°Slobulin. B2~ m *cr°8l°bulin could be clearly observed in the 
fractions containing the a chain. However, this 12KD component was not co-shifted 
with the a chain if the cells were extracted before W6/32 added.
The W6/32-shifted band ( Fig 5 ) was rather diffuse and the a chain appeared to 
be comigrating with another component with a very close mobility on SDS-PAGE. 
Several fractions containing Class I MHC-W6/32 complex were subjected to closer 
investigation to generate better defined images. It was shown clearly that W6/32 
antibody actually moved another component at about 45KD, in addition to the <x and 
fl chains of the antigen, It is not yet known which band is the a chain of Class I 
MHC. The apparent molecular mass of these two bands were 45KD and 43KD, 
respectively ( Fig 6 ).
When a second antibody, an anti-mouse Ig, was incubated with W6/32-treated cell 
extract before chromatograhpy, the antigen, together with the unknown component, 
were completely separated from other surface antigens and recovered from fractions 
2-4 ( Fig 5c ) ( Wu and Maddy, 1989 ).
Monoclonal antibody DA6/147 reacts with the framework determinants of Class II 
MHC a chain ( Guy et.al., 1981; Van Heyningen et.al., 1982 ). However, it was 
consistently found that both a and B chains of the antigen were brought forward two 
fractions on HPLC by mAb DA6/147 ( Fig 3c ). Coincidently both chains were 
decreased in the fractions where they were normally recovered ( Fig 3c, upper panel 
). By this method, two bands in band 8.4, a complex group of bands, have been 
clearly defined as the members of the HLA-DR family.
EZB54 is an IgG3 raised in this department by fusion between NS-1 cells and CLL 
immunogenised mouse spleen cells. The determinant recognized by EZB54 exhibited a
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restricted distribution—expressed only in certain normal and malignant cells of both 
lymphoid and myeloid origins. So far, repeated attempts by immuno-precipitation and 
Western blotting ( Maddy, personal communication ) to isolate the molecule have been 
unsuccessful. However, using HPLC the antibody was found to shift a component to 
fractions 13-14. This was a single band occupying a distinct position on 6-11.5% 
gradient SDS gels with an apparent molecular weight of 125KD under reduction ( Fig 
3d ). It has not been possible to distinguish the antigen in its uncomplexed form from 
the bands in this region of the matrix, but chromatography of two-column 
combination revealed a band with a similar molecular weihgt in fraction 18-20.
Monoclonal antibody EZB52 ( Brown et.al., 1985 ) is reactive with B-CLL and 
normal T cells as well as tonsillar B cells. The antibody precipitated a single band at 
105KD. With two B-CLL samples tested using this antibody on HPLC, no observable 
movement could be found.
CLL B cells with band 4.3 were investigated with monoclonal antibody RFB4 ( 
SAPU, code S053-201 ), which is specific for CD22. The antibody was tested in cell 
extract only and no shifting of the band was detected.
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4. Discussion
The CD45 antigen consists of, mostly, four components with apparent molecular 
weights ranging from 180 to 240KD according to different authors, showing a marked 
heterogeneity in molecular mass, glycosylation and antigenicity. In our system their 
molecular weights are 230, 215, 200 and 180KD, respectively.
PD7/26 is the prototype antibody which defines the epitope shared by 230, 215 and 
200KD chains. The results generated by HPLC are in consistent with previous work ( 
Pulido et.al., 1988 ). The two-dimensional matrix of HPLC-SDS PAGE suggests that 
PD7/26 antibody does not bind preferentially to any of the three components.
F8-11-13 ( Dalchau and Fabre, 1981 ) was one of the earliest antibodies defining 
the restricted human CD45RA. It precipitates the highest molecular weight members 
of the family. In our system, F8-11-13 can effectvely move the 230KD band of 
CD45 on HPLC but not the second chain of 215KD. Dalchau et.al. ( 1981,1986 ) and 
Brown et.al ( 1985 ) reported that F8-11-13 recognized two high molecular mass 
bands at 220 and 215KD, respectively. The difference could be attributed to the fact 
that two patients investigated in our system were both expressing predominantly the 
230KD component, which yielded most dramatic shift of the antigen, while the 
autoradiography was based on the average exposure. A faint band was just detectable 
after a prolonged exposure but its identity has not been clarified because of the heavy 
shading of the overexposed 230KD band.
The 180KD glycoprotein of the CD45 antigen is recognized by a monoclonal 
antibody UCHL1 ( Smith et.al., 1986 ). Research ( Cebrian et.al., 1987 ) has shown 
that UCHL1 reacts with an unique antigenic epitope on the 180KD form of the 
CD45. Our failure to identify UCHL1 might be due to the use of tissue culture 
supernatant as a source antibody which has lower immunoglobulin concentration 
although is appropriate enough for FACS. As the UCHL1 antigen maintains its 
antigenicity after denaturation by SDS and the antigen is precipitable under the 
presence of 1% NP-40 ( Terry et.al., 1988 ), it is unlikely that the unreactivity 
observed could be due to Triton X-100 destruction. We have found it somewhat 
difficult to use antibody tissue culture supernatant for the HPLC study with other
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antibodies as well, such as EZB52. One explanation could be that there are not 
enough immunoglobulin molecules around to saturate cell surface or the antigens in 
the extracts to form detectable complexes. As the 180KD component on the matrix 
has not been identified with antibody, its being CD45RO is largely based on its 
molecular weight and the observation of tonsilar B and T cells.
Although only part of the CD45 is shifted by both PD7/26 and F8-11-13 it is 
unlikely that the unshifted bands are from some unknown proteins because (1) the 
variations of these three components recognized by PD7/26 in different patients 
suggest that these three bands are interrelated, in patients who express predominantly 
lower bands there is an insignificant amount of F8-11-13 (2) the results of mitogen- 
induced changes of the antigen expression ( see Chapter 8 ) suggested the bands to be 
CD45 only. The incomplete shift may be attributed to incomplete binding of the 
antibodies.
The molecular weight of the antigen recognized by monoclonal antibodies of the 
CD44 panel has been demonstrated as 80-90KD ( non-reduced ) and 80-95KD ( 
reduced ) in different cells from the haemopoietic system ( Spring et.al., 1988 ). It is 
possible that the 80KD component consists of several distinct molecules, including 
CDw44. A possible relation of CD44 antigen to the lymphocyte homing receptor was 
suggested ( Omary et.al., 1988 ). Further experiment is desirable to distinguish and 
elabrate the molecules in this group since the surface Ig heavy chains also fall in this 
region which have long been a significant parameter of the cell physiology.
Both the reduced and non-reduced samples and the antibody-treated SDS-PAGE 
studies have proposed that band 4.2 consists solely of CD21 antigen and that band 4.3 
is a distinct component. In our system, band 4.2 ( CD21 ) has an apparent molecular 
weight of 140KD after reduction and 120KD when not reduced ( Chapter 5 ). By 
employing HPLC separation, we are able to effectively reveal band 4.3 which is 
partially overlapped by CD21.
CD22 antigen is a pair of highly glycosylated proteins with apparent molecular 
weights of 130 and 140KD, respectively ( Moldenhauer et.al., 1986; Dorken et.al., 
1986 ). The antigen has a peculiar distribution during B cell ontogeny ( Dorken et.al.,
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1987 ) and it is found present in the cytoplasm of all B cells. 75% of CLLs are 
positive but always weakly. CD22 expression in the cytoplasm may account for the 
failure to detect this antigen on HPLC because cytoplasmic CD22 antigen could 
compete for the antibody, preventing the complex formation of the radioactively 
labelled membrane CD22 with the antibody. In addition, the low expression of this 
antigen on cell surface itself could also be a reason for the negative results although it 
could be detected by FACS. Moreover, no band was ever silver stained in the 
molecular weight range around 120-140KD, which means that CD22 perhaps can not 
be stained by silver and any possible shift of the cytoplasmic CD22 by the antibody 
would not be detectable. From this point, it is desirable to investigate the CD22 on 
intact cells by employing monoclonal antibodies on HPLC system.
From the HPLC results, it is demonstrated that either bands 6.1 or 6.2, or at least 
part of the bands, is CD43. Immunoprecipitation also resulted in two bands ( 
Stefanova et.al., 1989 ). It is more obvious on neuraminidase-treated tritiated samples 
in which CD43 antigen was displayed in a distinct position of 150KD and shifted 
with the added antibody although a weaker band was found to overlap with it. The 
gpL115 ( CD43 ) antigen can actually be better located on the tritiated gels where 
there are fewer bands as shown by Fig 6. The nature of the co-shifted band is still 
not clear and remains to be identified. The tritiated results also show that the gpL115 
epitope activity is not affected or disrupted by cleavage of sialic acid residues, 
implying that the determinant is not located on the terminal sialic acid. By direct 
comparison of the autoradiographic patterns of the B cells of CLL patients, it was 
found that CD43 antigen was present in some patients but absent from others. 
However, no certain correlation has been found with respect to other documented 
surface antigens.
The nature of the band which was co-shifted with Class I MHC is unknown. 
Immunoprecipitation has been reported, at 45KD range, to generate only a single 
band ( Parham et.al., 1979 ). Therefore, it is unlikely that the double band is a 
consequence of polymorphism. It seems that these two bands are associated as: (1) 
treatment of either cell extract or intact cells by W6/32 produced identical positive 
results and (2) both bands were shifted with indistinguishable retention times. It is
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likely that the co-shifted component is in association with the a chain of the antigen 
rather than cross-react with the antibody.
The Class II MHC complex is composed of two non-covalently bonded polypeptide 
chains with an apparent molecular mass of 35KD for a chain and 28KD for 6 chain, 
respectively. The association between the a and 13 chains is found to be stable in non- 
ionic detergent as both components have the same retention times in the column and 
the combination of either two GF-450s and one GF-450 with one GF-250 failed to 
resolve the a and 6 components, indicating that the similarity of their retardation is 
not caused by the limitation of column resolution. The integrity of the molecule after 
chromatography suggests that the analytical conditions established in this study are 
suitable for some weak interactions.
It is observed that the a component is more strongly iodinated than the J3 
component in some patients while the position is reversed in other cases. No 
correlation has been noted between the relative intensities of the a and B chains and 
any other characteristics of the patients.
According to the previous study in this lab, the determinants recognized by 
monoclonal antibody EZB54 have a very restricted distribution, only expressed by 
some normal and malignant cell types of both lymphoid and myeloid origins. FACS 
shows that B-CLL cells are EZB54 positive. However, attempts to isolate the antigen 
by either Western blotting and immunoprecipitation have always met with failure. 
The success of identifying this antigen by HPLC suggests that (1) the antigen is a 
protein iodinatable by the method used in this study (2) neither the determinant of 
the antigen nor the binding of the antibody to the determinant are destroyed by 
solubilization as previously suggested (3) the failure of isolating the antigen by 
conventional methods may well be caused by the harsh conditions and low binding 
affinity.
This chapter describes the methodology of HPLC size exclusion, in combination 
with monoclonal antibodies, for the identification of surface antigens of lymphocytes. 
The technique has been proven to be a specific, consistent and one-step simple 
method. As size exclusion is a gentle physical process, one should expect that non-
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covalent interactions between polypeptides, low affinity binding of antibody, and 
molecular integrity would survive under such a mild procedure. It has been observed 
that some silver stained bands, which were not surface-iodinatable, were co-migrating 
with some iodinated bands which were shifted after complexing with their antibodies. 
However, it is beyond the scope of this thesis to examine and discuss the silver 
stained HPLC-SDS PAGE profiles. But it would certainly be valuable to make a close 
investigation of these gels.
Although the amount of an antibody employed is based on flow cytometric 
titration for the maximum bindings, usually at the same dilution, the actual ratio of 
an antibody to the antigen may not be at its optimum because if a surface antigen is 
also expressed within the cytoplasm, after solubilisation of cells, the quantity of the 
antigens could be greatly increased in the medium. Therefore, caution must be taken 
in determining the antibody amount. Usually an 10-30% excess of antibodies is used 
in our routine studies. For some bands on SDS-PAGE, a shift does not necessarily 
exclude the presence of other bands with the same mobility in SDS-PAGE, hence 
optimum ratio of antibody to antigen could be essential.
Applying a second antibody to the first-antibody-antigen complex has been proven 
very effective to identify and to separate an antigen from a protein mixture, as 
demonstrated by mAb W6/32 in this study. The narrow distribution of the shifted 
multi-complex indicates that, under the conditions employed, the polyclonal antibody 
( the second antibody ) did not yield a broad spectrum of cross linking at different 
levels, generating complexes with widely different molecular masses. It is preferable 
to apply the first antibody to intact cells as the excess antibody can be washed away, 
it is particularly advantageous when the second step involves polyclonal antibody ( 
Wu and Maddy, 1989 ). In such case, it might be crucial to avoid using too large an 
excess of antibody and a too prolonged incubation time, otherwise, immuno- 
precipitation or a highly cross-linked surface protein network might occure. In 
addition, one should always use the minimum incubation time to avoid secondary 
effects of excessive incubation, neverthless reduction of cell viability, changing of the 
surface protein expression and of the physiological statue of interactions between 
receptors and the underlying cytoskeleton could become significant.
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CHAPTER 7. PHENOTYPE ANALYSIS OF LYMPHOCYTES BY HPLC-SDS PAGE 
1. Introduction
The lymphocyte cell surface has the specialised function of recognizing external 
molecules. The consequences of this recognition are closely related to lymphocyte 
proliferation and differentiation to immunocompetent memory and effector cells. 
Mostly, this recognition is carried out by membrane surface glycoproteins.
Some surface glycoproteins are cell-type specific while others are common to more 
than one type of cell. In normal leucocytes, studies have shown that the expression of 
certain glycoproteins is associated with paritcular stages of cell development. As finer 
details of B-cell surface phenotypes are revealed, it is found that some surface 
markers are detectable only in some of the B cells, which helps to group B cells into 
distinct subsets with respect to the expression of these specific markers, i.e. MRBC+ 
and CD5+
However, this correlated expression of surface proteins becomes disrupted in 
neoplastic cells. The neoplastic transformation of CLL cells involves a monoclonal 
expansion of the lymphocyte, accompanied by a heterogeneous expression of surface 
membrane proteins. Recently, new approaches have been developed to correctly 
define different B-cell populations and/or maturation stages and to compare B-cell 
malignancies to their putative normal counterparts ( Gobbi et.al., 1983; Dighiero and 
Binet, 1987 ). But a direct comparison of surface phenotypes is complicated by the 
fact that CLL cells frequently express markers of both early and later B cell 
development, such as the expression of cytoplasmic Ig which is reminiscent of the 
pre-B stage of normal lymphocytosis and of CD23 which is normally expressed on 
activated cells. This disordered asynchronous expression of markers is also 
demonstrated in other types of leukaemias, e.g. PLL.
Attempts have been made to exploit the heterogeneity of CLLs, both in terms of 
their surface phenotypes and the clinical progression. Foon et.al. (1982) and Anderson 
et.al. (1984) examined the surface phenotypes of entire range of leukaemias and 
lymphomas and found that the different types of phenotype showed a continuous
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variation and this variation can be correlated to the differentiation sequence of 
normal B lymphocytes. Systematic studies in this laboratory ( Smith et.al., 1985; 
Brown et.al., 1985 ) have revealed that the expression of CD45 antigen in CLL 
exhibits a continuous spectrum, varying from typical B cell patterns to a T cell-like 
profile with intermediate forms between the two extremes. Later work in this lab 
established the correlation between slg expression and that of CD45RA ( Brown et.al., 
1987 ). There have been a few reports on other differentiation markers, atttempting 
to depict interrelationships between different leukaemias.
Conventional methods for phenotypic investigation present difficulties in direct 
comparison of several markers in different patients and are also restricted to only 
known markers. This chapter describes the application of the HPLC technique for the 
analysis of neoplastic cell surface phenotypes and the construction of the membrane 
protein repertoire.
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2. Materials and Methods
CLL lymphocytes were prepared as described in Chapter 5. Washed cells were 
surface-labelled by either iodination catalysed by lactoperoxidase or neuraminidase- 
galactose oxidase tritiation. Routinely, 2.5-5xl07 cells were adequate for one run on 
the column.
All samples were subjected to chromatography within 24 hours. Normally 24 
fractions were collected, first 15 of them subjected to SDS gel electrophoresis either 
on 6-11.5% or 8-15% gradient polyacrylmide gels, depending on the molecules to be 
examined. Autoradiography was carried out as stated ( Chapter 5 ). For the purpose 
of comparison, films were exposed to produce equivalent densities for different 
patients and different runs of the same patient.
Bands were designated as stated in Chapter 5.
The same panel of patients were also investigated by flow cytometry ( by A.H. 
Maddy ). The FACS data were compared with the HPLC observations and used as a 
comlementary source for the study.
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3. Results
During the course of this study, 30 patients with B-CLL, one with PLL and one 
with T-CLL have been examined. The B-CLL patients were diagnosed at different 
stages of the disease progression. Comparison of the surface phenotypes was based on 
their HPLC-SDS PAGE autoradiographic patterns in conjuction with silver stained 
gels and FACS data. It was found that in all the patients band 3 was constant in 
intensity relative to other bands and showed no significant change. Studies in this lab 
have shown the variation of CD45 expression ( Smith et.al., 1985 ) in B-CLL and its 
correlation with slg ( Brown et.al., 1987 ). In addition, the CD45 molecule was well 
separated by HPLC from other components and easily defined in the front fractions. 
Therefore both molecules were employed as bases for the comparison of 
autoradiographic intensity. The relative autoradiographic intensities of these related 
bands are tabulated in Table 1 of the appendix. The arabic numbers are the band 
numbers quoted from Fig 1 of Chapter 5. Band 3 intensity is employed as a criterion, 
which is rated five pluses. All ratings only mean relative value and were largely based 
on visual observations. However, the majority of these results are confirmed by at 
least two individual investigations of each patient and have demonstrated high 
consistency and reproducibility.
In the light of the intensity variation of three CD45 bands, namely 230KD, 215KD 
and 200KD, cell phenotypes are classified into two types, 1A and IB.
3.1. 1A Type
Thirteen patients in this group were investigated by HPLC, consisting of about 
43% of the patients investigated. They are:
1A Type(i): McG, Lot (1987), Cur, Jac, Kay, Pau, Wal 
1A Type(ii): Lyn, Bur, Cla(?), Sea, Ore, Ske, Gil.
The 1A form of CLL was correlated with the following phenotypic traits ( Fig 1 ):
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_!_. Typical 1A phenotype of B-CLL cells, with a schematic presentation showing 
different surface components and their relative intensity. The schematic 

























































3.1.1. This group is featured by a strong CD45RA ( 230KD and 215KD ) with, 
sometime, weak 200KD forms of the CD45 family. Previous study by FACS ( Smith 
et.al., 1985 ) has demonstrated that the level of UCHL1 expression is very low in this 
group. Similarly, HPLC-SDS PAGE only detected a very weak or no 180KD band in 
the vicinity of other CD45 bands. As the expression of 230KD varies greatly, it is, 
therefore, helpful to subdivide this group according to the relative intensities of 
230KD and 215KD bands. lA(i) type is characterized by the predominance of 230KD 
and weak 215KD forms of the CD45 antigen while 200KD band is consistently 
undetectable. By this criterion, seven patients were included in this catalogue. lA(ii) 
type features relatively strong 215KD chain and significantly increased intensity of 
200KD band of the CD45 although 230KD was still the predominant component. This 
classification of the autoradiographic patterns was found to be consistent with that of 
the FACS results by Smith et.al. (1985), for the same panel of patients. Other 
common features of 1A type CLL B lymphocytes, in addition to CD45 expression, are 
described as follows:
3.1.2. The 140KD band of CD21 was strongly expressed by this group of patients 
although weak expression was observed in 2 lA(ii) type patients. It was demonstrated 
that a high level of 230KD was consistently accompanied by a high level of CD21 
expression, i.e. lA(i) patients have higher CD21 than lA(ii) patients. The intensity of 
autoradiography of this 140KD band was comparable to band 3, a 220KD component. 
Monoclonal antibody to CD21 could shift the 140KD band almost completely, which 
means that the band is contributed solely by CD21. In addition, CD21 is strongly 
positive in P-LL ( Fig 3a ) and normal tonsillar B cells but very weak in T-CLL ( 
Fig 3b ) with respect to both autoradiography and flow cytometry.
3.1.3. Band 4.1, a component of 150KD, was present in all patients of this group with 
high positivity. This 150KD molecule was positively correlated to 230KD band of 
CD45RA expression. The behaviour of this polypeptide under reduction and non- 
reduction has been described in Chanter 5. Band 4.1 was also observed to be strongly 
expressed by PLL, normal tonsillar B cells ( Fig 3c ) and malignant cell lines ( see 
Chapter 10 ). This component was eluted to fraction 8-10, always one or two 
fractions later than CD21 although it has a higher apparent molecular weight. Normal
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tonsilar T cells were found to express this component, probably strongly as shown in 
Fig 2 of Chanter 6.
3.1.4. Band 4.3, of an apparent molecular weight of 135KD in fraction 10-11, is 
present in all 1A type CLL B cells and with significant amounts in PLL. This 
component was found in the vicinity to band 4.2 on SDS-PAGE and partially 
overlapping band 4.2 but the band 4.3 was sharp and well defined. The band was 
unlikely to be artifactual since (1) the component was detected only in 1A type CLLs 
and consistently expressed by individuals within this category (2) its autoradiographic 
intensity was constant within individuals over the course of investigation and (3) 
more importantly, its expression was reduced by mitogenic activation of the cells ( see 
Chapter 8 ). In addition, this component was unreactive with a monoclonal antibody 
to CD22 and its mobility was not affected by reduction-non reduction SDS-PAGE. 
These observations exclude its being CD22. The band, however, was detected on 
neither normal tonsillar B nor normal tonsillar B and T cell mixtures ( Fig 2 in 
Chapter 6 ).
3.1.5. Band 7.1 is one of the major surface proteins with respect to its 
autoradiographic intensity. This 78KD polypeptide is present on all B-CLL, PLL and 
normal tonsillar B cells but B-CLL 1A and PLL were found among the strongest 
while tonsillar B cells, somewhat, weaker. lA(i) type patients usually possess higher 
levels of band 7.1 than lA(ii). The expression of this component is correlated 
positively with that of CD45RA.
3.1.6. A fairly faint band with an apparent molecular weight of 170KD was 
consistently found in fraction 6-8. This band appeared to co-elute with 230KD chain 
of CD45RA and to be associated with lA(i) type only. Of course, it is possible that in 
other patients, this faint component is shaded by lower forms of CD45 bands. In 
PLL, this band was clearly defined and quite strongly expressed. However, it was 
undetectable on normal tonsillar B or B and T cell mixtures.
3.1.7. All IA type B-CLL demonstrated relatively high surface immunoglobulin. In 
comparison, PLL showed even higher expression of slgM. It seemed to be that the 
PLL case studied only expresses slgM as shown by Fig 3a. Normal tonsillar B
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lymphocytes were also strongly surface Ig positive but overall intensity was lower 
than PLL and it has been observed to express both slgD and slgM with higher IgD 
than IgM, so as indicated by FACS.
3.1.8. Two patients out of ten in this category were found to express a strong band of 
60KD in fraction 12-14. Little is known about it.
3.2. IB tvoe
Eleven patients are grouped into this category, they are:
IB Type(i): Tho, Col, Sul, Web, Bla , Sow, For. 
IB Type(ii): Tot, Par(87), And, Woo.
The rest of the tested patients could not be definitly grouped into either of these 
categories either becuase of (1) poor gel patterns (2) not typical 1A or IB patterns, 
which, therefore, were called * intermediate '.
3.2.1. The lower forms of the CD45 antigen are now predominant, usually with 
different combinations of band intensities. This type can also be subdivided into two 
subgroups by their CD45 expression. The IB(i) type cells usually contain all four 
chains of the antigen, i.e. 230KD, 215KD, 200KD and 180KD ( the UCHL1 ) while 
the IB(ii) type lacks or expresses very weakly 230KD form, and much more 
prominant 200K.D and the UCHL1 components. Extreme IB(ii) type B-CLL cells 
showed complete absence of 230KD band of CD45 antigen and extraordinarily high 
UCHL1 expression as shown in Fig 2, a feature represented by T-CLL cells ( Fig 3b 
). This 180KD component, eluted gradually following the other three chains of the 
CD45 antigen, was not observed on normal tonsillar B cells but apparently present on 
tonsillar B and T cell mixture ( Fig 2 in Chapter 6 ). Other features of this type 
include:
3.2.2. All IB cells express an unique component, band 2, a sharp band with an 
apparent molecular weight of about 300KD, being usually found in fraction 8-10 ( 
Fig 2 ). By its molecular mass, this component appeared to be anormalously retarded
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by the column, it should be excluded from the column earlier than the CD45 
components. Its mobility on SDS gels appears not to be affected by reduction-non 
reduction prior to electrophoresis. The level of this component varies considerably in 
different individuals. Generally, IB(ii) exhibits higher band 2 than IB(i). Those 
patients with strong 200KD or 180KD of CD45 showed strong expressions of the 
component. The expression of this molecule varied upon cell activation. 1A type B- 
CLL lymphocytes acquired this component while IB type showed elevated expression 
following phorbol ester treatment ( see Chapter 8 ). Band 2 might have positive 
correlation with UCHL1 expression but it is still imponderable. An attempt to raise 
monoclonal antibodies to it is being undertaken.
3.2.3. Generally, band 4.1 expression was weak, with considerably lower levels than 
in 1A cases. The positive correlation between band 4.1 and CD45RA ( 230KD ) has 
been further substantiated by B-CLLs in this group, the band 4.1 declined in parallel 
with the reduction of the CD45RA expression. This 150KD component was found 
very weak or undetectable in IB(ii) type cells.
3.2.4. CD21 expression varied in different patients of this group. Largely its 
expression is positively correlated with CD45RA expression although exceptions were 
observed. However, it has been noticed that in those with a fair amount of UCHL1 
expression CD21 is always low. One IB(i) type patient was shown with exceptionally 
high CD21 with other features being typical of IB(i).
3.2.5. Band 4.3 was rarely observed in most of the patients in this category. It was 
only weakly expressed when present.
3.2.6. Band 7.1 is weaker in IB type than in 1A type and shows the similar 
relationship with CD45RA as described for 1A type cells.
3.2.7. In all cells of this group, surface immunoglobulin is decreased significantly, as 
detected by either autoradiography or FACS, in comparison with those in 1A type.
In addition to B-CLL lymphocytes, one prolymphocytic leukaemia and one T cell 
CLL have been investigated in this study. PLL has very similar patterns to the
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extreme 1A type, but with much higher surface immunoglobulin, IgM, as shown by 
both HPLC-SDS PAGE and flow cytometry.
Normal tonsillar B cells are also found to be similar to 1A type cells with respect 
to band 4.1, CD21, CD45RA and band 7.1 ( Fig 3c ). However, two marked 
differences have been observed. (1) there is a band co-migrating with 230KD chain 
of CD45 with an apparent molecular weight of 250KD. This component is not band 2 
because of its fractionation and the molecular weight (2) normal tonsillar B cells do 
not express band 4.3.
T-CLL exhibits features of IB type CLL cells with respect to the absence of 
230KD of CD45RA, a strong 200KD chain of CD45 and the UCHL1, the expression 
of band 2 and absence of CD21. However, band 4.1 is abnormal. It is highly 
expressed but appears to have higher molecular weight than in B-CLL cases. It 
appears to be about 170KD. This band might not be band 4.1, and needs further 
identification.
3.3. in vivo Changes of CLL Phenotvpic Presentations
Surface phenotypes of patients normally remain stable over the course of the 
disease but two unusual cases have been found to change those surface phenotypes 
progressively which distinguish 1A type from IB type. The findings provide back-up 
evidence for the typing system as well as the correlations among these markers.
Example one. Lot
Investigation of this patient extended over more than two years. Distinct changes 
were found during this period ( Fig 4 ). In 1987, when the first investigation was 
conducted, the patient was a typical 1A type, having only 230KD band of the CD45 
antigen as revealed by autoradiography of HPLC-SDS PAGE ( Fig 4a ). By 1989 the 
230KD component had decreased while the 215KD appeared and the 200KD band 
was the strongest among three as shown by Fig 4b. Band 2, absent in 1987 samples, 
was expressed in 1989 as the CD45RA declined. In addition to these shifts, both 
CD21 and band 4.1 markedly decreased in intensity. The band 4.1 was stronger than
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CD21 in 1987, but was weaker in 1988 and 1989, indicating its close correlation with 
the CD45RA expression. The band 4.3 disappeared as the patient developed from 1A 
type to IB type phenotype as elaborated by Fig 4b. In 1988, the phenotype was found 
at an intermediate stage ( data not shown ), where 215KD and 200KD bands were 
emerging although other changes were still unnoticeable. It was noticed that the 
lymphocytosis of the patient increased in severely over this period.
Example two. Par.
Patient Par was initially shown to be typical of IB characteristics ( Fig 5a ). 
Investigated by HPLC in 1987, the patient showed a very low 230KD expression of 
the CD45 antigen, positive band 2, weak band 4.1 and negative 4.3 ( Fig 5a, I and II 
). One year later, in a routine investigation, it was discovered that the phenotype 
developed towards 1A type. The 1988 autoradiograph ( Fig 5b ) indicated that the 
CD45RA gained an equal intensity as the 200KD chain, being distinct from those of 
1987. Moreover, band 2 no longer existed while band 4.3 could be clearly defined. 
The most dramatical change was band 4.1, which became one of the strongest bands, 
comparable to band 3 in the term of autoradiographic intensities.
Above changes were also confirmed by FACS study but the autoradiographs 

























Fig 3. The fluorographic profile of a two-dimensional HPLC-SDS PAGE matrix of some 
other lymphocytic leukaemias, (a) PLL, showing its similarities with B-CLL 1A 
with respect to the expression level of CD45RA, CD21, band 4.1 and 4.3 as well 
as high surface immunoglobulin (b) T-CLL, showing its similarities with B-CLL 








































































































































































































































































































































































The study in this chapter examined the phenotypes of the B lymphocytes from 
patients with chronic lymphocytic leukaemia. The phenotypes vary among patients 
and show a spectrum of continuous changes across the patient panel. HPLC has 
confirmed the earlier findings in the variation of CD45 expression in the same panel 
of B-CLL patients and its correlation with slg expression ( Brown et.al., 1987 ). In 
addition, four new surface components have been described with respect to their 
relationships with CD45 expression and more delicate associations of surface markers 
with CLL heterogeneity have been revealed.
The CD45 expression on B-CLL cells shows marked heterogeneity, ranging from 
the typical of B cells to the profile featured by normal peripheral T cells. The B 
lymphocytes of CLL appear to frequently express the lower molecular mass forms of 
the CD45 antigen with a concomittant reduction of CD45RA. Such a reciprocal 
relationship has been demonstrated by flow cytometry ( Smith et.al., 1985; Maddy 
et.al., 1989 ). The continuously progressive expression of the four chains of CD45 
antigen within the CLL panel suggests a relationship between the antigen expression 
and the physiological conditions of the cells. Considering the differential expression 
of the CD45RA, various cells tested can be ranked in the order of PLL, tonsillar B 
lymphocytes, 1A CLL, IB CLL and T-CLL in the order of decreasing CD45RA 
expression. Therefore the 230KD+ and 230KD~ cells are at the both extremes along 
the spectrum of CD45 expression with cells bearing different combinations of the 
four chains in the middle. This finding is consistent with flow cytometric data by 
Smith et.al. (1985). The significance of this delineation is that the variation of CD45 
expression is continuous and in an interrelated differential way and may indicate the 
differences of maturity as the expression of individual members of the CD45 antigen 
is controlled not only in a cell-type-specific fashion ( Scheid and Triglia, 1979 ), but 
also by the maturational states of the cells ( LeFrancois and Bevan, 1984; Katz et.al., 
1985 )
Band 2 has been described for the first time in lymphocyte. In order to ascertain 
whether band 2 is originated from T cell contamination in B-CLL or whether normal 
B cells bear this component, normal tonsillar B cells, and a B and T cell mixture ( T
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cells > 25% ) were analysed by chromatography. The autoradiographs showed that this 
component was neither present in the purified B cells nor in the B+T cell mixture, 
suggesting that band 2 is not expressed in either normal tonsillar B or T lymphocytes. 
On the other hand, pure tonsillar B cells displayed a dominant 230KD band while the 
B+T cell mixture generated a pattern with four chains of the CD45 among which two 
distinct bands of 230KD and 180KD were discretly defined, the 180KD is likely to 
be CD45RO contributed by the T cells while pure B cells consistently lack this 
component.
Band 2 could be biologically interesting as its expression is closely associated with 
CD45RA~UCHL1 + cells, ( i.e. T-cell features ) and its exclusive absence from 1A 
type CLLs raised an interesting question about its expression. The finding of band 2 
on T-CLL cells further indicates its tendentious association with cells bearing more T 
cell features. The enhancement of band 2 on mitogen-activated CLL B cells suggests 
that it might be linked with a more advanced stage of differentiation. The 
significance of the absence of this component in either normal tonsillar B or T cells is 
that this component might be specifically associated with CLL malignancy or certain 
stages of the malignancy. The acquisition of the component as in the Lot case 
described above is such an indication of staging. The reciprocal change of CD45RA 
and band 2 has been noticed to be concomittant with the clinic frequency of the 
patients as exemplified by two clinical examples abovementioned, i.e. as the 
phenotype was approaching IB the clinic frequency went up, vice versa. But this 
relationship needs to be further investigated.
The expression of band 2 exclusively in IB type patients suggests that this band is 
not from T cell contamination of B-CLL. T cell contamination in the B-CLL cell 
preparation used was routinely below 5%. Moreover, the correlated expression of 
band 2 with the change-over of CD45RA to 200KD-predominant in Lot, and vice 
versa in Par, further excludes the possibility of being T cell contamination and 
supports its validity as a marker for IB type CLL. Actually the proportion of T cells 
in B-CLL decreases as the lymphocytosis increases. Therefore, it is unlikely that the 
enhancement of band 2 is resulted from T cells in malignant B lymphocytes. These 
data strongly imply that the band is in association with malignant state of B 
lymphocytes in B-CLL patients. But it obviously requires further study to clarify
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whether the acquisition or enhanced expression of this band is associated with a 
certain stage of lymphocyte maturation and the prognosis of the disease.
Though little is known about band 2, its unique expression is of great interest: 
prolymphocytic leukaemia is negative, all CD45RA-predominant B-CLL is negative 
while 200KD- and 180KD-predominant B-CLL is positive, particularly those 
CD45RA". T-CLL is strongly positive. Evidence that band 2 may be a maturational 
marker of B-CLL is provided by in vitro activation of B-CLL lymphocytes by TPA ( 
manuscript in preparation ). CD45RA+UCHLl-band2- B-CLL cells were converted 
to CD45RA-UCHLl+band2+ after 4-day TPA incubation. The effect of TPA on 
lymphocytes has been extensively described ( Nadler et.al., 1981; Lida et.al., 1983; De 
La Hera et.al., 1988 ) but the acquisition of a 300KD ( band 2 ) polypeptide upon 
such stimulation has not been previously reported. In other cases, the enhanced 
expression of band 2 in CD45RB+UCHLl+band 2+ patients by TPA also indicates 
maturational differences among CLL clones. A detailed discussion is given in Chapter 
8 and the general discussion.
The variation in the expression of band 4.1 is strongly correlated with that of 
CD45RA although a weak expression can be detected on CD45RA" cells. De La Hera 
et. al. (1988) immunoprecipited a 150KD polypeptide from CD5+ B-CLL cells by 
using HC1/1 monoclonal antibody specific for CDllc. In term of the apparent 
molecular weight, it seems to suggest that band 4.1 could be CDllc, but the 
expression of band 4.1 and CDllc with respect to cell types is distinct ( De La Hera 
et.al.,1988 ). In addition, the expression of band 4.1 was reduced drastically upon 
TPA activation ( see Chapter 8 ), in contrast to recent studies that CDllc" B-CLLs 
acquired the antigen after in vitro activation ( De La Hera et.al., 1988 ). These data 
indicate that CDllc and band 4.1 are distinct proteins. The nature of this protein 
deserves further study.
The high expression of this 150KD protein in prolymphocytic leukaemia together 
with other features further substantiates the positioning of PLL along the 1A side of 
CLL, well in concert with its CD45RA expression and the lack of band 2.
118
In this study, CD21 is found in positive correlation with CD45RA, although it is 
expressed in some IB type ( 230KD weak ). However, comparing with other surface 
markers, such as band 4.1, CD21 lacks consistent correlation with CD45RA cross the 
whole patient panel. It is likely that this molecule involves central role of the 
complement system and acts as a receptor for the pivotal component, C3d ( Weis 
et.al., 1984; Mold et.al., 1986 ) and the Epstein-Barr virus ( Fingeroth et.al., 1984; 
Frade et.al., 1985; Nemerow et.al., 1985 ), and its expression is relatively stable 
within a narrow span of differentiation, unlike the CD45 antigen in CLL, whose 
expression, although also confined to a rather narrow stage, is in a differential 
fashion along B cell maturation. Campana et.al. ( 1985 ) and Bofill et.al. ( 1985 ) 
found that in subpopulations of normal resting B cells, peripheral blood, bone marrow 
and secondary lymphoid organs, CD21 was negative on the majority of IgM+/IgD~ 
cells and positive in the majority of IgM+/IgD+ cells. The finding of this study, 
however, is not in favour of this observation as shown in Table 1. The discrepancy 
might be due to differences of cell types or more likely of the techniques.
The positive correlation between band 4.3 and CD45RA has been established. By 
SDS gel electrophoresis of non-reduced samples, band 4.3 can be readily defined. The 
observation in Chapter 6 has demonstrated that band 4.3 is not CD22. At present 
little is known about this component but its marked expression in 1A type patients 
and reduced expression upon in vitro mitogenic activation ( see Chapter 8 ) are 
suggestive of its possible association with cell development.
Band 7.1 shows a decreasing trend along the CD45RA+ to CD45RA" sequence in 
autoradiographic intensity. This 78KD protein is ubiquitously expressed in most of B- 
CLL cells, tonsillar B cells, PLL, and probably some Namalwa cell lines ( see Chapter
9 ), ( but not in Jurkat line ), with considerable variation of the expression level. A 
protein with a similar apparent molecular weight can be detected on neuraminidase- 
treated, sodium borohydride tritiated samples. Monoclonal antibodies G28-8 and G28-
10 ( Ledbetter et.al., 1987 ) react with and precipitate a 85KD and a 80KD peptides 
from tonsillar lymphocytes. The antigens have been clustered as CD39. CD39 was 
found restricted to B cells in peripheral blood and tonsils, about 60% B-CLL and 
100% B cell lymphoblastoid lines ( Ledbetter et.al., 1987 ). The behaviour of band 7.1 
under reduction and non-reduction prior to electrophoresis is also similar to CD39 (
119
Ledbetter et.al., 1987 ). The similarities of the abovementioned characteristics 
between these two molecules are reminiscent of that the component may be CD39 but 
FACS observation ( by Maddy, personal communication ) did not find any correlation 
between CD39 and CD45RA expression in our panel, which implicates that band 7.1 
is probably not CD39.
The reduced expression of band 7.1 upon cell activation ( see Chapter 8 ) may 
suggest that this molecule functions in the regulation of B cell activation.
Band 9 is an interesting component in terms of its short retention time ( 8:00 min ) 
and its consistent elution in the vicinity of CD45RA, implicating its possible 
association with some other molecules. Only some patients possess this band and no 
certain relationship has been found with either cell types or other surface protiens. 
The knowledge about this component is very poor. In Chapter 5. this band is 
discussed in detail.
In summary, the phenotypes of B-CLL, T-CLL and PLL as well as normal 
tonsillar B cells have been demonstrated inter-related with respect to their surface 
protein expression. On the basis of the expression of their membrane proteins, such as 
CD45RA, band 4.1, band 4.2, 4.3, CD21 and band 2, both in qualitative and 
quantitative terms, different types of cells can be arranged at such an order from 
PLL, normal tonsillar B cells, 1A B-CLL and IB B-CLL to T-CLL. The significance 
of this finding is discussed in Chapter 11.
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CHAPTER 8. HPLC ANALYSIS OF TPA-1NDUCED DIFFERENTIATION OF CLL
LYMPHOCYTES
1. Introduction
Development of cells in the normal haematopoiesis is regulated by specific growth 
and differentiation factors and involves, in a programmed fashion, cell lineage 
specific phenotypic changes. These events are called differentiation and proliferation. 
Differentiation is a process that cells progress towards more advanced stages with 
specified functions which are essential for their physiological committment, whereas 
proliferation allows for the necessary self renewal or the expansion of the cell 
population. Immature cells have the highest potency of proliferation and the 
proliferation process comes to cease when a cell of a given differentiation lineage has 
reached the terminal differentiation stage. The two events appear to be coupled 
processes. However, in some circumstances, such as lymphoid cells and neoplastic 
cells, the cells appear to have either proliferation or differentiation without the 
concomitance of the other process.
For long, this uncoupling had been assumed irreversible until Sachs (1980) 
demonstrated in vitro in a mouse leukaemia that differentiation is inducible. It is now 
generally believed that differentiation in human leukaemias and lymphomas may be 
induced with their cellular changes towards the terminally differentiated features. 
According to studies in the HL-60 promyelocytic leukaemia ( Huberman and 
Callaham, 1979; Nilsson and Totterman, 1984 ) and the U-937 histocytic lymphoma ( 
Nilsson et.al., 1981; Nilsson and Totterman, 1984 ) cell lines, the phenotypic changes 
upon induced differentiation seem to be equivalent to that of normal cells.
Although increased Ig production has been found in the case of B-cell lines upon 
induction of differentiation, malignant human lymphoid cells show resistance to such 
induction. However, even the picture of the induced differentiation of B-cell lines is 
less than clear as only a few differentiation markers have been documented and the 
increase of Ig production could be simply due to a modulation of the capacity of Ig 
secretion ( Rosen and Klein, 1983; Nilsson and Totterman, 1984 ). However, studies 
in some T cell leukaemias have demonstrated that the activated T cells undertake
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phenotypic changes and develop a decreased proliferative capacity, which are also 
observed in normally differentiating T-cells.
Attempts to induce proliferation and differentiation in CLL cells by conventional 
T- and B-cell mitogens had largely failed. Later, phytohemaglutinin was found to 
result in an elevated secretion of a single isotype light Ig chain in some CLL 
populations ( Maino et.al., 1977 ). Robert (1979) and Juliusson et.al. (1983) were able 
to induce non-Ig secretory CLL to proliferate and secret Ig using T-cell-dependent ( 
PHA, LPS et.al. ) and -independent ( EBV ) B-cell mitogens. The previous 
observations that mitogen and allogeneic helper cells/factors induced plasmacytoid 
differentiation in CLL cells ( Fu et.al., 1979 ) were further extended by Kishimoto's 
work ( Saiki et.al. 1980 ) and they showed that PWM and allogeneic T-cells induced 
Ig secretion, proliferation and class-switching in a secretory population.
CLLs of B-cell type have become a focus for the investigation of B-cell 
differentiation since B lymphocytes of this leukaemia are found to be readily 
inducible, by a phorbol ester, 12-O-tetradecanoyl-phorbol-13-acetate ( TPA ) ( 
Totterman et. al., 1980 ), towards maturation and to develop features of 
lymphoblasts-plasmablasts but without significant proliferation. The mechanism of 
TPA activation differs from those other stimuli by the fact that TPA does not 
interact with a cell surface receptor but directly activates protein kinase C, mimicking 
the physiological activator diacylglycerol ( Niedel et.al., 1983; Leach et.al., 1983 ). 
Nilsson et.al. (1985) proposed a mechanism suggesting the involvement of small 
subsets of autologous T cells during TPA activation. Upon activation, B-CLL cells 
undergo distinct phenotypic changes in their surface antigens. A wide scale of 
investigation of the phenotypic changes during TPA stimulation by Caligaris-Cappio ( 
1984 ) confirmed the previous results on slg and MRBC, and showed that B-CLL 
cells became CD22 ( RFA-4 ) and TRAP positive after being activated by TPA. B- 
CLL cells are almost totally TRAP negative with a very small population being CD22 
( RFA-4 ) positive. CD22 is expressed by both B-PLL ( Gobbi et.al., 1983 ) and, to a 
less extent, HCL cells. TRAP is virtually not expressed by PLL while high TRAP is a 
feature of HCL.
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It is believed that TPA drives B-CLL cells, which are regarded as being blocked at 
certain stages of the B lineage differentiation pathway, to differentiate towards a 
more advanced level but it is still controversial whether the induced B-CLL cells 
approach PLL-like characteristics or resemble HCL cells. TPA induction of PLL-like 
characteristics is featured by the loss of MRBC-rosetting and the gaining of CD22 
and FMC-7 ( Gobbi et.al., 1983; Catovsky et.al., 1981 ) whereas the loss of slg and 
the expression of Cyt IgM ( no Cyt IgD ) and of TRAP are more compatible with an 
early plasmacytic differentiation ( Preud'Homme, 1977 ). The induction of hairy 
features in B-CLL by TPA has also been extensively discussed ( Caligaris-Cappio 
et.al., 1984; 1985; Ziegler-Heitblock et.al., 1986 ). However, the conclusions are not 
compelling and often jeopardized by controdictory results of different surface 
markers examined ( Caligaris-Cappio et.al., 1984 ). Evidence has suggested that CLL, 
PLL and HCL could be derived from different lineages ( Yukihiro et.al., 1989 ). 
Before scrutiny of the individual differentiation markers in normal B cell maturation 
is accomplished, a wider investigation of surface markers may provide a more 
comprehensible approach for the understanding of the changes in their expression 
upon in vitro mitogenic induction.
The relationships between several surface markers established in Chapter 7 provide 
a strong indication of the heterogeneity of B-CLL lymphocytes as represented by the 
interrelated phenotypic changes. The possible correlation of this phenotypic variation 
and the maturational position of the CLL cells is strongly inferred by some well- 
documented markers ( such as slg, CD45 etc. ) ( Maddy et.al., 1989 ). TPA 
stimulation of B-CLL cells would be able to further demonstrate, or even verify, 
these correlations. The variation of phenotypes induced by TPA might confirm a 
differentiation progression reflected by the phenotypic presentations of the cells.
To explore this possibility, the study of the TPA-induced differentiation was 
conducted by HPLC-SDS PAGE, in conjunction with FACS technique, which is 
proven to be a new approach for such an investigation.
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2. Materials and Methods
Preparation of B lymphocytes was as described in Chapter 2. The cells were 
suspended at 1x10^ per ml in RPMI1640 supplemented with 10% heat inactivated 
PCS, 2 mM glutamine, 1 mM pyruvate, 50 units/ml penicillin, 50 ug/ml 
streptomycin, 5 ug/ml amphotericin, TPA at 1.6xlO~ 7 M and A23187 at 7xlO'7 M. 
The mixture was incubated at 37° C for up to 6 days.
The TPA-treated cells were then iodinated and extracted by Triton X-100 as in 
Chapter 2. The extracts were subjected to HPLC-SDS PAGE analysis.
Cells incubated under the same conditions without TPA were used as controls.
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3. Results
In this study, the expression of surface markers was investigated on 6 B-CLL cases 
of both 1A and IB types ( see Chapter 7 ). The cell responsiveness to TPA treatment 
was found to be maximal in 4 days by either flow cytometry ( carried out by Maddy 
et.al. ) or HPLC-SDS PAGE analysis. Longer incubation resulted in lower viability. 
Therefore, 4-day incubation was chosen for this study. 5 out of 6 patients responded 
well with respect to their CD45 antigen expression and other surface markers as 
described below. The following changes of cell surface proteins were observed after 
TPA treatment.
(1) There was a significant increase in the Class II MHC expression after TPA 
stimulation, as shown in Fig 1. 4-day TPA treatment elevated the expression of both 
a and fl chains of the antigen but the extent varied in different patients. Among 
these tested cells, one patient was found to exhibit an apparent inversion from B- 
predominant to a-chain predominant after TPA incubation. No correlation, however, 
has been found between the Class II MHC expression and other surface antigen 
expression, which is consistent with the FACS analysis and the results of others ( Guy 
et.al., 1986 ).
(2) The TPA treatment dramatically reduced the expression of CD45RA as shown in 
Fig 1 and 2, which was a 1A type patient with a dominant expression of the 230KD 
and 215KD chains of CD45 antigen. In other patients, of IB type, the 215KD band 
of the antigen was reduced markedly with a probably lesser reduction of the 200KD 
component. It was noticed that the whole autoradiographic intensity of CD45 
molecules decreased markedly upon TPA stimulaton, which was in contrast to the 
flow cytometric findings that the antibody binding of CD45 antigen remained 
unchanged during TPA treatment because the expression of the 200KD and 180KD ( 
CD45RO ) were enhanced, supplementing the decrease of the higher bands. But it 
was hard to document the alteration of UCHL1 on SDS-PAGE although a diffuse 
band of 180KD was detected after TPA treatment.
(3) The expression of Band 2, a 300KD component, was increased in IB patients 
while in 1A patients, who lack this band naturally, gained it after 4-day TPA
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treatment. The change is shown in Fig 2. The levels of the band 2 expression after 
TPA treatment were universely correlated with the initial CD45RA levels of the cells.
(4) Upon TPA induction, all patients consistently lost band 4.1 and band 4.3, lost or 
reduced CD21 markedly ( band 4.2 ) ( Fig 2 ). With the disappearance of CD21, a 
diffuse band was revealed with an apparent molecular weight of 130KD in fraction 
12-14. The nature of this band and the effect of TPA on its expression are unknown 
at the present.
(5) All patients tested with TPA express both u and <S heavy chains on their surface 
as demonstrated by flow cytometry ( Maddy, personal communication ). The 
autoradiography showed a reduced expression of the slg heavy and light chains. 
Research demonstrated that the percentage of slg positive cells dropped greatly after 
TPA treatment longer than 3 days ( Gordon et.al., 1984 ). This is in agreement with 
our findings.
(6) After surface Ig diminished, a polypeptide of 80KD was detected with an 
enhanced expression in fraction 10-11 (Fig 3 ). This component is very likely to be 
induced by TPA because the non-reduced SDS gels showed no trace of bands at that 
position of the gels when the slg remained as an intact complex.
(7) TPA also reduced band 7.1 drastically, band 7.4 and band 7.2 to an undetectable 
level. The 78KD band 7.1 component had a marked response to the TPA treatment.
(8) Above the band 7.1, a component of 90KD was induced by the TPA treatment ( 
Fig 3b ). This band was not present in any untreated cells tested in this study.
(9) Upon the TPA induction, a 43KD band was increased significantly though not 
markedly. This band recovered from fracton 15-17 was not detectable in tonsilar B 
cells but is expressed in CLL B cells ( Fig 3 ).
(10) Among the documented bands on the HPLC-SDS PAGE matrix, the most 
predominant component which was apparently unaffected by the treatment is band 3, 
a 220KD band ( Fig 1 and 2 ). In all samples tested it neither increased nor decreased
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significantly under the assay employed. Therefore, this band was used as a frame of 
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Fig 1. The phenotypic changes of B-CLL induced by the TPA activation. The CD45RA 
expression is significantly reduced, together with disappearance of band 4.1, 4.2 
and 4.3 while Band 2 is induced, (a) control (b) 4-day TPA treatment. Human 











































































































































































































































































B cell differentiation comprises a series of processes during which lymphoid stem 
cells mature into plasma cells, with correlated changes in the expression of certain 
surface antigens. The heterogeneity of leukaemic cells can be interpreted as being 
arrested at different points of maturation along lymphocytic lineages. The cells can be 
induced to continue to differentiate when provided with appropriate signals.
The TPA-induced phenotypic changes observed in this study support the suggestion 
that the heterogeneous phenotypes of B-CLL cells could be compressed towards a 
more homogeneous state ( Maddy et.al., 1989 ). Upon the TPA activation, cells from 
1A type patients were induced to differentiate towards the IB type extreme, showing 
decreased expression of CD45RA ( Maddy et.al., 1989 ), CD21, surface Ig and band 
4.1, with a concomittant induction of the 180KD chain of CD45 antigen as detected 
by UCHL1 binding ( Maddy et.al., 1989 ), and band 2. IB type patients showed the 
similar changes of their phenotypes but to a lesser extent. However, the increased or 
the decreased expression of the surface proteins of both 1A- and IB-type cells 
appears to have actually surpassed the IB type extreme as implied by the comparison 
between the TPA-induced patterns and the end IB patterns. The acquisition of band 
2 in 1A and the enhancement in IB cells suggest its expression is associated with later 
stages of B-CLL cell differentiation pathway. ( It seems that the differentiation 
diversity of B-CLL cells represents only a narrow span of this pathway while the 
expression of band 2 extends to perhaps more mature plasmacytoid cells as band 2, 
after TPA, is stronger than any IB CLLs tested ).
The overall radioactive intensity of the CD45 antigen is reduced drastically by TPA 
induction but the FACS study shows no significant fall of the antibody binding. This 
discrepancy may be due to the change of tyrosine contents when CD45RA expression 
inverses to the expression of lower forms of the antigen. It is shown, by protein 
sequencing, that exons A, B and C ( see Chapter 1 ) contain 19.7%, 10.6% and 16.7%, 
respectively, together consisting of 47% of the total tyrosine of the CD45 external 
domain. Therefore, the CD45RA/CD45RO inversion will cause a significant reduction 
of tyrosine residues available for iodination although the antigenic epitopes may 
remain constant.
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It is the first time that a 300KD component has been reported in B-CLL. The 
correlation between the band 2 expression and CD45RA/CD45RO inversion is further 
confirmed by the cell activation study and its association with a later stage of cell 
differentiation is strongly implicated. This 300KD component appears to start 
emerging when 230KD of CD45 decreases below the level of 200KD chain and its 
expression covers the whole IB range and likely much later stages of the cells, or, at 
least, the stage reached by TPA-induced differentiation. The absence of this 
component in both normal tonsilar B and T cell gives rise to an interesting suggestion 
that this component is specific to malignancies. The expression of band 2 in T-CLL 
but not in normal T cell may also suggest that the component is associated with 
neoplastic state rather than cell type. The question is whether this band is specific to 
CLL or is also found in other forms of leukaemias? If the band is expressed by 
malignant cells only, what is the significance? Before these questions can be 
answered, it is desirable to develop a specific antibody to this molecule.
The marked decrease of slg expression ( detected by HPLC-SDS PAGE ) 
consistent with previous reports ( Carlsson et.al.; 1988; Tokumine et.al., 1989 ), 
together with the accumulation of cytoplasmic immunoglobulin ( Gordon et.al., 1984; 
Tokumine et.al., 1989 ), is a strong indication of progression towards the terminal 
differentiation in the B-CLL populations. TPA was shown to induce CLL B cells to 
secrete IgM ( Gordon et.al., 1984 ) and even a class switch ( IgM > IgG ) has been 
observed in certain CLL clones although in normal cells no overt isotype switch from 
surface IgM to IgG has ever been detected.
Although the vast majority of resting B cells express both CD20 and CD21, the 
antigens can be expressed at quite different levels. Anderson and co-workers ( 1985 ) 
found that human splenic ( CD20+CD21+ ) cells responded to anti-Ig or anti-Ig and 
T-cell factors but not to T-cell factors alone. By contrast, however, the ( 
CD20+CD21' ) cells, while not proliferating in response to anti-Ig with or without T- 
cell factors, did respond and secret Ig, following co-culture with CD4+ T cells in the 
absence of mitogen. The finding suggests that ( CD20+CD21~ ) subset may represent 
a more mature or differentiated population and that CD21 (B2) antigen is associated 
with a less mature state.
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TPA study also confirms the correlation between CD21 and the CD45RA 
expression establised in Chapter 7. showing that CD21 antigen is lost when 230KD 
decreases, which is in consistent with the FACS analysis of the same panel of patients 
( Maddy et.al., 1989 ). The observation that in IB CLLs some cells express slg but 
lack CD21 leads us to suggest that CD21 is probably lost before the loss of slg. CD21 
is lost somewhat earlier than CD20 following activation and correlates with the loss of 
surface IgD ( Stashenko et.al., 1981 ) which is consistent with our findings that the 
TPA induction leads to the loss of both CD21 and slg expression.
In this study, several other distinct surface proteins have been found to respond to 
TPA activation, which have not been reported elsewhere. In addition to band 2, band 
4.1, band 4.3, band 7.1 and a 43KD and a 80KD components exhibit changed 
expression after TPA treatment. Band 4.1, band 4.3 and band 7.1 are of particular 
interest because their correlations with CD45RA are confirmed by this observation 
and in line with the conclusion drawn in Chapter 7. Although little is known about 
these proteins their correlation with cell differentiation appears to be strongly 
implicated by the evidence presented by both resting and activated ( TPA induced ) 
B-CLL cells. The significance of such a correlation will be interpreted in the General 
Discussion.
These lines of evidence confirm the correlations of surface proteins in Chapter 7 
and suggest that the differences of surface protein expression may result from the 
heterogeneity of CLL cells and that TPA does drive CLL cells to differentiate 
towards a more advanced stage. There seems to be an end stage at which the TPA- 
induced differentiation stops, as reflected by the fact that the phenotypic 
heterogeneity of CLLs is diminished by the treatment and similar phenotypic profiles 
are resulted from cells with different phenotypes.
In addition, the experimental protocol may suggest a new approach for tracing the 
differential expression of surface proteins during cell development. For example, 
leukaemic cells can be induced to differentiate to various levels of maturity by 
culturing with TPA in a series of different periods. The expression of the surface
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markers should change in a sequential way, therefore, the expression span of some 
markers may be understood.
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CHAPTER 9. ANTIBODY-INDUCED CAPPING 
1. Introduction
The capping phenomenon was first observed by Taylor et.al. ( 1971 ). When 
lymphocytes are treated with cross-linking ligands ( such as anti-slg and Con A ), the 
receptors on the plasma membrane, under certain conditions, undergo drastic changes 
in cell topology, forming clustered particles termed 'patching' or converging to a 
single pole of a cell called 'capping'. Like patching, capping is usually observed only 
with cross-linking ligands although there are several reports that certain non- 
physiological conditions could induce cap formation ( Yahara and Kakimoto- 
Sameshima, 1977 ); unlike patching, capping is an energy-dependent process which 
requires energy ( Taylor et.al., 1971 ). As the capping and co-capping phenomena 
involve molecular interactions, HPLC, therefore, should be a favourable method for 
the analysis of the molecular components present in a cap since as long as their 
association is resistent to Triton solubilisation the extent of the cross-linking will be 
reflected by the decreased retention times, thus, individual components are 
identifiable.
For certain receptors, ligands trigger highly programmed processes of receptor 
redistribution, ameboid movement and endocytosis which underpin the effector 
functions of adhesion, chemotaxis and secretory activity. The perturbations indicate a 
major regulatory influence of membrane receptors on the underlying cytoskeleton and 
conversely the control of cytoskeleton on the receptors. Studies in B-lymphocyte 
surface Ig cap formation, which has been investigated in detail, have demonstrated 
the corresponding involvement of microfilaments ( Karnovsky et.al., 1972; De Petris, 
S., 1975 ) and the coordinated accumulation of myosin ( Gabbiani et.al., 1977; 
Bourguignon et.al., 1978 ), and a-actinin ( Geiger and Singer, 1979; Hoessli et.al., 
1980 ) as well as microtubule redistribution ( Gabbiani et.al., 1977; Bourguignon 
et.al., 1978; Yahara and Kakimoto-Sameshima, 1978 ). More direct biochemical 
experimentation has indicated the ligand-induced association of surface Ig to actin ( 
Flanagan and Koch, 1978 ) and to the non-ionic detergent-insoluble cytoskeleton ( 
Braun and Unanue, 1978 ). The cap formation for other membrane receptors has been 
assessed but the knowledge is very limited and indirect ( Laub et.al., 1980 ).
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Capping in the CLL lymphocyte has been found sluggish or not to happen at all ( 
Cohen, H.J., 1975; Jarvis et.al., 1976 ) although the B-CLL cells can progress to patch 
formation ( Karnovsky et.al., 1972; de Petris, S., 1975 ). Lateral movement of 
membrane proteins is reported to be restricted on leukaemic cells even without the 
presence of external ligands. It had been demonstrated that leukaemic cells and 
normal lymphocytes bound equal amounts of the anti-serum ( Liebes et.al., 1978 ), 
therefore, the impaired capping ability of malignant cells should not be attributed to 
decreased binding of the cross-linking ligands but suggested defects of their 
cytoskeletal functions. Defects of cytoskeletal components have been reported in B- 
CLL and other neoplastic cells. F-actin microfilaments in B-CLL cells are shown to 
be abnormal and organized in a peculiar way ( Caligaris-Cappio et.al., 1986 ), and the 
adherent behaviour of these cells is different from normal cells, in vitro B-CLL cells 
adhere to substrates by dot-shaped close contacts refered to as podosomes rather than 
by conventional focal contacts known as adhesion plaques ( David-Pfeuty and Singer, 
1980; Marchisio et.al., 1984; Tarone et.al., 1985 ). B-CLL cells also exhibit some other 
unusual features in the organisation and function of their cytoskeleton ( Dighiero 
et.al., 1978; Liebes et.al., 1983; Stark et.al, 1984 ).
Both actin and tubulin, as a percentage of total protein, are decreased in CLL 
lymphocytes ( Stark et.al., 1982; Atkins and Anderson, 1982 ). A novel observation ( 
Bachvaroff et.al., 1980 ) was reported that both actin and tubulins were present on 
the surface of human lymphocytes undergoing blastogenic transformation, while 
normal resting lymphocytes do not possess surface actin and tubulins. Another 
striking feature of CLL cells is that during cap formation they lack organized bundles 
of intermediate filaments whereas normal lymphocytes show an intimate association 
between cap formation and the polymerization of the filaments ( Zucker-Franklin 
et.al., 1979 ). A relevant finding may be of particular interest that Sezary cells, which 
are considered to be leukaemic T lymphocyte and possess an abundance of 
intermediate filaments ( Zucker-Franklin et.al., 1974 ), are capable of capping as 
normal lymphocytes.
Luciana Bergui et.al. ( Luciana Bergui et.al., 1988 ) reported induction of CLL B 
lymphocyte cap formation with monoclonal antibodies against CD5 and CD21 under a
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prolonged incubation. The protocol of the present investigation is largely based on 
that method with some small modifications. The mild conditions used for HPLC 
should allow the cap with its associated cytoskeletal elements to be isolated intact. 
This study showed that monoclonal antibody PD7/26 ( Chapter 6 ) and EZB17 ( 
Brown et.al., 1985 ) could induce B-CLL to cap and several surface proteins co- 
capped with the antigen. It is, to my knowledge, the first report concerning CD45 
capping and co-capping in B-CLL lymphocytes.
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2. Materials and Methods
8x10' B cells from patients with chronic lymphocytic leukeamia ( CLL ), washed 
twice with ice-cold RPMI1640 containing 10% PCS, were suspended in 1 ml 
RPMI1640-10% PCS medium. 100 ul monoclonal antibody PD7/26 was added to the 
cell suspension and the mixture was incubated at the room temperature for 15 min. 
Unbound antibody was removed with two washings of RBC buffer pH 7.4 containing 
50 U/ml penicillin and 50 ug/ml streptomycin and the cells were suspended in 1 ml 
RPMI1640-10% PCS medium and 25 ul ( 50 times dilution ) FITC-conjugated anti- 
mouse IgG(ab)2 added as a second step. The cell suspension was cultured in 37° C 
with continuous rotation. At different time points from 10, 12, 15 and 18 up to 22 
hours, the capping was monitored by immunofluorescent microscopy ( Zeiss, 
Photomicroscope III ). The viability of the cells was checked by acridine 
orange/ethidium bromide staining.
The capped cells were washed twice with WBC buffer pH 7.4 and then surface 
125j labelled by the method described in Chapter 2 but with washings reduced to 
only once.
The conditions for HPLC chromatography and SDS-PAGE were identical to 
Chapter 5 except that the collection parameters were set at: wait: 4 min and 40 
fractions were collected.
Cells, treated with FITC-conjugated anti-mouse IgG(ab>2 but without the first 
antibody, were used as a control.
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3. Results
3.1. Incubation Time and Capping
The criteria for patching and capping were according to Taylor et.al. (1971), 
briefly, if the fluorescent ring on the cell surface clustered into discreet dots but 
occupying more than 50% of the circumference of the cell, it was refered to as 
'patching' and if the fluorescence was concentrated at one pole of a cell, forming a 
bright 'cap' with less than 50% occupation of the cell surface, the cell was considered 
as 'capped'.
At up to 10 hours of incubation, most of the cells showed patched structures, i.e. 
fluorescent dots were obvious, but spreading along the circumferences of the cells. 
Few cells were observed with capped fluorescent poles, but some cells showed 
transitional states from discreet fluorescent dots to converging accumulation of 
fluorescence at one or two poles of the cells. 15 hours incubation showed a significant 
increase of capped cells. At 17 hours more than 80% cells were capped and the 
remainder were patched. Longer incubation did not increase the proportion of the 
capped cells. Actually, a decreased percentage of the capped cells was observed at 22 
hours and long incubation tended to result in low viability and fragile cells. 
Therefore, 17 hours incubation was chosen for this study.
Control cells, incubated under the same conditions, were rarely capped and few 
were patched. Morphologically, they were round-shaped and no protrusion or 
microvillar structures were observed, in contrast to the capped cells which protruded 
bright poles with microvillar structures on the majority of the cells although they 
remained small cells.
A high percentage of PD7/26 or EZB17 treated-cells cultured with the second 
antibody while in the presence of 10 mM sodium azide were patched but virtually no 
cells were capped. The cells were morphologically similar to those of the control.
The viability of the cells was found to be usually not less than 70%. The capped 
cells tended to form clumps during the culture but they could be easily dispersed. It
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was also noticed that the control cells appeared to give better recovery after surface 
labeling.
3.2 HPLC and SDS-PAGE of the Capped Materials
Fig Ib shows the HPLC-SDS PAGE two-dimensional profiles of the CD45RB 
antigen capped by monoclonal antibody PD7/26. Although more than 80% cells were 
capped only a fraction of the CD45 radioactivity was shifted. The majority of the 
radioactivity of CD45 antigen remained in the fraction 5-7. In addition to the shifted 
CD45 molecules, there were several other iodinated components co-shifted with the 
antigen. The bands with dramatically shortened retardation appeared to consist of two 
groups by their peak distributions ( Fig Ib ): one group, from fraction 16 to 19 ( 
wait: 4 min ), contained the shifted PD7/26 antigens and three other major bands of 
78KD, 60KD and 50KD, respectively; another group, with a shorter retention time, 
composed of components of 78KD, 60KD and 50KD but without the shifted PD7/26 
antigen. The two groups also showed distinct differences in other minor components 
described bellow. Fig 1 shows that the PD7/26 antigen was shifted to fraction 2-4, 
with a reduction of the retention time of 0.6 min. But the amount of the moved 
antigen was, relatively, much less than that of the other components which were co- 
capped by PD7/26 mAb and that of the CD45 antigen shifted under non-capping 
conditions ( see Chapter 6 ). In the capped samples, the 78KD component was found 
in the fractions with a broad retention time from 5 to 9 min although the peak 
fractionation was at 7.2-7.8 min. A similar pattern of the distribution was also found 
for both 60KD and 50KD bands. The 78KD component was predominant. 
Comparison of the profiles of capped cells with that of the control ( Fig la ) revealed 
that the 78KD component may be band 7.1, or at least part of it since the fraction 
15-18 of the PD7/26-capped cells contained much less band 7.1 than that of the 
control. The band was moved forward more than 10 fractions, ie. a reduction of its 
retention time by more than 2 min. Meanwhile, the heavy chain of the surface Ig was 
found to have vanished from the fraction 12-14, implicating its co-capping with the 
cross-linked CD45RB antigens ( PD7/26 ). There seemed to be two 78KD components 
retarded to different extents by the column, fractionated into group 1 and group 2, 
respectively. They can be distinguished by their peak distributions. It is not yet
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known which is the heavy chain of surface Ig or whether the surface Ig is present in 
both groups.
Close examination found that the 60KD component was probably from band 7.4, 
which is weakly expressed in most of the patients ( see Chapters 5 and 7 ). However, 
we have been unable to locate the 50KD component, which was co-capped with the 
PD7/26 antigen, on the control gels. In some patients, a band, usually weak, was 
detected in fraction 13-18 with a similar mobility on SDS-PAGE. But this band 
showed enhanced expression after cells were incubated under the capping conditions. 
The enhancement of band 7.1 expression has been ascertained ( see Chapter 8 ), as 
also shown by the control ( Fig la ) for capping, which was under the same treatment 
except the addition of the first antibody.
In addition, there were some other minor components co-capping with the CD45 
antigen. One was the a chain of the Class II MHC and another was a component 
having a slightly different molecular mass as that of the class II MHC a chain. Both 
were fractionated, with same retardation, in fraction 1-4. In fractions of retention 
time of 6.6-6.8 min, two bands were discovered, one having an apparent molecular 
weight of about 160KD and another 130KD. While in fractions 5 and 6, a 40KD 
sharp band was detected.
Initially, it was suspected that the pre-column and the inlet filters of the column 
would capture those extensively cross-linked materials if the capped structures were 
big enough. Therefore, the pre-column packing and filters were extracted with the 
SDS sampling buffer ( see Chapter 2 ) and the extracts subjected to SDS-PAGE and 
autoradiography. The result ruled out such a possibility although insignificant 
amounts of 70KD, 60KD and 50KD bands could just be detected after prolonged 
exposure. However, a low molecular weight band of 10-15KD was found in the pre- 
column.
The PD7/26-treated cells, with the presence of sodium azide, yielded similar 
profiles as a normal PD7/26-treated sample except a small amount of 60KD 







Fig 1. The cap formation and the co-capping induced by mAb PD7/26 on CLL B 
lymphocytes, (a) control (b) the two-dimensional matrix of the Triton-X-100 
extract of the PD7/26-capped B-CLL cells. A significant amount of materials 
was shifted to the front of the elution. The observation was discussed in section 
2.2. Groups 1 and 2 were distinguished by their peak distributions and marked 
here by an arrow. The 'Time Mode' parameters were set at 'wait' 4 min., 
'collection' 40 fractions. The fractions No 20-30 for the control and fractions No 
15-25 for the PD7/26-capped were shown here. The numbers in the brackets 






































CD45 antigen is one of the major surface membrane glycoproteins. Previous studies 
showed that CD45 antigen was induced to form caps in various cells ( Bourguignon 
et.al., 1978; Turner et.al., 1988 ). Peanut agglutinin ( PNA ) has been reported to 
cause co-capping of T-200 antigens with PNA receptors on thymocytes ( De Petris, 
1984 ). Cap formation of T-200 and co-capping of molecularly independent surface 
proteins have been reported in thymoma cell lines ( Bourguignon et.al., 1978 ). 
However, knowledge of CD45 capping and co-capping of other proteins is scarce.
This study demonstrates that the CD45 antigen on B-CLL can be elicited to form 
caps after prolonged incubation, comfirmed Luciana Bergui et.al., and shows that 15- 
17 hours are sufficient for the induction of CD45 cap formation with the antibodies 
tested. Longer incubation is very likely to cause endocytosis or shedding which might 
account for the decreased percentage of capped cells observed in 20 hours upwards. 
Another problem caused by long incubation is that the cells are vulnerable to the 
subsequent washing procedures.
Although the cells cultured in the presence of sodium azide were extensively 
patched this lateral movement of the receptors seems to be only a physical 
aggregation which may not be stabilized enough to sustain the subsequent detergent 
treatment as implicated by the HPLC results. In this case, only a minor band of 
60KD and a pair of bands of 33KD and 28KD, respectively, were shifted with the 
CD45 antigen-antibody complex. In considering of the high percentage of patching, 
such a small quantity of complexing might not be significant.
It is surprising that the PD7/26-cross-linked CD45 ( as judged by 
immunofluorescent microscopy ) is moved forward for only 3 fractions, similar to the 
treatment under non-capping conditions ( see Chapter 6 ). It might be possible that 
the complex is actually disrupted by Triton X-100. On the other hand, the complex 
of the co-capped proteins apparently resists the detergent treatment. Another 
ambiguity is that the co-capped proteins appear not to be co-eluted with the capped 
CD45. It is not possible to explain these phenomena at this stage, but the co-capping
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of proteins is undoubtly caused by the capping treatment although their relationships 
with the shifted CD45 are unknown.
In Chapter 6 it was shown that CD45 antigen, shifted by specific monoclonal 
antibodies on HPLC column, did not show any components co-shifted with it and the 
antigen was absent from Triton X-100 insoluble fractions, suggesting that the CD45 
molecules are not in association with other surface membrane proteins or cytoskeletal 
filaments. The induction of CD45 cap and the co-capping of other proteins indicate 
that the association between these proteins is built up during the induction of 
capping. Stimulation of external ligands and long incubation may initiate the 
polymerization of actin filaments which plays the key role in the contractile 
movement of the surface receptors. However, the proteins, which are elicited to co- 
cap with CD45 antigen ( PD7/26 ), appear not to be associated with the detergent- 
insoluble fractions, suggesting that they may not be linked or extensively linked to 
the cytoskeletal filaments during the cap formation. ( The analysis of the non-ionic 
detergent-insoluble material of the capped cells revealed no significant amounts of 
proteins bound to the cytoskeletal framework.)
So far the knowledge about the interactions between CD45 antigen and the co- 
capped proteins is limited and it is not yet known how these proteins are elicited to 
move laterally and co-cap with CD45 antigens. A possible explanation is that binding 
of external ligands generates signals across the membrane bilayer, which may trigger 
the polymerization of cytoskeletal filaments. The contractile machinery may be 
associated only with some membrane proteins in the vicinity of the ligand receptors. 
These membrane proteins provide anchorage for the underlying cytoskeleton 
components. Such interactions could change cell topology and the relationships 
between surface proteins, eliciting the lateral movements of membrane proteins which 
are molecularly independent from either cytoskeleton or the anchorage proteins. 
Spacially or functionally related surface proteins, therefore, may be clustered around 
the ligand receptors but not actually associated with the cytoskeleton. Selectively 
clustering among heterogeneous membrane proteins has been demonstrated by 
antibody-blocking ( Flaherty and Zimmerman, 1979 ) and immunocytochemical ( 
Bourguignon, 1979; Raz and Bucana, 1980; Kuby and Wofsy, 1981 ) studies. In 
certain phospholipids ( Schroit and Pagano, 1981 ) and glycolipids ( Spiegel and
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Wilchek, 1981 ), similar clustering has also been observed, and it can be interrupted 
by cytochalasins and metabolic inhibitors. The function of such clustering is not clear, 
but it could, aside from direct transmembrane anchoring and molecular filtering ( 
Bretscher et.al., 1980 ), implicate the membrane protein interactions without the 
involvment of cytoskeleton.
The co-capping phenomenon observed in this study implies that molecularly 
independent proteins in the unperturbated cell membrane can be induced to interact 
with the antigens bound by specific ligands. This is in conflict with the view that 
molecularly independent receptors cap independently of one another ( Schreiner and 
Unanue, 1976 ) but in agreement with Turner et. al. (1988). The data in Chapter 6 
illustrate that the CD45 antigens are not associated with any other membrane proteins. 
The observed association in this study must be triggered by the signals delivered by 
the ligand binding. Similar findings have been reported in mouse cell lines ( 
Bourguignon et.al., 1978 ). Rabbit antibodies to T200 antigen induce co-capping of 
H-2, TL and Thy-1 antigens with T200 cap whitest it has already been demonstrated 
that TL, H-2 and Thy-1 antigens are molecularly non-related components in thymus 
cell membranes ( Loor et.al., 1975 ).
Braun and Unanue (1978) proposed that the attachment of the surface receptors to 
the cytoskeleton occurs at the patching stage before the actual cap formation. The 
results presented by this study appear to argue against that point in two aspects: (1) 
the HPLC-SDS PAGE profiles of the patched cells showed, basically, no differences 
from the control. If the cytoskeletal filaments formed associations with the membrane 
receptors, one should expect altered retardation of some proteins. On the other hand, 
majority of the surface proteins from the patched cells were solubilized by Triton X- 
100. (2) the HPLC profiles of the patched and the capped cells exhibit distinct 
differences which can only be generated by irreversible capped complexes. There 
have been some reports that paching is not a pre-requisit for cap formation ( 
Bourguignon et.al., 1981 ). A possible mechanism could be as proposed above, i.e. at 
the patching stage the cytoskeletal filaments are only associated with those anchorage 
proteins located at the vicinity of the receptors, which can be visualized by 
immunofluorescent microscopy, but not connected to the receptors.
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These explanations are probably premature as several observations in this study are 
still obscure and contradict with conventional view of capping event. Much future 
work needs to be done to both clarify and elabrate this preliminary observation of the 
capping phenomenon by HPLC. The first ambiguity to be clarified is whether the 
capped structure can remain intact after the detergent treatment. Application of 
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CHAPTER 10. THE STUDY OF BURKITTS LYMPHOMA CELL LINE NAMALWA 
1. Introduction
The Namalwa cell line is a human B-lymphoma line originated from the tumour 
cells of an African patient with Burkitt's lymphoma ( BL ) ( Klein et.al., 1972 ). The 
Namalwa sublines ( KN2, PNT, IPN/45 and 45.43 ) have been maintained as 
independent sublines for years ( Jeffreys et.al., 1985 ). The cytogenetic data ( Soos 
et.al., 1981 ) ascertained that the different sublines were derived from the same 
individual.
Heterogeneous expression of surface receptors has been demonstrated in Namalwa 
sublines. These sublines showed marked differences in the expression of surface 
immunoglobulin and MHC Class II antigens ( Guy et.al., 1986; Guy et.al., 1987 ), 
suggesting differentiation arrest at different stages of the pathway. Phenotypic 
variation of the Namalwa lines has also been investigated with specific monoclonal 
antibodies to surface antigens, such as CD21, CD20 and CD37 et al. ( Guy et.al., 1986 
). Rooney et.al. (1986) have concluded from the changes of cell surface antigens that 
cells from some freshly established Burkitt's lymphoma cultures progressed towards a 
more mature ( lymphoblastoid-like ) state.
The technique established by this study has provided, in principle, an effective 
methodology for the analysis of surface polypeptide constitution and the detection of 
differences in receptor expression which might be difficult to observe with 
conventional methods. The application of HPLC-SDS PAGE technique to the closely 
related Namalwa sublines presented an opportunity to test the resolution of the 
method and it has confirmed the considerable potential of the method in 
distinguishing minor diferences of the cells.
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2. Materials and Methods
Namalwa cells were pelleted out of the culture medium, washed and surface radio 
iodinated as described in Chapter 2. A 0.5% Triton X-100 extract was made and 
analysed by HPLC and SDS-PAGE as in Chapter 5.
The nomenclature system for B-CLL lymphocyte surface phenotype is used here 
but the identity of the nomenclature does not necessarily imply the identity of the 
molecules or similarity of their functions.
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3. Results
The autoradiographs were examined and compared between four sublines KN2, 
PNT, IPN/45 and 45.43. HPLC fractions containing bands of particular interests from 
the four sublines were analysed on the same gels to facilitate the comparison. In 
addition to surface Ig and MHC Class II antigens, several distinct differences were 
found among the sublines.
45.43 was the only subline which expressed three high molecular weight chains of 
the CD45 antigen ( Fig 1 ). The lower chain ( 200KD ) was predominant. None of the 
other three sublines were found to have the third band, they were all predominantly 
expressing the highest component ( 230KD ) of the CD45, with a weaker 215KD 
band. The order of the 230K.D band of the CD45 expression in ascent was 45.43, 
KN2, PNT and IPN/45. It was found that, with respect to the autoradiographic level 
of band 3 ( 220KD ), a consistent component which has been previously used as a 
frame of reference ( see Chapter 5 ), the KN2 subline showed somewhat weaker 
overall CD45 expression while IPN/45 and PNT were considerably higher.
All four sublines possessed a faint band of an apparent molecular weight of 
300KD, which in B-CLL lymphocyte is designated as band 2. By comparing different 
batches of autoradiographs with each other, it was concluded that 45.43 was the 
strongest in the expression of 300KD component and KN2 was the weakest while the 
rest were at intermediate. Because of limited numbers of the sublines available, no 
coincidental relationship has been established between this component and others.
A diffuse band with an apparent molecular weight of about 150KD appeared in 
exceptionally early fractions ( retention time shorter than CD45 ), usually 1-2 
fractions before that of CD45RA. All four sublines were positive and probably 
expressed the component at different levels. No equivalent band has been detected in 
CLL B cells.
Both band 4.1 and 4.2 ( CD21 ) were observed in all Namalwa sublines although 
the levels varied between the sublines. 45.43 exhibited very strong band 4.2 ( CD21 ), 
followed by PNT and IPN/45. KN2 was the weakest in band 4.2 expression and the
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overall intensity of both band 4.1 and 4.2 was low. The intensity variation of band 
4.1 was not as marked as band 4.2 ( CD21 ) and it was difficult to draw a conclusion 
with respect to its relative level of expression.
A band which was detected only in Namalwa cells was apparent in fractions 7-9 of 
all four sublines. The component had an apparent molecular weight of 130KD and 
was strongly expressed in 45.43 and comparatively weak in KN2. IPN/45 and PNT 
showed a similar level of the band. Another band with similar molecular weight but 
in fractions 10-12 was found to be considerably higher in 45.43 than other three 
sublines. It was one of the predominant bands detected by autoradiography in 
Namalwa cell line. This component was named as band 5 in B-CLL lymphocyte but 
generally at a much lower level.
Fig 1 shows band 6, a component of 110-120KD highly expressed in 45.43 and its 
intensity varies in the different cell lines. The four sublines can be placed in the 
order of 45.43, IPN/45, PNT and KN2 with descending expression of the component.
A 80KD component was found in fractions 10-12 of PNT and IPN/45 sublines but 
markedly decreased or absent in 45.43 and KN2. A similar component has been 
identified in B-CLL cells to be the heavy chain of the surface immunoglobulin. A 
band of 23KD was located in the same fractions and absent from both 45.43 and 
KN2. This band in B-CLL has been demonstrated to be the light chain of the surface 
Ig. SDS-PAGE analysis of the non-reduced fractions containing these bands showed a 
high molecular weight band of about 300KD when both 80KD and 23KD 
disappeared, confirming that two bands were the heavy and light chains of surface Ig, 
respectively. In autoradiographs, the expression of the surface Ig was found high in 
IPN/45 and PNT but undetectable in 45.43. KN2 showed low level expression 
observable after prolonged exposure.
MHC Class II was highly expressed in KN2 ( Fig 3 ) and very weakly in 45.43 
while PNT was higher than IPN/45. The four sublines can be ranked in the order of 
45.43, IPN/45, PNT and KN2, according to their increasing expression of Class II 
MHC antigens. A novel difference was noticed that the autoradiographic intensity of
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the B chain of the molecule in KN2 was much higher than the a. chain while in other 
sublines both were of very similar levels.
Fig 3 shows a 50KD component in fractions 14-16. The component had 
significantly higher expression in KN2 and PNT than in IPN/45 and 45.43 in which 
it was almost undetectable. Its expression and molecular weight are reminiscent of the 
ttchain of Class I MHC antigen.
A sharp band at the position of about 75KD was found in all the HPLC fractions 
except, usually, No 1-3 fractions. All four sublines had such a band and the band was 
consistently present at the same molecular weight range. Occasionally, similar band 
was detected in some B-CLL cells but, unlike in Namalwa cells, the band was not 
reproducible in B-CLL. The nature of the component is not yet understood but it is 
likely to be an artifact.
In comparison with the profiles of B-CLL lymphocytes, the Namalwa cell lines are 
very similar to B-CLL but bear some distinct features in their phenotypes and the 
designation system established in Chapter 5 can define most of the components in 
four sublines studied. However, the Namalwa cells tended to generate poorly defined 
and diffuse bands. At the low molecular weight range of SDS-PAGE, bands were 
usually less sharpened and resolved. The background density of the autoradiogram in 
such areas could be high.
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Fig 1. HPLC-SDS PAGE profiles of the Namalwa cell lines, showing the progressive 
decrease of 230KD determinant of CD45 antigen and the changes of other 
surface components, (a) INP45 (b) PNT (c) KN2 (d) 45.43. The samples 
















Fig 2. Detailed illustration of fractions 7-9 of the cell lines to show the differences in 
CD45 and 125KD expressions. (1) KN2 (2) IPN45 (3) PNT (4)45.43.
Fig 3. Detailed examination of fractions 13-15 of the KN2 and 45.43 sublines on their 
expressions of MHC Class II and a 43KD component. The left panel is KN2 and 
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4. Discussion
Limited investigations have been conducted on the phenotypic variation of the 
Burkitt's lymphoma cell line Namalwa. The four sublines ( KN2, PNT, IPN/45 and 
45.43 ) have been demonstrated to have marked differences in the expression of both 
Ig and MHC Class II antigens and, recently, differing patterns of expression of cell 
surface differentiation antigens were investigated by using the CD monoclonal 
antibodies ( Guy et.al., 1987 ).
According to the relative autoradiographic intensity of 230KD chain of CD45, the 
four Namalwa sublines can be placed in the order of IPN/45, PNT, KN2 and 45.43 
with respect to the decreasing levels of the antigen expression. This conclusion is in 
consistent with specific monoclonal antibody binding data ( unpublished results ). The 
order of increasing F8-11-13 binding in KN2, PNT and IPN/45 sublines as shown by 
FACS is the same as that of the 230KD levels detected by autoradiographs, implying 
that these three sublines are closely related in differentiation as the reciprocal 
relationship of the expression of the four CD45 components is suggested by cell 
activation study ( see Chapter 8 ). The levels of an overall CD45 expression were 
found, by flow cytomerty, to be in the same order. By contrast, although the CD45 
binding in 45.43 was indistinguishable from the other three sublines F8-11-13 
binding was markedly low ( 26% cell positive ). The FACS data of CD45 and 
CD45RA binding in 45.43 subline also suggest that the decrease of CD45RA is 
compensated by the increase of the lower component ( the 200KD component ) of the 
antigen, which was clearly exhibited by the HPLC-SDS PAGE autoradiographs. If the 
abovementioned coincidence of F8-11-13 binding and the 230KD intensity does 
implicate the distance of the maturational states of the sublines along the maturational 
pathway, the weak 230KD and strong 200KD of CD45 and low F8-11-13 binding ( as 
detected by FACS ) in 45.43 suggest that the subline must be at distinctly different 
stages of maturity.
The positive correlation between 230KD band of CD45 and the surface 
immunoglobulin ( slg M ) may exist in the Namalwa cells whereas they were found to 
be strongly correlated in B-CLL. However, this conclusion is of less certainty because 
the variation of CD45 antigen expression is very limited to a narrow spectrum within
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only four sublines and 45.43 did not have any detectable surface and cytoplasmic Ig 
which indicates its anomalous state.
It is difficult to construct a relationship between the 230KD or the 200KD chains 
of the CD45 family and the 300KD high molecular weight component as in B-CLLs 
because of limited observations. One striking difference of Namalwa cells from B- 
CLL lymphocytes is that in Namalwa cell lines, the expression of this 300KD 
component is not exclusive to the low CD45RA-high 200KD cells, actually all 
sublines are 300KD positive, although the higher the 230KD band is the weaker the 
300KD component is expressed.
The Ig synthesis has been correlated with Class II MHC expression ( Guy et.al., 
1986 ) by flow cytometric studies. Except for 45.43 subline which expressed no 
detectable cytoplasmic or secreted Ig, it is found that the Class II MHC and 
cytoplasmic Ig expression have a reciprocal relationship with CD45RA expression 
although, in B-CLL lymphocyte, no such a correlation was ever confirmed between 
Class II MHC and CD45RA by autoradiography ( see Chapter 7 ). There are some 
findings suggesting that the expression of Class II MHC antigens and immunoglobulin 
may be regulated under some common mechanisms. In both normal and malignant B 
cells, elevated level of Class II MHC was detected on cells activated by antibodies to 
surface Ig ( Kehrl et.al., 1985; Godal et.al., 1985 ). Dramatic increase of Class II 
MHC expression has been observed on B-CLL lymphocytes which were treated with 
phorbol ester and thereby .induced to differentiate ( Totterman et.al., 1981; also see 
Chapter 8 ). Biddison et.al. (1983) suggested that the increased levels of Class II MHC 
antigens on activated B cells may induce the activation of helper T cells and hence 
the synthesis and secretion of B cell growth and differentiation factors ( Kehrl et.al., 
1984 ). Therefore, elevated levels of Class II MHC may reflect more advanced stages 
of differentiation or activation of the cells. From this point, the ascending expression 
of Class II MHC in IPN/45, PNT and KN2 is in concert with the order of the 
CD45A expression, i.e. KN2 may be at a more advanced stage while IPN/45 at an 
earlier stage with PNT in the middle. With an exception of 45.43 subline which has 
no detectable MHC Class II antigens, the correlations between the order of MHC 
Class II expression and the order of the 230KD chain of CD45RA and slg expression 
are consistent with the observation conducted in B-CLL with TPA ( see Chapter 8 ),
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i.e. MHC Class II and surface Ig expression was markedly increased with a reduction 
of the 230KD component of CD45RA expression when CLL B cells were activated to 
differentiate by TPA ( see Chapter 8 ). Based on this assumption, IPN/45 may 
represent the least mature stage of differetiation in four sublines while KN2 or less 
likely 45.43 the most advanced stage, in contrast to the proposal by Guy et.al. (1986).
The variation of 50KD component is of interest with regard of its molecular 
weight similarity to Class I MHC which was reported to be lowly expressed in 45.43 
and comparatively high in KN2, PNT and IPN45 ( Guy et.al., 1986 ). The results 
with radiobinding assay, by using monoclonal antibody MHM5 ( Guy et.al., 1986 ), is 
in consistent with HPLC-SDS PAGE data of the 50KD component, showing that 
increasing Class I MHC and 50KD expressions are in the order of IPN/45, PNT and 
KN2 and illustrating the deficient expression in 45.43 subline. However, the identity 
of this component needs to be confirmed.
Studies have identified that there is impaired ability to synthesize either Ig heavy 
or light chains in Burkitt's lymphoma cell lines ( Benjamin et.al., 1982; Mclntosh 
et.al., 1983 ). Nevertheless, the majority of the Burkitt's cell lines are reported to 
synthesize both heavy and light chains ( Gunven et.al., 1980 ). The flow cytometric 
study ( Guy et.al., 1986 ) of the cytoplasmic and secreted Ig in Namalwa cells 
supports this suggestion. The negative staining of the 45.43 subline in either 
cytoplasmic or surface Ig is in concert with its very low Class II MHC expression and 
places itself at an anomalous position in relating to other sublines. This subline was 
found to be unstable in MHC Class II expression ( Guy, personal conmmunication ) 
although it was never high. With HPLC-SDS PAGE analysis, 45.43 was also found to 
be susceptable for change in some surface glycoproteins ( data not shown ). Therefore 
a question is raised whether 45.43 is a monoclonal line or actually a polyclonal or 
whether it is arrested stably at a certain differentiation stage. Further study is needed 
to elucidate these points.
Band 4.2 expression is positively correlated with 230KD of CD45 as established in 
B-CLL lymphocyte, with an exception of 45.43 subline which was strongly band 4.2- 
positive by autoradiography. Although band 4.2 has been identified to be CD21 in B- 
CLL lymphocyte the HPLC-SDS PAGE observation in Namalwa cells seems to be not
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in conformity with the data by indirect immunofluorescent assay which showed that 
only 11-24% 45.43/2 ( a subline of 45.43 ) cells were positive while more than 50% 
PNT cells were stained by CD2I antibodies ( BL-13, HB5 and F97-6B3 ) ( Guy et.al., 
1987 ). The data show great contrast to the radiolabeling observation which 
demonstrated 45.43 subline to have highest band 4.2. The discrepancy is not 
understood.
Band 4.1 has the same positive relationship with 230KD band of CD45 as band 4.2 
does in all sublines apart from 45.43 which does not show the correlation.
There are at least two components expressed only by the Namalwa lines but not 
other cell types examined. One is the 130KD predominant band which is absent from 
all B-CLL, T-CLL and PLL. With respect to its apparent molecular weight, this band 
is reminiscent of band 5 in B-CLL, but is present in much earlier fractions and 
clearly distinguishes itself from the band 5 ( Fig 2 ) which is also expressed in all 
Namalwa sublines. The 130KD, thus, is a distinct component of Namalwa cells and 
shows considerably variable levels of expression. CD22 seems to be a possible 
candidate for this component and the expression of CD22 in Namalwa cells, detected 
by FACS ( Guy et.al., 1987 ), was relatively high, in consistent with the results by 
autoradiography. The anomalously short retention time of this 130KD band may be 
explained by the possibility of complexing with some other components.
The 150KD band is another distinct component on Namalwa's surface phenotypes. 
The retention of the molecule by HPLC column ( GF-450 ) is nearly the same as 
band 9 defined in some B-CLL lymphocytes. But they are very unlikely to be the 
same molecules because of the markedly differing molecular weights unless they have 
greatly differing levels of glycosylation. Actually, the band profile is very diffuse and 
with features of being a highly glycosylated protein. A SDS-electrophoresis with 
reduced and non-reduced samples would help to elucidate the identity of the 
component.
As both are derived from the B lymphocyte lineage, the overall profiles of the 
Burkitt's lymphoma cell line are similar to CLL B lymphocytes. Individual sublines 
show limited heterogeneity in their surface phenotypes, suggesting their deviation and
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differentiational differences of the maturational pathway. From the results discussed 
above, it appears that the shift of the surface phenotypes in Namalwa line along the 
differentiation pathway compares well with that of B-CLL and the correlations of 
surface proteins and maturation established in B-CLL may be applicable to the 
Burkitt's lymphoma cells. With regard of this, KN2 could be more mature than 
IPN/45 while PNT can be possibly placed in the middle. 45/43 subline is anomalous 
with respect to its surface phenotype and this phenomenon is not understood. The 
identity of of the four sublines has been confirmed by 'DNA fingerprinting' with the 
33.15 hypervariable minisatellite probe ( Jeffreys et.al., 1985 ) and cytogenetic 
research ( Soos et.al., 1981 ). These studies established that the different Namalwa 
sublines are derived from the same individual. However, the poor expression of what 
is normally considered to be a pan-B marker on a substantial proportion of Burkitt's 
cells is of interest, for example, CD20 ( Bl ) whose expression is across the whole 
span of the B cell differentiation untill the terminal differentiated plasma cells is 
absent in 45.43 subline. While CD37 is usually highly expressed in more mature cells, 
such as hairy cell leukaemia, it is negative in 45.43. Caution must, therefore, be 
excercised in the interpretation of these data with respect to the maturational stages. 
One point needing to be particularly born in mind is that these cell lines have been 
cultured for a considerable period. Cells cultured in vitro could have down-regulated 
synthesis of the antigens. ( foetal calf serum was reported to have stimulatory effects 
on cultured cells ( Coutinho and Moller, 1973; Okamura et.al., 1982 )) and individual 
proteins may be affected to diferent extent. Therefore, the variability of antigens 
seen in the Namalwa cell line may differ from that in freshly prepared neoplastic B 
cells.
The study of Namalwa cell lines by HPLC also shows considerable potentials of the 
technique, particularly in detecting minor differences which could be difficult 
extremely valuable for those unknown components and for the study which does not 
require complete separation of the constituents.
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CHAPTER 11. GENERAL DISCUSSION
The establishment of the HPLC-SE technique in this study has facilitated the 
understanding of cell surface protein expression, particularly those of CLL B 
lymphocytes. The surface protein expression of B-CLL cells is found to be 
interrelated and this relationship can be extended to other types of malignant cells. A 
number of new surface proteins have been identified and their expressions are also 
confined to the relationships existing between other surface markers. The correlation 
of these surface proteins with the state of cell maturation is discussed here.
1. Differential Expression of CD45
The present investigation has confirmed the previous findings that the expression 
of the CD45 determinants by different B-CLL patients varies from typical B cell 
profiles ( 1A ), through a series of intermediate forms, to T cell-like patterns ( IB ) 
as characterized by 230KD/180KD inversion ( Smith et.al., 1985; Roxburgh and 
Cooper, 1987 ). This conclusion is also supported by a direct comparison of overall 
phenotypic profiles of normal tonsilar B cell, B-CLL and T-CLL, which is made 
possible by the HPLC method. It is not yet known whether this CD45RA/CD45RO 
switch is a progressive event for each cell or whether it is changed by altering the 
proportions of different subpopulations which bear certain determinants. But in this 
study discrete pattern, such as 230KD+215KD'200KD+, has been observed, which 
may implicate that the proportions of cells carrying distinct CD45 expression are 
changed. The present observation suggests that the diversity of CD45 expression may 
reflect the heterogeneity of B-CLLs and the differences of their maturational states. 
Kerray et.al. (1987) and Dominis et.al. (1987) suggest that CLL consists of 
heterogeneous populations which is in agreement with this study.
2. Correlation of CD45 with slg. CD21. Band 4.1. Band 4.3 and Band 2
The earlier reports have demonstrated that the average level of surface 
immunoglobulin expression in B-CLL is lower than normal lymphocytes ( Dighiero 
et.al., 1980; Brown et.al., 1987 ) and that the expression of CD45 seems to be 
correlated with that of slg. The present observation has largely confirmed the above
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findings. The fact that the majority of B-CLL bear slgM, slgD or both and 
occasionally cytoplasmic Ig positive indicates that B-CLL may be at a mature B cell 
stage of normal differentiation. However, this interpretation is jeopardized by the 
complexity of slg expression ( Ling, 1983 ) and by the fact that details of the time 
course of the appearance and the expression levels of slg and its modulation are not 
fully understood.
The restricted CD45 ( CD45R ) is found on cells of most cases of non-T-ALL 
which is regarded as at pre-B stage from which CD21 is invariably absent ( Tedder 
et.al., 1984 ). In normal development, the precursor cells appear to proceed through a 
pre-B cell stage ( Cooper et.al., 1983 ) and develop to mature B-cells by gradually 
losing CD10 and TdT activity, by orderly acquiring surface CD20, CD21, CD22 
antigens and by inserting IgM and subsequently IgD, to the membrane. The CD21 
antigen is lost during early stages of terminal B-cell differentiation with the loss of 
slg ( Boyd et.al., 1985 ). The CD21 expression appears to be confined to a rather 
narrow span of the cell differentiation and restricted to mature B cells. The present 
investigation implies that B-CLL represents a stage equivalent to the mature B 
lymphocyte and CD45RA+CD21 + may represent a less mature state than CD45RA" 
CD2T.
It is of great interest that the expression of band 4.1 and 4.3 are positively 
correlated with that of the CD45RA, particularly, as no clustered surface antigens 
have molecular masses come close except CD22 and CD11 antigens both of which 
have been ruled out by the antigen-binding test ( see Chapter 6 ). These two proteins 
are, therefore, probably unidentified surface markers and appear to be intimately 
related to cell activation. It is intriguing that the above correlations in the B-CLL 
panel are also echoed in PLL and normal tonsilar cells.
The 160KD band 4.1 is not only expressed by B cells but also by T cells, as 
demonstrated by two observations: (1) comparison of band 4.1 expression in pure B 
cells with B and T cell mixture shows that band 4.1 is increased considerably in B-T 
mixture. (2) T-CLL express a significant amount of band 4.1 although CD45RA and 
band 4.3 and CD21 are not detectable. Jurkat cell line, which is derived from T cell 
type ALL, possesses a strong band 4.1. Further work needs to be done to clarify this
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point before the established relationships of abovementioned proteins can be extended 
to T cell type malignancies.
The discovery of the band 2-CD45RA relationship is probably the most marked 
merit of the HPLC-SE application. The acquisition of this 300KD component appears 
to be linked to the inversion of CD45RA determinant to 200KD/180KD determinants. 
It is not known whether there is a threshold for its appearance or whether there is 
any relationship between its expression and the ratio of CD45RA to 200KD/J80KD. 
Analysis of normal purified tonsilar B, B and T cell mixtures suggests that band 2 is 
probably expressed only by malignant cells. Band 2 positivity in T-CLL further 
confirms the proposal. We have come to the conclusion that band 2 is associated with 
malignant state of cells rather than cell type. The detection of this component in 
Burkitt's lymphoma cell line ( Namalwa ) and particularly the finding of the 
correlated change of 1A and IB features further supports this point. However, it 
might also be possible that band 2 is associated with cell activation and the B-CLL 
cells of those patients who express this component may be differentiationally blocked 
at an activated stage. Similar investigation in normal B and T cells should be able to 
answer the questions.
Together with the conclusions discussed above and those previously described, 
different cell types have constructed a phenotypically continuous spectrum of surface 
antigen expression. CLL patients possess heterogeneous phenotypes which are 
distinguished by the expression of CD45, CD21, band 4.1, band 4.3 and band 7 and 
band 2.
3. Phenotvpic Changes Upon TPA Activation
With HPLC, the changes of surface markers caused by TPA are more pronounced 
than those detected with FACS. Band 4.1, band 4.3 and band 2 appear to be closely 
associated with cell activation. As it was reported that CD45 determinants changed in 
a similar fashion in B-CLL as during T cell development, band 4.1 in T cell may be 
expected to show similar alteration as in B-CLL. The levels of band 2 after TPA 









Fig 1. The schematic presentation of the correlations of surface proteins of B-CLL. The 
HPLC data are based on the levels of radiolabelling of the proteins. The broken 
lines in band 4.1 indicate the inconsistency of its expression at the IB end. The 
200KD bar refers to the 200KD chain of the CD45 antigen.
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Numerous experiments have suggested that TPA activation does induce cells 
towards to a more advanced stage as reflected by the decrease of CD20, CD21, slg 
and induction of cytoplasmic or even secreting Ig. Several authors have also shown 
similar surface phenotypic alterations during normal lymphocyte development ( 
Freedman et.al., 1987; Akbar et.al., 1988 ). Comparing the spectrum of phenotypic 
variations along 1A and IB cells with that of TPA-induced, it is possible that 1A 
represents a less mature state while IB a more mature stage, with intermediate stages 
in the middle.
4. Relationship Between CLL. PLL and HCL
This is a highly controversial topic as there is a huge body of contradictory 
observations available. The argument seems to involve mainly two different but 
related questions: are CLL, PLL and HCL confined to the same differentiation 
pathway and if they are, what are the relative positions of these leukaemias along the 
pathway? or do they belong to different lineages? The antigenic profile of the PLL is 
rather similar to that of B-CLL and consistent, showing CD10~ 
CD19+CD20+CD21+CD22+CD24+ but CDS' and strong slg+ which confines it to B- 
cell lineage. A striking feature of PLL is that it uniformly reacts with an unclustered 
B cell related mAb FMC-7 ( Catovsky et.al., 1981 ) but does not form rosettes with 
MRBC. The significance of these differences is still debatable. There are a few 
reports indicating that CLL cells, upon TPA activation, are induced to express FMC- 
7 ( Robert et.al., 1983 ). Although most cases of PLL are CDS' ( Gobbi et.al., 1984 ), 
CDS positivity has been observed in a few cases ( Stein et.al., 1984 ). On the other 
hand, caution must be excercised when MRBC receptors are regarded as a 
differentiation marker. It has been reported that the MRBC rosetting ability could be 
lost soon after normal purified MRBC+ cells were cultured in the absence of TPA ( 
Caligaris-Cappio et.al., 1984 ), as are also the case for malignant cells.
PLL is usually regarded as a variant of B-CLL but its maturation position is not 
certain. Morphologically, the PLL cells maintain an immature apperance with 1-2 
conspicious nucleoli ( Galton et.al., 1974; Catovsky, 1977 ) and may contain 
intracytoplasmic granules. PLL expresses far more slg than B-CLL, usually slgM, and
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low MRBC ( Koziner et.al., 1980 ). The reponsiveness of PLL to TPA is variable, 1 
of 6 samples became clg+ ( Ziegler-heitblock et.al., 1986 ).
In this study, the fall of slg level after B-CLL cell activation and a strong 
CD45RA expression in HCL both argue against the proposal. The TPA stimulation 
apparently does not drive CLL to PLL-like phenotype but rather away from it. 
Phenotypically, PLL is closely related to 1A type, therefore, being at a less mature 
state. The reponse of PLL to TPA stimulation is variable ( Ziegler-Heitbrock et.al., 
1986; Yukihiro et.al., 1989 ) and less consistent when compared with CLLs. It should 
be conceivable that the responsiveness of a given clone to the stimulant may be 
related to its stage of differentiation arrest reflecting its 'readiness' to receive 
appropriate external stimuli, i.e. there may a maturation stage beyond which TPA can 
not exert its effect. There are studies showing that CLL cells bearing high slg tend to 
respond to TPA poorly ( Okamura et.al., 1982 ).
The assignment of HCL to the B cell lineage was largely based on its intrinsic slg ( 
Rieber et.al., 1979 ) and the immunoglobulin-gene rearrangement ( Korsmeyer et.al., 
1983; Cleary et.al., 1984 ). HCL shares two common feature with B-CLL: (1). the 
expression of T-cell related features of E-rosette+ ( Burns et.al., 1977 ) and rosette 
receptor after in vitro mitogenic activation ( Guglielmi et.al., 1980 ) (2). the presence 
of autoimmune manifestations and autoimmune phenomena ( Westbrook and Golde, 
1985 ). However, several criteria in addition to the peculiar morphology, discriminate 
HCL cells from chronic B cell malignancies: strong cytoplasnmic TRAP activity ( 
Yam et.al., 1961 ), strong Tac+ ( CD25 ) reactivity ( Korsmeyer et.al., 1983 ) and 
positivity with mAbs such as SHCL3 ( CDllb ), HC1 and HC2 ( Schwarting et.al., 
1985 ). In addition, CDS is absent from the majority of HCL cases ( Stein et.al., 1984
Caligaris-Cappio et.al. (1984) found that CLL B cells bind CD22 and become 
strongly TRAP positive and Tac+ ( CD25 ) after TPA stimulation and suggested that 
cells of CLL and HCL follow the same differentiation pathway as TPA can induce 
CLL cells to express phenotypic and morphological features of HCL. However, 
recently, Yukihiro et.al. (1989) argue that the induction of TRAP activity is not 
related to the chronic B cell leukaemia cell type. The acquisition of hairy cell
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morphology in B-CLL after TPA activation is also a highly debatable topic. Some 
report such acquisitions ( Rosver and Golomb, 1980; Caligaris-Cappio et.al., 1984 ), 
the others do not ( Polliak et.al., 1986; Ziegler-heitblock et.al., 1986; Yukihiro et.al., 
1989 ). Conversely, HCL is not induced to develop B-CLL features although 
displayed abundant cytoplasmic Ig ( Caligaris-Cappio et.al., 1984 ), which may be in 
concert with mature features of HCL as indicated by its expression of slgG ( Jansen 
et.al., 1982 ) and reactivity with the plasma cell-specific mAbs PCA-1 and PC-1 ( 
Anderson et.al., 1985 ). These findings may regard HCL as an 'activated' B cell 
leukaemia.
As the expression of surface proteins, particularly those differentiation markers, is 
intimately related, any attempt to define cell differentiation stage and pathway by 
simply using a single marker is oversimplified and jeopardized by this complication, 
as exemplified by the changes of band 2 and band 4.3. Both components are only 
present at certain stages but form undissociable parts of the cellular events. 
Therefore, we here propose that the understanding of the differentiation events and 
cell lineages should be based on a comprehensive evaluation and assessment of the 
compilation of those related markers and the overall phenotypic variations.
Taking these observations together, it is hard to definitely conclude the placement 
of CLL, PLL and HCL along the differentiation pathway. However, a careful analysis 
of the present data suggests that B-CLL and PLL are closely related disorders. 
Evaluation of various features of PLL favours its less mature state, so as implicated 
by its similarities with 1A type CLL. The phenotypic alterations induced by TPA 
have further confirmed this hypothesis. As we have no opportunity to investigate 
HCL, a direct comparison of HCL with B-CLL, PLL and other cell types is not 
possible here. However, HCL appears to be a more mature variant of chronic B 
leukaemia, compared with B-CLL and PLL. However, the possibility that B-CLL, 
PLL and HCL originate from distinct lineages can not be excluded as conspicious 
phenotypic differences between FMC-7+ and CD5+ populations are documented ( 
Melo et.al., 1986 ). Such exclusive expression of FMC-7 and CD5 may have 
significant implication that different etiologies of B cell malignancy may depend on 
the original target B cell subset. Before the normal counterpart of B-CLL can be 
convincingly addressed, further information is desirable.
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According to the surface molecular profiles of HPLC-SDS PAGE two-dimentional 
matrix, the delineation of PLL, CLL and HCL, along the differentiation pathway, 
probably is: PLL > 1A CLL > IB CLL > HCL (?)
S.Putative Normal Counterparts of B-CLL. PLL and HCL
Accumulating evidence suggests that B-CLL lymphocytes represent the expansion 
of a subpopulation of B cells arrested at a stage between pre-B and mature B 
lymphocytes. It should be conceivable that a normal counterpart, bearing 
corresponding features of the malignant cells, can be found. Bofill et.al. (1985) and 
Caligaris-Cappio and Janossy (1985) described a B cell subpopulation in foetal 
primary follicles, which bears typical B-markers together with the T-cell-specific 
antigen CD5 though at a low level ( Bofill et.al., 1985 ). CD5+ B-cells are first 
detectable in the lymph nodes around the seventeenth week of gestation ( Bofill et.al., 
1985), becoming prominent at the early phase of the B cell development. The 
ontogenic investigation shows that the number of CD5+ B cells is inversely related to 
age ( Caligaris-Cappio and Janossy, 1985 ). About 40% of Ig+ lymphocytes in fetal 
spleen and lymph nodes are CD5 positive while in adults the numbers are critically 
lower—about 5% of lymph node B cells are CD5 + and they are confined to the edge 
of germinal centres in secondary follicles ( Caligaris-Cappio et.al., 1982 ). These 
CD5+ B cells also distinguish themselves from other B cells by the property of 
forming rosettes with mouse red blood cells ( MRBC ) ( Caligaris-Cappio et.al., 1982 
), resembling CLL B cells. In addition to the phenotypic similarities, CD5+ B 
lymphocytes of foetal lymph nodes and spleens share a number of other features with 
CLL B cells such as lectin unresponsiveness and the inability to cap sig. These lines 
of observation lead Caligaris-Cappio et.al. (1982) to postulate that this CD5+ B cell 
subpopulation is the normal counterpart of CLL B lymphocytes.
The murine homologue of CD5 is the Ly-1 antigen ( Manohar et.al., 1982 ). Ly-l + 
cells exhibit many similarities with the CD5+ B cells in human. cDNA clones have 
been isolated for both Leu-1 ( CD5 ) ( Jones et.al., 1986 ) and Ly-1 ( Huang et.al., 
1987 ). Both sequences show 63% identity and 90% homology in their carboxy 
terminal regions with conservation of a cystein-rich amino-terminal region. In most
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mouse strains including neonatal nude mice ( Hayakawa et.al., 1983 ), Ly-1 antigen is 
co-expressed with a cell population expressing slgM and slgD, which is mainly 
located in the spleen. Ly-l+ B cells appear early in ontogeny and progressively 
decrease with age ( Hayakawa et.al.,1983 ). Ly-l+ B cells can be stimulated, by some 
T-independent antigens, to polyclonally expand in NZB and ( NZB x NZW ) Fl mice 
and to secrete in vitro high levels of autoantobodies ( Hayakawa et.al., 1983 ). The 
progenitors of Ly-l+ B cells have been demonstrated to be distinct from that of Ly- 
1- B ( Hayakawa et.al., 1985 ) and follow a different developmental pathway ( 
Hayakawa et.al., 1985 ). Several biochemical similarities between Ly-1 and CD5 have 
been documented ( Caligaris-Cappio et.al., 1981 ). It seems that CD5+ B cells are the 
human counterpart of the mice Ly-l+ B subpopulation. Recent studies implicate that 
the CD5 population may be involved in the production of autoantibodies in man ( 
Casali et.al., 1987; Hardy et.al., 1987 ).
Although a substantial body of evidence supports the notion that CD5+ B cells may 
be the normal counterpart of B-CLL, proof that CD5" B cells may represent a 
distinct pathway of B-cell development is lacking. There have been reports that TPA 
( Smith et.al., 1985 ) can induce the expression of CD5 antigen in normal B cells and 
that of FMC7 in CLL B cells ( Caligaris-Cappio et.al., 1984 ). Anderson et.al. (1984) 
show that a small subset of circulating peripheral B lymphocytes bear a similar CD5+ 
B-CLL phenotype and that they are additionally C^ negative. CD5 expression in B- 
CLL appears to be an inherent feature as attempts to induce Ly-1 or CD5 expression 
on already differentiated ( slg+ ) B cells have consistently failed ( Ritz et.al., 1981; 
Hayakawa et.al., 1984 ).
PLL is characterized by its expression of FMC-7 ( Catovsky et.al,, 1981 ) and 
morphologically, immature appearance with prominent nucleoli ( Galton et.al., 1974; 
Catovsky, 1977 ). A tentative normal counterpart of B-PLL has been suggested. 
Robinson et.al. (1985) defined a subset of B-cells in normal peripheral blood B 
lymphocytes which were characterized by the presence of a prominent nucleolus and 
less nulear chromatin condensation and its reactivity with FMC-7. Caligaris-Cappio 
and Janossy (1985) found a subset of cells in the mantle zone of secondary follicles 
which show typical features of B-PLL: high slg, RFA4+ ( CD22 ) and CD5" and 
MRBC-.
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Very few observations are available for the designation of a normal counterpart for 
HCL. Robinson et.al. (1985) identified a population of B cells in peripheral B 
lymphocytes, with morphologically villous outlines and phenotypically being reactive 
with FMC-7 and aHCl and aHC2 ( Posnett et.al., 1982 ), both are anti-hairy cell 
mAbs. The authors claim that this B-cell subpopulation may constitute the normal 
counterpart of HCL. Normal MRBC+ B cells from tonsils were reported to acquire 
TRAP positivity and a lymphoblastoid appearance, but no sufficient data are available 
for an insight of the normal counterpart. It is also suggested that the 'hairy' feature 
may arise only as a consequence of the neoplasia ( Caligaris-Cappio et.al., 1984 ).
So far, all such hypotheses are tentative and the evidence is not compelling. 
Although all haematopoietic-originated cells share common precursors the potential 
'target' for malignancies is broad which may account for the complexity seen in 
leukemias. On the other hand, differentiationally arrested cells, though initially 
homogeneous, may still retain some capacity for further differentiation, therefore, 
developing phenotypic features distinguished from those of the cells which the disease 
was initiated. Malignant cells, even derived from the same lineages, should be
t
expected to have different morphological and phenotypical presentations if cells are 
transformed at different oncogenic sites.
Over the past decades, the surface phenotypic characteristics of malignant cells 
have been gradually elucidated by the extending availability of monoclonal antibodies. 
Remarkable progresses have been made in the identification on B-cells of a mosaic of 
molecules strictly associated to the process of differentiation, maturation and/or 
activation ( Bernard et.al., 1984; einherz et.al., 1986 ). The understanding of the tissue 
distribution, traffic characteristics and cell-cell interactions of malignant and normal 
B-lymphocytes is also updated. The expression of the B-cell-specific CDs ( CD19-23 
) and the B-cell-associated CDs ( CD9, 10 and 24 ) in a coherent fashion during 
normal B-cell differentiation suggests significant implications of the phenotypic 
features with respect to the physiological states of the cells. CLL lymphocyte provides 
an excellent model for this valuable venture as they possess some distinct abnormal 
features. The relationships between membrane protein reportiore and cellular events 
will greatly facilitate the understanding of not only the malignancies of the cells, but
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also the haemotopoietic events of normal lymphocytes, and, from a general view, the 
siginificance of the biological membrane functions.
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Appendix II (2): The relative positioning of the four sublines of Namalwa with respect
to their expression levels of surface markers. The arrow points the 
increase of the level. *••»-' means 'not concluded'. 230KD refers 
to the highest chain of CD45 antigen.
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APPENDIX III (1)





































Appendix III: Retention times ( in min ) of size-exclusion columns calibrated against 
standard proteins. The calibration was repeated for at least 2 times, 
mostly 3 times for each individual columns. The deviaitions of the 
retention time for individual proteins at different runs were not more 
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Identification of antigens by high-performance liquid chromatography
ZHIEVfl WU and ALUN H. MADDY
Department of Zoology, University of Edinburgh Kings
landings, West Mains Road, Edinburgh EH93JT, UK,
Traditional methods for the identification of antigens usually 
involve isolation of an antigen/antibody complex by precipi­ 
tation or binding to a solid-phase preparation of the anti­ 
body. Here we introduce an alternative method which 
identifies antigen by h.p.l.c. An appropriate antibody is 
added to a mixture of proteins containing the antigen and the 
cluiion profile of this mixture compared with the profile of 
the mixture in the absence of the antibody. The antigen is 
then recognized as the component whose retention time has 
been reduced by the addition of the antibody when it is 
cluted as an antigen/antibody complex.
Cells are washed and suspended in an isotonic Hepes 
buffer at pH 7.4 and iodinated in the presence of lactoper- 
oxidii.se (Thompson et at., 1980). After inclination, the cells 
;ire washed in the same buffer lacking divalent cations. Cells 
;5x |0 7 )are suspended in 100^1 of the buffer and extracted 
with 100 //I of a I % Triton X-100 solution in the buffer con­ 
taining EDTA, phenylmethanesulphanyl fluoride, aprotinin 
;md iodoacetamide, for 10 min on ice. Insoluble material is 
ccntrifuged out.
The saturating amount of each antibody is determined by 
flow cytometry of the intact cells and this amount of antibody 
ndded either to the iodinated Triton X-100 extract or to the 
intact cells before their extraction. In the latter case, excess 
antibody can be washed away and the appropriate anti- 
immunoglobulin antibody can be added as a second-step 
reagent to the mixture.
Extract, with and without antibody, is fractionated on a 
DuPont GF450 size exclusion column using a mobile phase 
of ().2/V/-phosphate buffer (pH 7.4) containing 0.5% (w/v) 
Triton X-100 and sodium azide as an antibacterial. Samples 
(100 //I) of the extracts containing the equivalent of 2.5 x 107 
cells are used for each run. Fractions are collected on a time 
mode at 0.2 min intervals. Each fraction is analysed by SDS/ 
polyacrylatnide-gel electrophoresis in a Laemmli buffer 
(Laemmli, 1970).
The method has been tested with antibodies against 
determinants on the surface of B-lymphocytes ranging from 
a molecular mass of around 200 kDa (the leucocyte-common 
antigen) down to class II major histocompatibility complex 
(MHC) with a mass of around 40 kDa. Fig. 1 illustrates the 
method using the antibody W6/32 (ex Serotec), a mono­ 
clonal antibody against class 1 MHC. The radioactive 45 kDa 
"I the determinant is found in fractions 16-17 in the sample 
without antibody. After addition of the antibody to the cells, 
before Triton X-100 extraction, me determinant is found in 
fractions 12-13 in the subsequent eluate. When anti-mouse 
immunoglobulin has been added to the extract a still larger 
complex is formed and the radioactive MHC molecule is 
"o\v found in fractions 3-4.
We have drawn attention to the potention of h.p.l.c. as a 
technique for the identification of antigens. The combination 
<>f h.p.l.c with SDS/polyacrylamide-gel electrophoresis is 
Mso a powerful method for the analysis of the polypeptide 
composition of a complex mixture of proteins such as is 
found in u membrane. The proteins are displayed as a two- 
tlimcnsiona) matrix, the position of each band having been 
'Icicrmined by several factors. Minor differences between 
•he mixtures, e.g. those found between different clones 
derived from a tumour, are readily resolved. The method has
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Fig. 1. Effect of the addition of anti-class I MHC antibody on
the elution of the class I determinant of human chronic
B-lymphocytic leukaemia lymphocytes
(a) No antibody, (b) Antibody added to cells before Triton 
X-100 extraction, (c) Anti-mouse immunoglobulin added to 
Triton X-100 extract before chromatography. The Figure 
represents the fluorograph prepared from cells iodinated by 
lactoperoxidase. Abbreviation: SDS/PAGE, SDS/polyacryla­ 
mide-gel electrophoresis.
certain advantages over other methods for the identification 
of antigens as it is a one-step procedure involving no pro­ 
longed washing which could disrupt the binding of anti­ 
bodies of low affinity. In many cases the antigen can be 
located on the gel by silver staining without recourse to a 
radioactive label. The method can be extended in several 
ways, e.g. the analysis of the epitopic specificity of antibodies. 
If a determinant is challenged with a mixture of antibodies 
against the same epitope only one immunoglobulin molecule 
will be bound, but if the antibodies are directed against dif­ 
ferent determinants more than one immunoglobulin mole­ 
cule may bind with a commensurate greater effect on the 
retention time of the antigen. The method can, in principle,
Vol.16
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The identification of antigens in antibody/antigen complexes 
using high performance liquid chromatography
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A method for the identification of antigens in a complex mixture of proteins is described. It exploits the 
effect which addition of a monoclonal antibody and resultant formation of antibody/antigen complexes 
has on the apparent retention time of the antigen on a size exclusion column. An antigen in the mixture 
can be identified as that component whose retention time is decreased by addition of its antibody. The 
principle of the method is demonstrated using an HPLC size exclusion column (DuPont GF450) and three 
MoAbs, PD7/26, DA6 147 and W6/32 which are directed against three antigens of the lymphocyte 
surface, the leucocyte-common antigen, class II MHC and class I MHC respectively.
Key words: Chromatography, high performance liquid; Antigen identification
Introduction
The identification of an antigen usually in­ 
volves its solubilisation and precipitation from 
solution by its antibody, or adsorption onto its 
antibody on a solid phase (Coding, 1986). In 
either case the other proteins in the solution must 
be separated from the antigen/antibody complex 
by some washing procedure. The process is com­ 
plicated in the case of insoluble antigens such as 
membrane proteins by the requirement for deter­ 
gents to be present throughout the procedure to 
retain the antigen in a soluble state. The alterna­
tive approach by Western blotting is unsuitable 
for use with monoclonal antibodies if the relevant 
epitope is labile during the SDS-PAGE step which 
precedes the blotting. We here present a technique 
for the identification of antigens by size exclusion 
HPLC which obviates the need for a washing 
procedure and the use of SDS prior to addition of 
the antibody. The method exploits the increase in 
the apparent size of an antigen when it is associ­ 
ated with its antibody in the antigen/antibody 
complex. The antigen can therefore be dis­ 
tinguished from other proteins in the eluate as the 
component whose retention time is decreased by 
the addition of the antibody.
Correspondence to: A.H. Maddy, Department of Zoology, 
University of Edinburgh, West Mains Road, Edinburgh EH9 
3JT, U.K.
Abbreviations: CLL, chronic Jymphocytic leukaemia; 
EDTA, ethylenediammetetraacetic acid; SDS, sodium dode- 
cylsulphate; Hepes, hydroxyethylpiperazine-ethanesulphonic 
acid; HPLC, high performance liquid chromatography; MoAb. 
monoclonal antibody; PAGE, polyacrylamide gel electrophore- 
sis; PMSF, phenylmethylsulphonyl fluoride.
Methods
Cell preparation
B-CLL lymphocytes isolated from whole blood 
on Ficoll-Paque (Pharmacia) were washed and 
suspended in a solution consisting of 133 mM 
NaCl, 4.5 mM KC1, 5 mM MgCK and 2 mM
0022-1759/89/503.50 ' 1989 Elsevier Science Publishers B.V. (Biomedical Division)
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CaCl : buffered to pH 7.4 with 10 mM Hepes 
(buffer 1).
Lactoperoxidase catalysed iodinalion
1 x 10 8 cells were suspended in buffer 1 con­ 
taining 10 mM glucose, 0.05 U glucose oxidase 
(Aspergillus niger, Sigma), 1.5 U lactoperoxidase 
(bovine milk, Sigma), 0.5 /xM K127 I and 100 juCi 
Na125 I and incubated for 20 min at 37°C. Un­ 
bound iodine was then removed by repeated wash­ 
ing with ice-cold buffer 1.
Triton extraction
The cells were washed once in buffer 1 lacking 
divalent cations (buffer 2). 1 X 10 8 cells were then 
suspended in 200 jul of buffer 2 and 200 jul of a 
1% Triton X-100 solution in buffer 2 (containing 
EDTA (2 mM), PMSF (1 mM), aprotinin (0.5 
TlU/ml) and iodoacetamide (5 mM) to inhibit 
proteolysis) and the mixture incubated on ice for 
10 min. Insoluble material was centrifuged out at 
900 X g for 10 min.
Addition of antibody
The requisite concentration of antibody was 
initially determined by titration of the cells against 
a series of antibody concentrations, measuring 
antibody binding by flow cytometry (Brown et al., 
1987). Antibody was then added to this saturating 
concentration, either to the iodinated Triton ex­ 
tract or to the iodinated intact cells, and in­ 
cubated for 45 min on ice. In the latter case excess 
antibody was washed away before the Triton ex­ 
traction and rabbit anti-mouse immunoglobulin 
(Dako) was added as a second-step to this extract 
using 80 jug/200 /nl extract to enhance the change 
in apparent retention time of the antigen.
High performance liquid chromatography (HPLC)
The Triton extract was fractionated by a 
DuPont GF450 size exclusion column (250 X 9.4 
mm) on a Gilson Model 302 HPLC apparatus at a 
flow rate of 1 ml/min and a pressure of 30 bar. 
Zorbax PSM 150 DIOL was used as a packing 
medium for a precolumn. The mobile phase con­ 
sisted of 0.2 M phosphate buffer (pH 7.4) contain­ 
ing 0.5°t Triton and 0.005% sodium azide as an 
antibacterial agent. The eluate was monitored at
243 nm which was found to be a window in the 
spectrum of the detergent where proteins could be 
detected. Fractions were collected on a time mode 
at 0.2 min intervals. 100 jul of Triton extract 
containing the equivalent of 2.5 X 10 7 cells were 
used for each run.
Gel electrophoresis
100 jul of 125 mM Tris-HCl containing SDS 
10%, glycerol 20%, bromophenol blue, 1 mM 
EDTA and 1 mM dithiothreitol were added to a 
200 jul HPLC fraction and the mixture heated for 
15 min at 50 ° C. The mixture was then fractionated 
in a discontinuous buffer system (Laemmli, 1970) 
on a 6-11% polyacrylamide gradient, the gel fixed 
in methanol/ acetic acid/ water (2:1: 7) and fi­ 
nally stained with silver (Thompson, 1987). Radio­ 
active components were detected by fluorography 
using an intensifying screen and pre-flashed X ray 
film.
Results
The efficacy of the method was demonstrated 
using three MoAbs against antigens covering a 
wide range of molecular masses which are ex­ 
pressed on the surface of human B lymphocytes 
from patients with chronic lymphocytic leukaemia 
(B CLL).
Fig. 1 shows the effect of the antibody PD7/26 
(CD45RB) which is bound by three polypeptides 
of the leucocyte-common antigen (Pulido et al., 
1988). In our system these polypeptides have 
molecular masses of 230, 215 and 200 kDa range 
(Smith et al., 1985) and it is seen that three chains 
of this size have been moved from fractions 7-8 in 
the control to fractions 4-5. Fig. 2 shows a similar 
shift produced by the addition of DA6 147 which 
is an antibody against the a chain of class II 
MHC (Guy et al., 1986). Since the chromatogra­ 
phy was performed in mild non-ionic detergent 
both a and ft subunits of the antigen have shifted 
as a complex (fractions 14-15 to 11-13) although 
the antibody is specific for the a chain.
Fig. 3 illustrates an extension of the technique 
using anti-mouse immunoglobulin as a second step 
reagent. In Figs. 1 and 2 antibody was added to 
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Fig. 1. Autoradiographs showing the effect of the addition of 
the anti-leucocyte common MoAb PD7/26 on the retention 
time of the antigen. It is seen that addition of the antibody has 
shifted the antigen from the HPLC fractions 7-8 in the un­ 
treated control (A) to fractions 4-5 in the eluate of the 
extract + antibody ( B ).
the cells by Triton extraction. In Fig. 3 an anti-class 
I MHC antibody W6/32 (Barnstable et al., 1978) 
has been added to the intact cells prior to Triton 
solubilisation and, as shown in Fig. 3B, the effect 
is very similar to Figs. 1 and 2. In Fig. 3C the shift 
in the position of the antigen has been amplified 
by addition of the anti-mouse immunoglobulin to 
the Triton extract. When a second step reagent is 
used it is preferable to add the first step to the 
intact cells, as shown here, since this provides the 
opportunity to wash away excess first antibody 
before addition of the second step.
Discussion
The combination of HPLC and SDS-PAGE 
provides a powerful technique for the analysis of 
complex mixtures of proteins, particularly those 
containing high molecular weight proteins. The
proteins can be displayed as a two-dimensional 
matrix and each cell type has a characteristic 
pattern. The patterns shown in this paper were 
obtained from human B CLL lymphocytes. The 
polypeptide composition of the plasma membrane 
of these cells from different patient differs in 
detail (Smith et al., 1985) and, since three different 
patients were used these differences are reflected 
in the SDS gels in Figs. 1-3. Although the method 
discussed here arose from the need to identify the 
individual components of such polypeptide matri­ 
ces, this technique can be extended as a general 
method for the identification of antigens recog­ 
nised by monoclonal antibodies.
The technique of antigen identification can 
complement other procedures which are generally 
available. The isolation of the antigen/antibody 
complex is a simple, rapid, one-step process and 















Fig. 2. Autoradiographs showing the effect of the addition of 
the anti-MHC class II antibody DA6 147 on the retention 
times of the MHC a and /? chains. The antigen is moved from 
fractions 14-15 m the untreated control ( A ) to fractions 11-13 

























Fig. 3. Identification of the MHC class I antigen by HPLC. A: 
control eluate. no antibody added. The antigen was recovered 
in fraction 16-18 (not shown). B: the anti-MHC class I 
antibody W6/32 has been added to the surface iodinated 
intact cells and the antigen found in fractions 12-14. C: the 
W6/32 has been added to the intact iodinated cells, the cells 
extracted with Triton X-100 and rabbit anti-mouse immuno- 
globulin added prior to chromatography. The antigen is now 
found in fractions 2-4.
advantage for antibodies of low affinity. As SDS 
is not added prior to the interaction of antigen 
uith antibody, the destructive effect of SDS which 
restricts the use of MoAbs in Western blotting is 
avoided. The method can dispense with the need
for a radioactive label by locating the antigen by 
silver staining. However, impurities in antibody 
preparations often confuse results obtained by 
silver staining. In these circumstances it is prefer­ 
able to add the antibody to intact cells so that 
such impurities can be washed away.
The three antibodies used are well characterised 
MoAbs (Barnstable et al., 1978; Warnke et al., 
1983; Guy et al., 1986; Pudido et al., 1988). 
PD7/26 was obtained as a culture supernatant 
and the other two as ascites fluids. The observed 
changes in retention times are consistent with the 
formation of 1 :1 complexes. The method has not 
been tested against polyclonal antibodies since 
such antibodies immunoprecipitate with facility 
and are generally amenable to Western blotting. 
Furthermore, as an antigen can bind several com­ 
ponents of a polyclonal antibody, depending on 
the number of epitopes the antigen expresses, the 
effect of addition of a polyclonal reagent on the 
retention time of its antigen would be complex 
and might produce insoluble precipitates. For this 
reason addition of a polyclonal second step must 
be carried out with caution and the second step 
used at lower concentrations than would be 
customary for immunoprecipitation. We have been 
able to identify the determinant of an anti-leuco­ 
cyte MoAb raised in this laboratory by this method 
when immunoprecipitation and Western blotting 
were unsuccessful.
The method may, in principle, be extended in a 
number of ways. It could be used to explore the 
epitopic specificity of antibodies. If a pair of 
antibodies do not compete for the same epitope 
two immunoglobulin molecules will bind to the 
antigen, resulting in a greater change in retention 
time than when either is used alone. Again, the 
method is not restricted to the detection of anti­ 
gens but could be used for the identification of 
any ligand/receptor complex where the size of the 
ligand is appreciable relative to the size of the 
receptor and the complex stable in the non-ionic 
detergent.
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